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The foundation of modern basic science is formed by the building of 
models that mimic the events we can observe in the real world, and can be 
used to make new and testable predictions. Biomedical research only 
partly follows this pattern. In clinical studies it usually is impossible to 
construct models that behave like they should, and here a different route is 
commonly taken (figure 1). Hypotheses are central in this alternative 
strategy. They can arise as wild ideas, from theoretical considerations or 
from the world as we observe it. This hypothesis generating phase is 
followed by a hypothesis testing phase. 
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Figure 1:
 The scientific process in clinical research.
Hypothesis testing studies can take the form of uncontrolled intervention 
studies, controlled intervention studies or observational studies. These 
same study types play a role in the final confirmation phase. Many clinical 
studies are of the hypothesis-testing and hypothesis-generating kind at the 
same time, although this usually is not explicitly stated. How well these 
studies reflect what happens in the real world depends on the non-
randomness of the sample selected for study and on the objectivity of 
researchers, reviewers and editors, factors generally referred to as bias. 
 
Various forms of bias operate at the level of the study itself, for instance 
selection-bias and investigator-bias. Bias can also operate at other levels. 
One example is publication-bias, caused by the reluctance of authors and 
journals alike to publish negative results. The bottom line is that no matter 
how many measures are taken to prevent bias, clinical studies will never 
reflect what happens in the "real" world with 100% accuracy. Purely 
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observational studies, if properly conducted, probably come closest to this 
ideal. Descriptive studies are different in that they are not studies at all, but 
merely descriptions. They can, however, lead to the generation of 
hypotheses. 
 
When these ideas are applied to the eight papers in the following five 
chapters, three fall in the category of descriptive studies, three are mainly 
hypothesis generating observational studies and two are hypothesis 
testing observational studies. All papers deal with clinical aspects of liver 
transplantation. First an outline of the Rotterdam liver transplantation 
program, that has generated all of the data reported in this thesis is given 
in chapter 2. The next part concentrates on what happens during the 
period between enlistment for liver transplantation and the operation itself, 
and on the survival after transplantation. 
 
In chapter 3a simplified model predicting survival on the waiting list for liver 
transplantation is proposed. The effect of patient selection on the outcome 
of transplantation for cholestatic liver disease is described in chapter 3b. 
Two different techniques for transplantation are compared in chapter 4. 
Acute liver failure as specific indication for transplantation is the subject of 
chapter 5. Finally acute rejection of the graft, one of the frequent 
complications after liver transplantation, is studied in chapter 6. A separate 
chapter is devoted to a summary of what we can learn from the Rotterdam 
program and, last but not least, what still needs to be done. 
 
Medical science is a work in progress. There is much we simply don't 
know, and much of what we do know probably will no longer be relevant or 
even true at some point in the future. Both the fact that only just over half 
of the studies in this thesis potentially contribute to our current knowledge 
and the finite half-life of truth in medicine urge against exaggerated claims 
based on these studies. On the other hand, purely clinical studies form 
only a minority of the publications in biomedical journals, even though they 
are the most important guides for everyday medical treatment decisions. In 
short, the value of the studies in this thesis should neither be 
overestimated nor underestimated. Whether there is any real truth in them 
can only partly be determined at present. 
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SUMMARY 
 
Background The moment of reperfusion is the starting point of most 
studies on liver transplantation. However, prior to this moment important 
decisions in patient care have to be made. In order to identify the problems 
arising at each stage of the liver transplantation process, both before and 
after the operation, we performed a cohort study on all patients referred to 
our centre from the start of the liver transplantation program in 1986 
through 2002. We focussed on patient selection and treatment outcomes. 
Patients and methods During the study period 940 patients were referred 
for liver transplantation. All data were retrieved from an existing electronic 
database and from patient files. Referral was for acute liver failure in 143, 
cirrhosis in 597, hepatocellular carcinoma in 110 and other diseases in 90. 
Decisions and outcomes were tabulated for different groups. Survival was 
calculated according to the Kaplan-Meier method. For comparisons logistic 
regression analysis and Cox regression analysis was used. 
Results The yearly number of referred patients has risen from 10 in 1986 
to 107 in 2002. No indication for transplantation was present in 29% of the 
patients and contraindications in 20%. There were 9% deaths without 
transplantation and 37% of the referred patients were transplanted. The 
waiting time has increased to a median of 260 days over the same time 
period, with a concomitant rise in waiting list mortality and in the number of 
patients removed from the list because of tumour progression or other 
reasons from 8% in the period 1986-1995 to 25% in 2001 and 27% in 
2002. After transplantation for acute liver failure a 5-year survival of 66% 
was found. In the chronic liver disease group the 5-year survival ranged 
from 71% for patients with cholestatic liver disease to 31% for patients with 
hepatocellular carcinoma. The incidence of early acute rejections declined 
from 40% to 18% after the introduction in 1998 of interleukin-2-receptor 
blocking agents as part of the primary immunosuppressive regimen. 
Conclusions In this descriptive study on a large single-centre cohort of 
liver transplantation candidates several points emerge. On the positive 
side are the results in patients with acute liver failure and chronic 
cholestatic liver diseases. On the other side there are some problems that 
require more attention. The main one is the waiting list policy. 
 
 
INTRODUCTION 
 
For most studies on liver transplantation the time of enlistment or of the 
operation is the starting point. However, important decisions on patient 
management also have to be taken prior to enlistment. Descriptions of 
transplantation candidate cohorts are available from the Netherlands, from 
the United States, from France and from the United Kingdom1-9, but most 
deal with alcoholic liver disease. After several years of preparation, in 1986 
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a clinical liver transplantation program was started in Rotterdam. It began 
as a program of heterotopic liver transplantation, but since 1991 only 
orthotopic liver transplantations have been done. From the outset, data on 
all patients referred for liver transplantation have been recorded. Here we 
describe the patients referred to our centre for liver transplantation 
between 1986 and 2002, the treatment decisions in this patient group and 
the outcomes in various subgroups. This study was aimed at identifying 
problems arising at all stages of the liver transplantation process. 
 
 
PATIENTS AND METHODS 
 
Study population All consecutive patients referred for liver transplantation 
from 1986 through 2002 were included in this study. Our criteria for 
transplantation were published in 199810 (table 1). These guidelines have 
also been followed in previous years. Data were collected from our liver 
transplantation database and from patient files. Follow-up was complete 
until December 31, 2004. Until the end of 2002, 940 candidates for 
transplantation have been evaluated (figure 1). The reason for referral was 
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Figure 1: primary indications in patients referred for liver transplantation
acute liver failure (ALF) in 143 patients (15%). Of the 797 patients referred 
for transplantation on an elective basis (ELE), 120 (15%) had alcoholic 
cirrhosis (ALC), 192 (24%) chronic viral hepatitis (VIR), 171 (21%) 
cholestatic liver disease (CHO), 110 (14%) hepatocellular carcinoma 
(HCC), and 204 (26%) a variety of other liver diseases (OTH). 
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Statistics Survival was calculated according to the Kaplan-Meier method. 
For comparisons between groups Fisher’s exact test, logistic regression 
analysis and Cox regression analysis were used. 
 
Table 1: Indications and contraindications for liver transplantation 
according to the Dutch protocol for adult patients, revised version 2002. 
INDICATIONS 
Hepatitis B Encephalopathy grade III or IV and 
Factor 5 < 20% (age ≤ 30 years) 
Factor 5 < 30% (age > 30 years) 
Paracetamol Arterial pH < 7.30 or all 3 criteria: 
Encephalopathy grade III or IV 
Prothrombin time > 100 sec. / INR > 6.5 
Creatinine > 300 µmol/l 
Acute liver failure 
Other causes Prothrombin time > 100 sec. or 3 of 5: 
Interval jaundice – encephalopathy > 7 days 
Age < 10 or > 40 years 
Prothrombin time > 50 sec. / INR > 3.5 
Bilirubin > 300 µmol/l 
Cause non-viral or unknown 
Cirrhosis Child-Pugh score ≥ 9 or ≥ 7 if 
Low quality of life or progressive disease 
Metabolic Life-threatening complications 
Chronic liver disease 
Polycystic Low quality of life 
Liver tumors Hepatocellular 
Carcinoma 
Single tumor ≤ 5 cm or 
Two tumors ≤ 3 cm 
 Other types Hemangioendothelioma 
APUDoma 
Contraindications 
Absolute Systemic extrahepatic infections 
Extrahepatic malignancy (if not definitely cured) 
Irreversible brain damage 
Irreversible multi-organ failure 
Substance abuse (if not abstinent for ≥ 6 months) 
Relative HIV seropositivity 
Age ≥ 65 years 
Mental incapacity 
Extrahepatic disease limiting the chance of survival 
Residency outside the Netherlands (unless emergency) 
 
 
RESULTS 
 
Indications and contraindications for transplantation The number of 
patients referred for liver transplantation has gradually risen from six in 
1986 to 107 in 2002 (figure 2). The proportion of patients in whom  
transplantation was not indicated because of the availability of an 
alternative form of treatment was 29% on average and varied from 15 % in 
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the HCC group to 38% in the group with other liver diseases. 
Contraindications were found in 20% of patients overall, ranging from 9% 
in the other liver diseases group to 55% in the HCC group. A treatment 
decision could not be made prior to death in 4% of patients, and 5% died 
on the waiting list. The sum of these two figures gives 9% as the overall 
mortality without transplantation, with a high of 13% in the alcoholic 
cirrhosis group and a low of 4% in the HCC group. Eventually, 37% of the 
patients were transplanted, the lowest proportion (19%) in the HCC group 
and the highest (46%) in the cholestatic liver disease group (table 2). 
  
Table 2: Numbers and proportions of patients with different liver diseases 
referred for liver transplantation, enlisted and transplanted, 1986-2002 
 Referred Enlisted Transplanted 
Total 940 (100%) 416 (44%) 344 (37%) 
Acute liver failure 143 (100%) 72 (50%) 65 (45%) 
Alcoholic cirrhosis 120 (100%) 44 (37%) 33 (28%) 
Chronic viral hepatitis 192 (100%) 94 (49%) 73 (38%) 
Chronic cholestatic liver disease 171 (100%) 91 (53%) 78 (46%) 
Hepatocellular carcinoma 110 (100%) 32 (29%) 21 (19%) 
Other liver diseases 204 (100%) 83 (41%) 74 (36%) 
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Other outcomes were recorded for 5% of all patients, these either refused 
transplantation, were referred to other centres or were still waiting on 
December 31, 2004, the closing date of this study (figure 3). 
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Waiting time and waiting list events The overall median waiting time for 
elective transplantations has risen exponentially since the early nineties, 
Figure 4:
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reaching 260 days in 2002 (figure 4). This was due to a rise in the yearly 
number of patients enlisted from 2 in 1986 to 63 in 2002, without a 
concomitant increase in the number of donor organs. There are 
differences between blood groups, but the trend remains the same. Deaths 
on the waiting list were infrequent until 1995, with a mean of 0.8 per year. 
From 1996 onwards the incidence has risen to 6 in 2001and 7 in 2002. In 
the same period an increasing number of HCC patients had to be removed 
from the waiting list because of tumour progression. The proportion of 
patients from all diagnostic categories enlisted for elective liver 
transplantation that could not be transplanted was 8.2% between 1986 and 
1995, and rose to 25.0% in 2001 and 26.3% in 2002 (figure 5). 
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Figure 5: dropouts from the liver transplantation waiting list
Heterotopic liver transplantation Between 1986 and 1990 23 heterotopic 
liver transplantations were performed in 21 patients. The survival at 1, 2 
and 5 years after heterotopic transplantation for chronic liver disease was 
71% (95% CI 43% to 87%), 53% (95% CI 28% to 73%) and 24% (95% CI 
7% to 45%), respectively11. There were three patients in this category who 
survived for more than 10 years12. Four patients underwent heterotopic 
transplantation for acute liver failure, including one with acute on chronic 
liver failure. In this group there was one long-term survivor whose own liver 
regenerated so she could be taken of immunosuppressive drugs13. The 
other three patients all died in the early postoperative period. 
 
Cholestatic liver disease Primary Biliary Cirrhosis (PBC), Primary 
Sclerosing Cholangitis (PSC) and a small number of other cholestatic liver 
diseases formed the third largest category in our series, and accounted for 
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171 (18%) of the 940 referrals for liver transplantation. This fraction has 
declined somewhat over time (figure 6), due to a lower number of patients 
Figure 6:
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with PBC referred after 1995. From 1986 through 1995 patients with PBC 
contributed 13% to the total of referred patients against 4% in later years, 
while the contribution of patients with PSC remained constant at around 
10%. There were 55 patients in this group that did not meet our minimum 
criteria for enlistment. Contraindications were found in 17 patients, 3 were 
referred to other centres and 5 died during the work-up for transplantation. 
We enlisted 91 patients, 10 of these died, 2 were removed from the waiting 
list because new contraindications emerged, 1 was still waiting at the 
closing date of the study, and 78 were transplanted. The survival at 1, 2 
and 5 years after transplantation in this patient category was 78% (95% CI 
67% to 86%), 74% (95% CI 63% to 82%) and 71% (95% CI 59% to 80%), 
respectively. 
 
Hepatocellular carcinoma The proportion of patients with hepatocellular 
carcinoma among those referred for liver transplantation was 13% overall, 
with a peak at around 25% in the early nineties, and a decline to around 
10% later on. The tumours were considered to be inoperable in 52 (47%) 
of the 110 patients referred for hepatocellular carcinoma, 16 (15%) were 
offered partial hepatectomy and 32 (29%) were enlisted for transplantation. 
Of the remaining 10 patients 5 refused transplantation, 4 were referred to 
other centres and 1 died during the work-up for transplantation. Of the 32 
enlisted patients, 3 died while on the waiting list, 7 had to be removed from 
the list because of tumour progression and 1 emigrated before she could 
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be transplanted. Eventually, liver transplantation was performed in 21 
(19%) of the patients. The 1-year survival in the transplanted group was 
81% (95% CI 57% to 92%), the 5-year survival was 31% (95% CI 13% to 
51%). When we assume that the nine patients removed from the waiting 
list because of tumour progression died within six months, the 5-year 
survival calculated on an intention-to-treat basis was 22% (95% CI 9% to 
38%). There were 10 deaths at more than 1 year after transplantation, all 
caused by tumour recurrence. Hepatocellular carcinoma presumably was 
the cause of death in 20 of the 32 patients enlisted for liver transplantation 
because of this tumour. In contrast, 17 previously undetected tumours 
were found during the waiting time or in explanted livers of patients with 
other indications, and only one of these 17 patients died of tumour 
recurrence. 
 
Acute liver failure Between 0% and 30% of the yearly total number of 
patients in the period from 1986 to 2002 was referred for acute liver failure, 
with a mean of 15%. Of the 143 patients, 3 died before the indication for 
transplantation could be established and 47 did not meet the criteria for 
transplantation. Transplantation was refused in one case, and one patient 
was referred to another centre. Absolute contraindications were present in 
19 patients. Of the 72 patients that were enlisted 7 died and 65 were 
transplanted. The 1-year survival after transplantation was 69% (95% CI 
56% to 79%). Survival at 2 years was 68% (95% CI 55% to 78%) and at 5 
years 66% (95% CI 53% to 76%). When calculated on an intention-to-treat 
basis the 1-year survival was 63% (95% CI 50% to 73%). Transplantation 
improved the survival of enlisted patients, but significance was not reached 
(relative risk of death after transplantation 0.50, 95% CI 0.13 to 1.99, 
P=0.33, Cox analysis with transplantation as time-dependent factor). 
 
Acute rejection The overall incidence of acute rejection during the first 3 
months after liver transplantation in our patients was 31% (95% CI 26% to 
36%), with a peak at day 7. In the 155 patients treated with Interleukin-2 
Receptor Blocker's (IL2RB's) it was 18% (95% CI 13% to 26%), versus 
40% (95% CI 33% to 47%) in the 212 others (hazard ratio 0.37, 95% CI 
0.24 to 0.57, P<0.001, Cox regression analysis). In a preliminary univariate 
Cox analysis with acute rejection as time-dependent factor there was no 
effect on overall mortality (HR 1.15, 95% CI 0.76 to 1.72, P=0.509). Deaths 
between 10 and 182 days after transplantation were due to infections in 36 
(84%) out of 43 patients, contrary to earlier (9%) and later (23%) periods. 
When only these 32 intermediate-term deaths were analysed the effect of 
acute rejection was significant (HR 1.87, 95% CI 1.02 to 3.44, P=0.043). 
For earlier deaths the hazard ratio was 2.25 (95% CI 0.55 to 9.28, 
P=0.260) and for later ones 0.82 (95% CI 0.39 to 1.74, P=0.614). 
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DISCUSSION 
 
Indications and contraindications for transplantation The indications 
for liver transplantation fall within 7 broad categories. In the Netherlands 
there has been a large shift from the other liver diseases to acute liver 
failure, alcoholic liver disease and chronic viral hepatitis, with no changes 
for cholestatic liver diseases and HCC (table 3). 
 
Table 3: Composition of two Dutch groups of patients referred for liver 
transplantation in different periods. 
Center Groningen Rotterdam 
Period 1977-1985 1986-2002 
Acute liver failure 6 (2%) 143 (15%) 
Alcoholic liver disease 10 (3%) 120 (13%) 
Chronic viral hepatitis 0 (0%) 192 (20%) 
Cholestatic liver disease 67 (18%) 171 (18%) 
Hepatocellular carcinoma 56 (15%) 110 (12%) 
Other liver diseases 224 (62%) 204 (22%) 
 
Half of the patients referred to our centre for liver transplantation between 
1986 and 2002 had either no indication or various contraindications. This 
proportion has remained constant over time, in spite of more awareness of 
the possibility of liver transplantation as treatment of severe liver disease 
and the growing numbers of referrals. Apparently the greater awareness is 
not matched by an increase in the knowledge of the criteria for this form of 
treatment. It is up to the liver transplantation centres to put more effort into 
educating the referring physicians and the general public on the indications 
and contraindications of liver transplantation. This kind of knowledge 
transfer certainly would be worthwhile if the number of referrals based on 
unrealistic expectations could be reduced. 
 
Waiting time and waiting list events One of the major problems, in our 
centre as well as in many others, is the growing discrepancy between the 
number of patients on the liver transplantation waiting list and the number 
of available donor organs. As a consequence the waiting time for elective 
transplantations has increased to a median of 260 days in 2002, and the 
waiting list mortality has also risen. Changes in the allocation system were 
made to improve the situation, but these have not been very successful. 
Expanding the donor pool by accepting marginal donors and non-heart-
beating donors has become unavoidable14,15. The shortage of donors has 
also led to the expansion of living related donor transplantation16. 
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These measures cannot, however, be regarded as the most appropriate 
solutions of the problem, since they increase the risks of transplantation. 
Of the factors defining marginal donors, steatosis and prolonged ischemia 
have a negative influence on graft survival, especially when both are 
present14. In the case of living donor transplantation a second person, the 
donor, faces morbidity and even death17,18. We are, therefore, in urgent 
need of other measures aimed at optimising the use of the donor potential. 
In the mean time, the allocation system has to be improved in order to 
minimise the waiting list mortality and to optimise chances of a successful 
outcome of transplantation. One of the tools that has proven its value in 
this respect is the MELD-score19. It might, however, be possible to further 
enhance the efficiency of the liver graft allocation system by using a 
modified version of the MELD-score20. 
 
Heterotopic liver transplantation Our short-term experience with the 
heterotopic technique did seem to support the hypothesis that avoidance 
of the anhepatic phase during liver transplantation for chronic liver disease 
leads to better outcomes21. In practice heterotopic liver transplantation has 
not withstood the test of time, even though this hypothesis has not been 
tested in a formal study until recently. A definite answer could have been 
given by a comparison with orthotopic liver transplantation in a randomised 
controlled trial, but such a trial has never been done. Therefore, we have 
to rely on less direct evidence based on a case-control study11. Some 
patients in the heterotopic group have survived for at least 10 years12, but 
overall the results of orthotopic liver transplantation appeared to be better. 
The number of patients with acute liver failure in our heterotopic group is 
too small for a meaningful analysis. A larger number, including our 
patients, was reported in a multicentre study13 that unfortunately did not 
use a case-control design. Heterotopic transplantation for acute liver 
failure also failed to find general acceptance. 
 
Cholestatic liver disease Whereas the proportion of patients referred for 
PSC has remained constant over time, that of patients with PBC dropped 
by 75%. European Liver Transplant Registry data on the yearly numbers of 
transplantations for PBC also show a decline. One of the possible 
explanations is that the more widespread use of Ursodeoxycholic acid in 
the treatment of PBC has led to a better prognosis and a reduced need for 
transplantation22. In this category the proportion of referred patients that 
went on to transplantation was larger than in any of the other diagnostic 
groups, but a considerable number of patients either died on or had to be 
removed from the waiting list. As far as survival after transplantation is 
concerned, patients with cholestatic liver disease do better than most 
others. Still, there appears to be room for improvement by transplanting 
patients earlier in the course of their disease23. 
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Hepatocellular carcinoma Patients with HCC form a special category in 
several respects. First, because of the availability of an alternative form of 
treatment and the presence of contraindications in most of the referred 
patients, transplantation was considered to be possible in only 29% of the 
patients. Second, a third of those accepted for transplantation either died 
on the waiting list or had to be removed from the list because of tumour 
progression. Although we have applied the Milan criteria24 ever since they 
were first published, our drop-out rate from the waiting list exceeds that 
reported by others25-27 (table 4). Finally, it is generally accepted that 
survival after liver transplantation for HCC is lower than that after 
transplantation for other indications28, and the Rotterdam program is no 
exception to this rule. There clearly is a need to improve selection criteria 
and preoperative measures to control tumour progression29. 
 
Table 4: Rates of dropout from the waiting list and of transplantation for 
patients with hepatocellular carcinoma in different centers. 
Reference Year Enlisted Dropout Transplanted 
Llovet25 1999 87 8 (9%) 79 (91%) 
Yao26 2002 46 13 (28%) 21 (46%) 
Maddala27 2004 54 8 (15%) 46 (85%) 
Total  187 29 (16%) 146 (78%) 
Present study  32 11 (34%) 21 (66%) 
 
Acute liver failure First of all, there is little doubt that the dismal prognosis 
of patients with acute liver failure can be improved considerably by 
emergency liver transplantation, although it is hard to find statistical proof 
of this idea because an appropriate control group is lacking. Our updated 
figures are very similar to those we published in 200230. The 1-year 
survival is lower than that for elective transplantations, but the number of 
life-years gained probably is higher. In our series, one-year survival is 
above the European average, there were only few late deaths and most 
long-term survivors have been doing well, even though they develop a 
growing number of complications over time31. 
 
Acute rejection Even though acute rejection had no effect on overall 
mortality, it might be associated with a higher medium-term mortality. This 
discrepancy suggests that factors that protect against acute rejection lead 
to a higher late mortality. One obvious candidate is immunosuppression, 
but a more detailed analysis will have to be done to find support for this 
hypothesis. Meanwhile, there is every reason to aim at the lowest level of 
immunosuppression possible for every individual patient. To reach this 
goal a model to estimate the risk of acute rejection for transplanted 
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patients is needed, preferably based on a limited number of characteristics 
that are known immediately after transplantation. A model that might be 
used for such an estimate has been developed32, but the score based on 
this model requires external validation before it can be applied in practice. 
 
General conclusion Our study is one of the few describing the fate of 
patients referred for liver transplantation in some detail. Taken together, 
patients with acute liver failure and with chronic cholestatic liver diseases 
form one third of the total group. In these subgroups, the proportion 
moving on to enlistment and transplantation is higher than in any of the 
other categories, and the long-term results are at least comparable to the 
European average. However, some problems requiring more attention or 
further study were identified. Apparently more efforts are required to 
develop referral guidelines in co-operation with referring physicians. 
Development and testing of models that can be used to design a more 
efficient waiting list strategy is urgently needed. The incidence of early 
acute rejections has dropped since the introduction of potent new 
immunosuppressive agents, but this might well come at the cost of over-
immunosuppression and its negative effects. A more rational approach to 
the potentially harmful primary immunosuppressive regimen after liver 
transplantation could also serve to improve the results. 
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SUMMARY 
 
Background The Model for End-stage Liver Disease is used to establish 
priority on liver transplantation waiting lists. We analysed the predictive 
value of the model’s components in our chronic liver disease patients 
awaiting transplantation, since their independent contribution has not been 
proven in this setting. 
Methods We studied 359 chronic liver disease patients enlisted for 
transplantation in Rotterdam between 1986 and 2003. The model’s 
components were tested by logistic regression analysis and multivariate 
Cox analysis, in unaltered form and after logarithmic transformation. 
Survival was calculated using the Kaplan-Meier method. For external 
validation data on 271 patients from Brazil were used. 
Results Logarithmic transformation resulted in improvement of the 
predictive value of all three components of the original model. In the Cox 
analysis ln(bilirubin) (P<0.001) and ln(creatinine) (P=0.030) were 
significant, while ln(International Normalised Ratio) (P=0.216) was not. A 
score consisting of 10.1xln(ln(bilirubin in µmol/l)) + 8.9xln(ln(creatinine in 
µmol/l)) was derived from this model. The modified score was superior 
when compared to the MELD-score using logistic regression analysis in 
the modelling dataset. Minor differences were found for the Cox model c-
statistics, that was 85% using the MELD-score and 84% for the simplified 
model. These findings were partly confirmed in the validation dataset. 
Conclusion The use of log-transformed data led to simplification of the 
original model by deletion of the methodologically dubious International 
Normalised Ratio, without a significant loss of predictive value. To 
determine its general applicability our modified EMERALD-score requires 
further testing in patients enlisted for liver transplantation. 
 
 
INTRODUCTION 
 
Identifying predictors of survival for patients with liver diseases is important 
because they provide insight in disease mechanisms and can be used as 
an aid in decision making. Survival models can help in deciding when to 
offer liver transplantation to patients with progressive liver disease. Also, 
they can be used to give sicker patients a higher priority on the transplant 
waiting list. A number of models have been developed to predict survival of 
patients with chronic liver diseases. The Child-Pugh model1 is the oldest 
and the most frequently used one. Besides bilirubin, albumin and 
prothrombin time it uses two subjective parameters, namely clinical 
grading of ascites and encephalopathy, which can be seen as a 
disadvantage. Moreover, the Child-Pugh model treats bilirubin, albumin 
and prothrombin time as categorical variables, and disregards the 
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differences within the categories. Some of the newer models are specific 
for certain diseases such as Primary Biliary Cirrhosis2 or Primary 
Sclerosing Cholangitis3 and, therefore, are not suitable for general use. 
Others rely on invasive procedures like liver biopsy or on tests that are not 
widely used4-8. 
 
Recently the Model for End-stage Liver Disease9 (MELD) was developed 
to predict 3-month survival based on three readily available biochemical 
tests: bilirubin, creatinine and prothrombin time expressed as International 
Normalised Ratio (INR). The MELD-score is being used in clinical research 
as well as in liver transplantation waiting list and allocation systems10-16. 
Although the use of the MELD-score in the United States liver allograft 
allocation system has resulted in a reduction of both the number of newly 
registered patients and the waiting list mortality, it still has its 
shortcomings, as highlighted in a recent editorial17. The MELD-score was 
not specifically developed for patients with inborn errors of bilirubin 
metabolism, intrinsic renal disease or anticoagulant therapy with coumarin-
derivatives, and gives false predictions in these cases. Also, MELD may 
underestimate mortality in patients with refractory ascites. One of the 
proposed remedies is the addition of extra factors, such as serum 
sodium18. Another approach is a critical reappraisal of the predictive value 
of each of the individual MELD-score components, alone and in 
combination. We, therefore, studied the value of the MELD-score in 
predicting the outcome of our chronic liver disease patients awaiting liver 
transplantation. We also analysed the contribution of each of the MELD-
score components. Based on this second analysis we developed a 
simplified score that possibly offers advantages over the original version. 
Finally we subjected this simplified score to external validation. 
 
 
PATIENTS AND METHODS 
 
All consecutive patients with chronic liver diseases enlisted for 
transplantation at our center between October 1, 1986, and October 1, 
2003, were entered in the study. Clinical data and biochemical test results 
at the time of enlistment were retrieved from our liver transplantation 
database. All biochemical tests were done using standard automated 
techniques. Of the 372 patients entered in the study 13 were excluded 
because no INR was available. The final study group consisted of 215 
males and 144 females with a median age of 50 years (range 16-68 
years). The primary indication for transplantation was chronic viral hepatitis 
in 95 patients, alcoholic cirrhosis in 42, Primary Biliary Cirrhosis in 39, 
Primary Sclerosing Cholangitis in 47, cryptogenic cirrhosis in 36 and 
hepatocellular carcinoma in 32, various other liver diseases were present 
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in 68. The median MELD score was 13 (range 0-64). The distribution of 
the MELD scores is shown in figure 1. 
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Figure 1: distribution of MELD-scores in 359 patients enlisted for
liver transplantation in Rotterdam between 1986 and 2003
 
Of the 359 patients 257 were transplanted and 14 were removed from the 
waiting list. The main reason for removal from the list was tumor 
progression in patients with hepatocellular carcinoma. At the closing date 
of the study, 46 patients were still on the waiting list. The total number of 
patients who died on the waiting list was 42, with 27 deaths during the first 
three months after enlistment and 10 between four and six months. The 
waiting time was at least three months for 176 patients and at least six 
months for 102 patients. All deaths were directly attributable to liver failure. 
Over 90% of the follow-up was contributed by patients enlisted from 1997 
onwards, along with 30 of the 42 deaths (71%). 
 
The data used for external validation came from a group 271 of patients 
enlisted for liver transplantation in Porto Alegre, Southern Brazil, between 
January, 2001, and August, 2003. This group consisted of 165 males and 
106 females with a median age of 52 years (range 17-74 years). The 
primary indication for transplantation was chronic viral hepatitis in 151 
patients, alcoholic cirrhosis in 31, Primary Biliary Cirrhosis in 3, Primary 
Sclerosing Cholangitis in 2, cryptogenic cirrhosis in 13 and hepatocellular 
carcinoma in 51, various other liver diseases were present in 20. The 
median MELD score was 13 (range 2-49). Here 170 patients were 
transplanted and at the closing date of the study 33 patients were still on 
the waiting list. There were 68 deaths on the waiting list, 32 during the first 
three months after enlistment and 20 between four and six months. The 
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waiting time was at least three months for 214 patients and at least six 
months for 169 patients (table 1). 
 
Table 1: characteristics in the patient groups used for development and 
validation of the new liver transplantation waiting list survival model 
Variable  Modelling 
dataset 
Validation 
dataset 
Patients n 359 271 
Male/Female n / n 215 / 144 165 / 106 
Age in years median (range) 50 (16 – 68) 52 (17 – 74) 
Chronic viral hepatitis n (%) 95 (26%) 151 (56%) 
Alcoholic liver disease n (%) 42 (12%) 31 (11%) 
PBC or PSC n (%) 86 (24%) 5 (2%) 
Cryptogenic cirrhosis n (%) 36 (10%) 13 (5%) 
Hepatocellular carcinoma n (%) 32 (9%) 51 (19%) 
Other liver diseases n (%) 68 (19%) 20 (7%) 
MELD-score median (range) 13 (0 – 64) 13 (2 – 49) 
Transplanted n (%) 257 (72%) 170 (63%) 
Dead on waiting list at <3 months n (%) 27 (8%) 32 (12%) 
>3 months on waiting list n (%) 176 (49%) 214 (79%) 
Dead on waiting list at <6 months n (%) 37 (10%) 52 (19%) 
>6 months on waiting list n (%) 102 (28%) 169 (62%) 
Dead on waiting list total n (%) 42 (12%) 68 (25%) 
Alive and waiting at end of study n (%) 46 (13%) 33 (12%) 
 
The predictive value of each of the components of the MELD-score was 
tested by multivariate logistic regression analysis with 3-month survival as 
end-point, and by multivariate Cox regression analysis. The time of 
enlistment was the starting point of the analysis. In the Cox analysis, 
patients were censored at the moment of transplantation, at removal from 
the waiting list for other reasons, or when still alive and waiting on October 
1, 2003, the closing date of the study. Since the distributions of the values 
for bilirubin, creatinine and INR were skewed, all factors were tested again 
after logarithmic transformation. A step-backward approach was used to 
arrive at a modified model. For each patient a score was derived from this 
modified model in a manner analogous to that used to calculate the MELD-
score, by adding the natural logarithms of the relative risks for the 
components of the model and multiplying the sum by 10. Survival was 
calculated for different risk groups according to both scores using the 
Kaplan-Meier method. The value of both scores in predicting survival at 3 
and at 6 months was compared by logistic regression analysis and in 
predicting overall mortality by Cox regression analysis. We also compared 
the Receiver Operating Characteristic (ROC) curves at both time points 
CHAPTER 3a: MELD simplification 
 
33 
and the c-statistics of the two models. The method described by Harrell19 
was used for calculation of the c-statistics. All statistical tests were done 
using STATA (version 5.0, Stata Corporation, 702 University Drive East, 
College Station, TX 77840 USA). 
 
 
RESULTS 
 
First, the original MELD-score was tested in the 203 patients that either 
died within three months or had a follow-up of at least three months. Using 
univariate logistic regression analysis with 3-month survival as the end-
point, the MELD-score proved to be a highly significant predictor with a 
hazard ratio of 1.21 (95% CI 1.12-1.31, P<0.001) and a value of 0.857 for 
the area under the ROC curve. Then the three individual components of 
the MELD-score were entered in a similar analysis. The hazard ratio for 
bilirubin in mg/dl was 1.08 (95% CI 1.03-1.12, P=0.001) for creatinine in 
mg/dl 1.25 (95% CI 0.70-2.26, P=0.453) and for the INR 2.12 (95% CI 
0.90-4.98, P=0.085). The corresponding hazard ratio’s in a Cox analysis 
were 1.06 (1.04-1.08, P<0.001), 0.81 (95% CI 0.54-1.21, P=0.302) and 
1.85 (95% CI 1.21-2.84, P=0.004). In the original model the hazard ratio’s 
were 1.46, 2.61 and 3.06, respectively (table 2). 
 
Table 2: Logistic regression-analysis and Cox-analysis of Model for End-
stage Liver Disease components in patients awaiting liver transplantation. 
VARIABLE  Original MELD         
odds ratio 
Logistic regression 
analysis odds ratio 
(95% CI) 
Cox analysis hazard 
ratio (95% CI) 
Patients  N = 203 n = 359 
Bilirubin 1.461,2 1.08 (1.03 to 1.12)1,2 1.06 (1.04 to 1.08)1 
Creatinine 2.611,2 1.25 (0.70 to 2.26)1,2 0.81 (0.54 to 1.21)1 
INR 3.062 2.12 (0.90 to 4.98)2 1.86 (1.21 to 2.84) 
1) Calculated using concentrations in mg/dl 
2) Calculated with 3-month survival as endpoint 
 
The linearity and the predictive value for each of the individual MELD-
score components improved significantly after logarithmic transformation. 
In a second multivariate Cox-model using log-transformed data the hazard 
ratio for ln(bilirubin in µmol/l) was 2.49 (95% CI 1.78-3.49, P<0.001), for 
ln(creatinine in µmol/l) 1.93 (95% CI 1.07-3.49, P=0.030) and for ln(INR) 
2.06 (95% CI 0.65-6.50, P=0.216). When the INR was dropped from the 
model both bilirubin and creatinine remained significant, with P-values 
<0.001 and hazard ratio’s of 2.74 (95% CI 2.04-3.68) and 2.43 (95% CI 
1.53-3.88), respectively (table 3). A modified risk score consisting of 
10.1xln(ln(bilirubin in µmol/l)) + 8.9xln(ln(creatinine in µmol/l)) was derived 
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from this model, that was called the Erasmus Model for End-stage 
Resistant-to-therapy All-aetiology Liver Disease (EMERALD). 
 
Table 3: Multivariate Cox-analysis of Model for End-stage Liver Disease 
components in 359 patients awaiting liver transplantation. 
VARIABLE  Original 
MELD  
odds ratio 
Cox analysis               
hazard ratio 
(95% CI) 
Final Cox model          
hazard ratio 
(95% CI) 
Brazil dataset 
hazard ratio 
(95% CI) 
Bilirubin  1.461 2.49           
(1.78 to 3.49)2 
2.74               
(2.04 to 3.68)2 
2.14               
(1.56 to 2.96)2 
Creatinine 2.611 1.93           
(1.07 to 3.49)2 
2.43               
(1.53 to 3.88)2 
5.04                  
(2.86 to 8.90)2 
INR 3.06 2.06            
(0.65 to 6.50)3 
-- -- 
1) Calculated using concentrations in mg/dl 
2) Calculated using log-transformed concentrations in µmol/l 
3) Calculated using log-transformed values 
 
For each individual patient the MELD- and EMERALD-score was 
calculated and rounded to the nearest integer. Next, different risk 
categories were formed based on both scores, with cut-off points that were 
chosen so that each category contained at least 10 patients (figure 2). For 
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Figure 2: EMERALD versus MELD, survival at 3 and at 6 months
for different scores in 359 patients enlisted for liver transplantation
in Rotterdam between 1986 and 2003
EMERALD-scores up to 24 the survival at three months was 100%, with a 
gradual decline to 26% for scores of 32 or more. At six months a similar 
pattern was seen, with a decline to a survival of 46% for patients with a 
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score of 31, and 0% for scores of 32 or more. The survival at three months 
was 91-100% for MELD-scores up to 19, and declined to 50% for scores of 
20 or more. At six moths these figures were 79-100% and 27%, 
respectively. 
 
The EMERALD-score was compared to the MELD-score in a multivariate 
logistic model with both 3- and 6-month survival as end-point and in a 
multivariate Cox model. For survival at 3 months the MELD-score odds 
ratio was 1.09 (P=0.141), against 1.51 (P=0.024) for the EMERALD-score. 
With 6-month survival as the end-point these figures were 1.13 (P=0.063) 
versus 1.71 (P=0.005). In the Cox model the hazard ratio for the MELD-
score was 1.02 (P=0.468) and for the EMERALD-score 1.51 (P=0.001). 
We also calculated the sensitivity and the specificity of both scores. The 
ROC curves for the two scores predicting three-month and six-month 
mortality were almost identical (figure 3). The areas under the curve were 
86% and 85% for the MELD-score, respectively, versus 85% and 87% for 
the EMERALD-score. The Cox model c-statistics were 85% for MELD and 
84% for EMERALD. 
3 MONTHS
0
20
40
60
80
100
0 20 40 60 80 100
100 - specificity (%)
s
e
n
s
iti
v
ity
 
(%
)
EMERALD
6 MONTHS
0
20
40
60
80
100
0 20 40 60 80 100
100 - specificity (%)
s
e
n
s
iti
v
ity
 
(%
)
MELD
Figure 3: receiver operating characteristics for EMERALD- and
MELD-scores with 3-month and 6-month survival as endpoint in 359
patients enlisted for liver transplantation in Rotterdam, 1986-2003
 
In the validation dataset we checked the predictive value of ln(bilirubin in 
µmol/l) (hazard ratio 2.14, 95% CI 1.55-2.96, P<0.001), and ln(creatinine in 
µmol/l) (hazard ratio 5.05, 95% CI 2.86-8.90, P=<0.001) using Cox 
regression analysis. Here too we compared both scores in multivariate 
models. For survival at 3 months the MELD-score odds ratio was 1.20 
(P=0.002), against 1.00 (P=0.982) for the EMERALD-score. With 6-month 
survival as the end-point these figures were 1.15 (P=0.004) versus 1.04 
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(P=0.787). In the Cox model the hazard ratio for the MELD- and 
EMERALD-score was 1.11 (P=<0.001) and 1.07 (P=0.294), respectively 
(table 4). 
 
Table 4: multivariate comparisons of the MELD- and EMERALD-scores in 
the modelling and validation datasets using different endpoints 
Statistical test Endpoint Score Modelling 
dataset      
P 
Validation 
dataset      
P 
Logistic regression 
analysis 
3-month mortality MELD 
EMERALD 
0.141 
0.024 
0.002 
0.982 
Logistic regression 
analysis 
6-month mortality MELD 
EMERALD 
0.063 
0.005 
0.004 
0.787 
Cox regression 
analysis 
overall mortality MELD 
EMERALD 
0.593 
<0.001 
<0.001 
0.294 
 
Finally we calculated the area under the ROC curve for both scores. For 
MELD with 3-month mortality as endpoint this value was 78%,  against 
74% for EMERALD. With 6-month mortality as endpoint values of 71% and 
70%, respectively, were found. Here the Cox model c-statistics were 70% 
for MELD and 68% for EMERALD (table 5). 
 
Table 5: comparison of the performance of the MELD- and EMERALD-
scores in predicting 3-month, 6-month and overall mortality in the 
modelling dataset and the validation dataset. 
End-
point 
Data z-score Area under the receiver 
operating characteristic 
curve 
  MELD EMERALD MELD EMERALD 
Modelling set 4.921 5.311 0.86 0.85 3-month 
mortality Validation set 5.081 4.371 0.78 0.74 
Modelling set 5.051 5.251 0.85 0.87 6-month 
mortality Validation set 4.781 4.191 0.71 0.70 
Modelling set 9.871 9.021 0.852 0.842 overall 
mortality Validation set 8.381 4.891 0.702 0.682 
1) P<0.001 
2) c-statistics 
 
 
DISCUSSION 
 
For validation of the MELD-score and of its individual components in a liver 
transplantation waiting list setting, we used logistic regression analysis in 
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our cohort of patients, with 3-month survival as end-point. Our study 
confirms the predictive value of the MELD-score, with an area under the 
ROC curve similar to that found in one study16 but lower than that found in 
another18. However, of the hazard ratios for the three MELD-score 
components calculated from the model specifications, only that for the INR 
was found to lie within the 95% confidence interval found in the present 
study, and only the serum bilirubin concentration proved to be significant in 
our patients. These findings can be explained by the fact that our patient 
group differs from those used for development and validation of the MELD-
score. 
 
Compared to logistic regression analysis, Cox analysis has the advantage 
of allowing incomplete follow up, so more patients can be included and a 
longer period can be studied. This last point is important since at the 
moment waiting times for liver transplantation exceed 3 months for many 
patients. The result of our Cox analysis was similar to that of the logistic 
regression analysis, but the INR regained its significance. Logarithmic 
transformation improved the performance of each of the individual MELD-
score components, but in a multivariate Cox-model only serum bilirubin 
and creatinine concentrations remained as independent predictors. 
 
The INR is included in the MELD-score, but is not a factor in our simplified 
score. Apart from its lack of significance, there are two other points that 
make the INR less suitable for use in establishing priority on 
transplantation waiting lists. First, it has not been proven that calculation of 
the INR is the proper way to standardise prothrombin time measurements 
in patients with liver failure20,21. Second, the INR can be influenced by 
factors not directly related to liver failure, such as vitamin K deficiency, 
treatment with oral anticoagulants or intravenous administration of 
coagulation factors. 
 
We, therefore, propose a modification of the MELD-score based on a 
simplified model derived from a Cox-analysis in an actual waiting list 
patient cohort, consisting of only the log-transformed serum bilirubin and 
creatinine concentrations, that solves at least one of the problems of the 
original version. An earlier study by others using logistic regression 
analysis in a different patient group resulted in a similar model also 
containing log-transformed serum bilirubin and creatinine concentrations22. 
In another study mentioned earlier18 the serum sodium concentration was 
found to be an independent predictor of death when added to the original 
MELD-score. Identification of an additional risk factor is of course useful, 
but does not necessarily lead to a significantly better predictive model. In 
fact, the improvement reached by adding the serum sodium to the MELD-
score can at best be called modest, with an increase of the area under the 
ROC curve by less than 2 percent points. 
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Like all new scoring systems ours requires external validation. This was 
done in collaboration with the group from Porto Alegre in Southern Brazil. 
Although the prognostic value of the two log-transformed components of 
our model was confirmed, the overlap between the 95% confidence 
intervals of the hazard ratios was less than 50% for the serum creatinine 
concentration. The area under the receiver operating characteristic curve 
for the EMERALD-score was about equal to that for the MELD-score in the 
modelling dataset as well as in the validation dataset with both 3- and 6-
month mortality as endpoint. The same can be said for the Cox model c-
statistics. The EMERALD-score performed less well in the validation 
dataset than in the modelling dataset, but so did the MELD-score. There 
are, however, differences between the two patient groups, not only in the 
distribution of the indications for transplantation but also in waiting times 
and waiting list mortality. Although these differences may explain the 
results of our comparison, further testing and probably some adjustment of 
our model remains necessary. 
 
Still, our simplified score has advantages over the original MELD-score. It  
was developed in a more relevant patient population, and operates over a 
longer time period. Also, it eliminates the problems associated with the use 
of the International Normalised Ratio. On the other hand, it still is not clear 
how patients with inborn errors of bilirubin metabolism, intrinsic renal 
disease or a decline of their renal function due to other factors should be 
dealt with. Calculation of our modified score requires a double logarithmic 
transformation of both bilirubin and creatinine values, but this can be done, 
for instance, using web-based tools like the one for calculating the MELD-
score (http://www.mayoclinic.org/gi-rst/mayomodel5.html). Our modified 
score is not perfect, and it does not correctly identify all patients who will 
and will not survive until transplantation. Nevertheless, the use of log-
transformed values for bilirubin and creatinine probably will improve our 
ability to predict the fate of patients on the waiting list for liver 
transplantation. 
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SUMMARY 
 
The current opinion is that liver transplantation for chronic cholestatic liver 
disease should be done before the terminal, high-risk stage. However, most 
studies do not take waiting list mortality into account. We analysed 113 
consecutive patients with chronic cholestatic liver disease, stratified 
according to estimated survival. Overall and post-transplantation survival 
was calculated using the Kaplan-Meier method. Including patients who died 
awaiting transplantation lowered the one-year survival by 19% in the high-
risk category. In this group survival at 4 years was 45%, with an estimated 
survival benefit of 45%. For the intermediate- and low-risk groups these 
numbers were 56% and 36% versus 81% and 7%. Including the waiting list 
period in the analysis of the benefits of liver transplantation strengthens the 
case for early transplantation. Our study confirms that liver transplantation 
should be considered before the high-risk stage of chronic cholestatic liver 
disease is reached. 
 
 
INTRODUCTION 
 
For patients with chronic liver disease and a poor prognosis or a low quality 
of life, liver transplantation is the treatment of choice. A patient-centred 
approach leads to priority for the sickest patients on the transplantation 
waiting lists. There are, however, more ways to determine the optimal timing 
of transplantation for patients with chronic liver disease. When viewed from 
the perspective of the donor, the aim should be a maximal survival after 
transplantation. Yet another goal is a maximal survival benefit, calculated as 
the difference between estimated survival without transplantation and 
estimated or actual survival with transplantation. Each of these approaches 
requires estimation of the risk of dying without transplantation, which can be 
done for groups but is unreliable for individual patients. Primary Biliary 
Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC) are chronic 
cholestatic liver diseases that are routinely treated with Ursodeoxycholic 
acid but, nevertheless, usually are progressive. PBC and PSC can serve as 
prototypes to study the effect of liver transplantation, since survival models 
are available for both1,2. 
 
The current opinion in the United States3 as well as in Europe4 is that in 
patients with chronic cholestatic liver disease transplantation should be 
carried out before they reach the terminal, high-risk stage of their disease, 
as the larger number of life-years gained by transplantation in the high-risk 
category is offset by a lower survival after transplantation. However, only 
one study on this issue has included patients who died on the waiting list for 
transplantation5. Patients that die awaiting liver transplantation could have 
an important impact on survival estimates, and including them might 
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strengthen the case for early transplantation. We therefore studied the 
survival in our series of 113 patients with cholestatic liver disease enlisted 
for liver transplantation. We calculated the 1- 2-, 3- and 4-year survival for 
all patients and for transplanted patients only in three different risk 
categories. We also compared the estimated and the actual survival of all 
patients at 1, 2, 3 and 4 years for the different risk categories. 
 
 
METHODS 
 
Study design and study population 
We included all consecutive patients with cholestatic liver disease who were 
accepted as candidates for liver transplantation from October, 1986, through 
September, 2004. Indications for liver transplantation were end-stage liver 
disease as evidenced by a score > 8 points in the Child-Pugh classification6. 
Patients in earlier stages of their disease were also enlisted because of life 
threatening complications like spontaneous bacterial peritonitis, recurrent 
bacterial cholangitis and recurrent oesophageal variceal bleeding, or a 
severely diminished quality of life because of pruritus or fatigue. Persistent 
extrahepatic infectious foci, extrahepatic malignancy including cholangio-
carcinoma and other diseases that directly influence the prognosis with or 
without liver transplantation were considered as absolute contra-indications. 
 
The time of entry for this study was defined as the date of enlistment for liver 
transplantation. Patient characteristics and the most recent clinical and 
laboratory data available at the moment of inclusion needed to apply the 
Mayo models for survival of PBC and PSC patients were extracted from the 
patient files. The moment of liver transplantation was defined as the time 
and date of reperfusion of the transplanted organ. The follow up of all 73 
surviving patients is complete until 30 September 2004, the closing date of 
this study. 
 
Statistics 
The Mayo risk score at entry in the study was calculated for all PBC patients 
{[0.871xln(bilirubin in mg/dl)] – [2.53xln(albumin in g/dl)] + [0.039x(age in 
years)] + [2.38xln(prothrombin time in s)] + [0.859x(edema score)]} and for 
all PSC patients {[0.03x(age in years)] + [0.54xln(bilirubin in mg/dl)] + 
[0.54xln(AST in U/l)] + [1.24x(variceal bleeding Y=1/N=0)] – [0.84x(albumin 
in g/dl)]}. 
 
Patients were classified as high risk with an estimated median survival of 
up to one year when they scored more than 8.2 points in the Mayo PBC 
formula or more than 3.9 points in the Mayo PSC formula. The 
intermediate risk category with an estimated median survival of 1 to 3 
years was formed by patients with a score of 6.8 to 8.2 in the Mayo PBC 
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model or 2.6 to 3.9 points in the Mayo PSC model. The low risk group with 
an estimated median survival > 3 years comprised the remaining patients. 
 
The survival probabilities without transplantation for each individual patient 
at 1, 2, 3 and 4 years were estimated from the risk score using the 
appropriate model. The 1, 2, 3 and 4 year survival for the total group and for 
the transplanted patients only was estimated using the Kaplan-Meier 
method. 
 
 
RESULTS 
 
Included were 113 patients, 48 males and 65 females, with a median age of 
49 years (range 15 to 67 years). Over two-thirds of the patients were 
enlisted in the second half of the study period, and <10% in the period 
before 1990. The liver disease was PBC in 46 patients and PSC in 67 
patients. Liver transplantation was performed in 85 patients. At least one 
retransplantation was necessary in 14 patients. There were 2 peroperative 
deaths and 27 postoperative deaths in this series. Of the PBC patients 18 
fell in the high-risk category, 16 in the intermediate risk category and 12 in 
the low risk category against 4, 22 and 41 of the PSC patients, respectively. 
 
 At the closing date of the study 14 patients were still on the waiting list, 
three were removed from the waiting list because of extrahepatic 
malignancies, and 11 died while waiting. The median waiting time for 
transplantation was 23 days (range 2-104 days) in the high-risk group, 40 
days (3-593 days) in the intermediate-risk group, and 166 days (7-459 days) 
in the low-risk group (table 1). The median follow up of the 73 survivors was 
1810 days (range 18-5499 days). 
 
Table 1: Waiting times and outcomes in the different risk categories. 
————————————————————————————————————————— 
Risk category High Intermediate Low 
————————————————————————————————————————— 
Estimated median survival < 1 year 1-3 years > 3 years 
 Total  22  38  53 
PBC 18  16  12 
PSC   4  22  41 
 Still waiting or removed, n=  1  4  12 
Waiting time in days, median (range) 375 (-)  113 (18-246) 320 (44-949) 
 Deaths on the waiting list, n=  7  2  2 
Waiting time in days, median (range) 30 (6-89) - (129-390) - (212-446) 
 Transplanted, n=  14  32  39 
Waiting time in days, median (range) 23 (2-104) 40 (3-593) 166 (7-459) 
 Per- and post-operative deaths, n=  6  15  8 
 All deaths, n=  13  17  10 
————————————————————————————————————————— 
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The 1-year survival calculated according to the intention-to-treat principle 
was 45% in the high-risk group, 69% in the intermediate risk category and 
94% in the low risk category. When only transplanted patients are 
considered the 1-year survival rises from 45% to 64% in the high-risk 
category, with no major changes in the other two groups (table 2). 
 
Table 2: Effect of patient selection on survival in the different risk groups. 
————————————————————————————————————————— 
Risk category High Intermediate Low 
————————————————————————————————————————— 
All candidates, n= 22 38 53 
- Actual 1-year survival, % - 45 - 69 - 94  
- (95% confidence interval) - (24-64) - (51-82) - (82-98) 
Transplanted patients, n= 14 32 39 
- Survival 1 year post OLT, % - 64 - 69 - 89  
- (95% confidence interval) - (34-83) - (49-82) - (74-96) 
————————————————————————————————————————— 
Note: The actual 1-year survival percentages were calculated using the Kaplan-Meier method. 
 
In the high-risk group the survival at 2, 3 and 4 years remains 45%. The 
survival at 2, 3 and 4 years was 63%, 63% and 56% in the intermediate-
risk group, versus 84%, 84% and 81% in the low-risk group. The largest 
survival benefit of transplantation is found in the high risk category, here 
the difference between estimated survival without liver transplantation and 
actual survival is 18% at 1 year, 38% at 2 years and 45% at 3 and 4 years. 
These figures are -3%, 14%, 32% and 36% in the intermediate risk group, 
and 0%, -3%, 4% and 7% in the low risk group, respectively (table 3). 
 
Table 3: Comparison of the estimated survival without transplantation with 
the actual survival in the different risk categories. 
———————————————————————————————————————— 
Risk category High Intermediate Low 
———————————————————————————————————————— 
All candidates, n= 22 38 53 
Median estimated survival at 
 1 year, % (range) 27 (0-49) 72 (50-83) 94 (86-100) 
 2 years, % (range)   7 (0-24) 49 (22-69) 87 (70-100) 
 3 years, % (range)   0 (0-6) 31 (7-49) 80 (57-100) 
 4 years, % (range)   0 (0-2) 20 (2-39) 74 (44-100) 
Actual survival at 
 1 year, % (95% CI) 45 (24-64) 69 (51-82) 94 (82-98) 
 2 years, % (95% CI) 45 (24-64) 63 (45-77) 84 (69-92) 
 3 years, % (95% CI) 45 (24-64) 63 (45-77) 84 (69-92) 
 4 years, % (95% CI) 45 (24-64) 56 (37-71) 81 (65-90) 
Median survival benefit at 
 1 year, % 18  -3   0 
 2 years, % 38 14  -3 
 3 years, % 45 32   4 
 4 years, % 45 36   7 
———————————————————————————————————————— 
Note: The estimated survival probabilities were calculated using the Mayo-models for PBC 
and PSC. The actual survival was calculated using the Kaplan-Meier method. 
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DISCUSSION 
 
There were two questions that led to this study. The first one is about the 
effect of including the waiting list period in the analysis of the survival of 
liver transplantation candidates. Our data on patients with chronic 
cholestatic liver disease show a considerable difference between the total 
group and the transplanted patients in the category with the highest risk. In 
the patient group with an estimated survival of 1 year or less, the actual 1-
year survival decreases by 19% when patients who die without 
transplantation are included. The magnitude of the effect of including the 
waiting period in the analysis of survival depends on the waiting time, 
which is relatively short in our high-risk patients. This effect probably will 
be larger when the waiting time increases. In the intermediate and the low 
risk categories, with an estimated median survival of 1 year or more, 
survival is not significantly influenced by the waiting list mortality. Here, 
too, a larger effect might well be found with longer waiting times. 
 
The second question is what the overall outcome is for the different risk 
categories in terms of absolute survival and survival benefit. As expected, 
the highest absolute survival is found in our low-risk patients, but in this 
group there appears to be no meaningful survival benefit at a follow up of 
up to 4 years. In our study the effect of the waiting list mortality is 
negligible in the intermediate-risk group, but the postoperative mortality 
approaches that in the high-risk category. The largest survival benefit of 
liver transplantation is found in the group with the lowest estimated 
survival, even when patients who die without transplantation are included. 
This gain comes at the price of a one-year mortality of 55% in our high-risk 
patients. 
 
The final point is what the implications of our study are for the waiting list 
policy. It would be unfair to deny high-risk patients the chance of liver 
transplantation because of an increased postoperative mortality, and the 
largest survival benefit is found in this group. Although the current 
postoperative survival for high-risk patients may be higher than in our series, 
it is likely to remain worse than in the other groups. The effect of the waiting 
list mortality will not disappear, and can only become stronger with longer 
waiting times. When high-risk patients are informed about their prognosis, 
the waiting list mortality certainly should be included. 
 
When a lower postoperative mortality than in our series can be attained, 
intermediate-risk patients are the most attractive candidates for liver 
transplantation. Both waiting list mortality and postoperative mortality will be 
lower than in high-risk patients, and there is a substantial survival benefit, 
certainly on the longer term. Thus two of the three goals mentioned in the 
introduction would be reached. For selected low-risk patients with a 
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relatively good prognosis but a poor quality of life, liver transplantation also 
seems worthwhile, since it does not diminish survival on the short term and 
may well improve it on the longer term. In general, a policy of transplantation 
in an early disease stage would reduce the waiting list mortality and improve 
both overall and post-transplantation survival. Whenever possible, 
transplantation should not be postponed until the terminal, high-risk stage of 
chronic liver disease is reached. 
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Introduction
For patients with chronic liver disease and a poor prog-
nosis or a low quality of life, liver transplantation is the
treatment of choice. A patient-centred approach leads to
priority for the sickest patients on the transplantation
waiting lists. There are, however, more ways to determine
the optimal timing of transplantation for patients with
chronic liver disease. When viewed from the perspective
of the donor, the aim should be a maximal survival after
transplantation. Yet another goal is a maximal survival
benefit, calculated as the difference between estimated
survival without transplantation and estimated or actual
survival with transplantation. Each of these approaches
requires estimation of the risk of dying without trans-
plantation, which can be done for groups but is unrelia-
ble for individual patients. Primary biliary cirrhosis
(PBC) and primary sclerosing cholangitis (PSC) are chro-
nic cholestatic liver diseases that are routinely treated
with ursodeoxycholic acid but, nevertheless, usually are
progressive. PBC and PSC can serve as prototypes to
study the effect of liver transplantation, as survival models
are available for both [1,2].
The current opinion in the United States as well as in
Europe is that in patients with chronic cholestatic liver
disease transplantation should be carried out before they
reach the terminal, high-risk stage of their disease, as the
larger number of life-years gained by transplantation in
the high-risk category is offset by a lower survival after
transplantation [3,4]. However, only one study on this
issue has included patients who died on the waiting list
for transplantation [5]. Patients that die awaiting liver
transplantation could have an important impact on survi-
val estimates, and including them might strengthen the
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Summary
The current opinion is that liver transplantation for chronic cholestatic liver
disease should be done before the terminal, high-risk stage. However, most
studies do not take waiting list mortality into account. We analysed 113 con-
secutive patients with chronic cholestatic liver disease, stratified according to
estimated survival. Overall and post-transplantation survival was calculated
using the Kaplan–Meier method. Including patients who died awaiting trans-
plantation lowered the 1-year survival by 19% in the high-risk category. In this
group survival at 4 years was 45%, with an estimated survival benefit of 45%.
For the intermediate- and low-risk groups these numbers were 56% and 36%
vs. 81% and 7%. Including the waiting list period in the analysis of the benefits
of liver transplantation strengthens the case for early transplantation. Our study
confirms that liver transplantation should be considered before the high-risk
stage of chronic cholestatic liver disease is reached.
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case for early transplantation. We therefore studied the
survival in our series of 113 patients with cholestatic liver
disease enlisted for liver transplantation. We calculated
the 1-, 2-, 3- and 4-year survival for all patients and for
transplanted patients only in three different risk categor-
ies. We also compared the estimated and the actual survi-
val of all patients at 1, 2, 3 and 4 years for the different
risk categories.
Methods
Study design and study population
We included all consecutive patients with cholestatic liver
disease who were accepted as candidates for liver trans-
plantation from October, 1986, through September, 2004.
Indications for liver transplantation were end-stage liver
disease as evidenced by a score >8 points in the Child-
Pugh classification [6]. Patients in earlier stages of their
disease were also enlisted because of life threatening com-
plications like spontaneous bacterial peritonitis, recurrent
bacterial cholangitis and recurrent oesophageal variceal
bleeding, or a severely diminished quality of life because
of pruritus or fatigue. Persistent extrahepatic infectious
foci, extrahepatic malignancy including cholangiocarcino-
ma and other diseases that directly influence the progno-
sis with or without liver transplantation were considered
as absolute contra-indications.
The time of entry for this study was defined as the date
of enlistment for liver transplantation. Patient characteris-
tics and the most recent clinical and laboratory data avail-
able at the moment of inclusion needed to apply the
Mayo models for survival of PBC and PSC patients were
extracted from the patient files. The moment of liver
transplantation was defined as the time and date of reper-
fusion of the transplanted organ. The follow-up of all 73
surviving patients is complete until 30 September 2004,
the closing date of this study.
Statistics
The Mayo risk score at entry in the study was calculated
for all PBC patients {[0.871 · ln(bilirubin in mg/
dl)] ) [2.53 · ln(albumin in g/dl)] + [0.039 · (age in
years)] + [2.38 · ln(prothrombin time in s)] + [0.859 ·
(oedema score)]} and for all PSC patients {[0.03 · (age
in years)] + [0.54 · ln(bilirubin in mg/dl)] + [0.54 ·
ln(AST in U/l)] + [1.24 · (variceal bleeding Y ¼ 1/N ¼
0)] ) [0.84 · (albumin in g/dl)]}.
Patients were classified as high risk with an estimated
median survival of up to 1 year when they scored more
than 8.2 points in the Mayo PBC formula or more
than 3.9 points in the Mayo PSC formula. The inter-
mediate risk category with an estimated median survival
of 1–3 years was formed by patients with a score of
6.8–8.2 in the Mayo PBC model or 2.6–3.9 points in
the Mayo PSC model. The low risk group with an esti-
mated median survival >3 years comprised the remain-
ing patients.
The survival probabilities without transplantation for
each individual patient at 1, 2, 3 and 4 years were estima-
ted from the risk score using the appropriate model. The
1, 2, 3 and 4 year survival for the total group and for
the transplanted patients only was estimated using the
Kaplan–Meier method.
Results
Included were 113 patients, 48 males and 65 females,
with a median age of 49 years (range 15–67 years). Over
two-thirds of the patients were enlisted in the second
half of the study period, and <10% in the period before
1990. The liver disease was PBC in 46 patients and PSC
in 67 patients. Liver transplantation was performed in
85 patients. At least one retransplantation was necessary
in 14 patients. There were two peroperative deaths and
27 postoperative deaths in this series. Of the PBC
patients 18 fell in the high-risk category, 16 in the inter-
mediate risk category and 12 in the low risk category
against 4, 22 and 41 of the PSC patients, respectively.
At the closing date of the study 14 patients were still on
the waiting list, three were removed from the waiting
list because of extrahepatic malignancies, and 11 died
while waiting. The median waiting time for transplanta-
tion was 23 days (range 2–104 days) in the high-risk
group, 40 days (3–593 days) in the intermediate-risk
group, and 166 days (7–459 days) in the low-risk group
(Table 1). The median follow up of the 73 survivors was
1810 days (range 18–5499 days).
The 1-year survival calculated according to the inten-
tion-to-treat principle was 45% in the high-risk group,
69% in the intermediate risk category and 94% in the
low risk category. When only transplanted patients are
considered the 1-year survival rises from 45% to 64% in
the high-risk category, with no major changes in the
other two groups (Table 2). In the high-risk group the
survival at 2, 3 and 4 years remains 45%. The survival at
2, 3 and 4 years was 63%, 63% and 56% in the interme-
diate-risk group, vs. 84%, 84% and 81% in the low-risk
group, respectively. The largest survival benefit of trans-
plantation is found in the high risk category, here the
difference between estimated survival without liver trans-
plantation and actual survival is 18% at 1 year, 38% at
2 years and 45% at 3 and 4 years. These figures are )3%,
14%, 32% and 36% in the intermediate risk group, and
0%, )3%, 4% and 7% in the low risk group, respectively
(Table 3).
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Discussion
There were two questions that led to this study. The first
one is about the effect of including the waiting list period
in the analysis of the survival of liver transplantation can-
didates. Our data on patients with chronic cholestatic
liver disease show a considerable difference between the
total group and the transplanted patients in the category
with the highest risk. In the patient group with an esti-
mated survival of 1 year or less, the actual 1-year survival
decreases by 19% when patients who die without trans-
plantation are included. The magnitude of the effect of
including the waiting period in the analysis of survival
depends on the waiting time, which is relatively short in
our high-risk patients. This effect probably will be larger
when the waiting time increases. In the intermediate and
the low risk categories, with an estimated median survival
of 1 year or more, survival is not significantly influenced
by the waiting list mortality. Here, too, a larger effect
might well be found with longer waiting times.
The second question is what the overall outcome is for
the different risk categories in terms of absolute survival
and survival benefit. As expected, the highest absolute
survival is found in our low-risk patients, but in this
group there appears to be no meaningful survival benefit
at a follow up of up to 4 years. In our study the effect of
the waiting list mortality is negligible in the intermediate-
risk group, but the postoperative mortality approaches
that in the high-risk category. The largest survival benefit
of liver transplantation is found in the group with the
lowest estimated survival, even when patients who die
without transplantation are included. This gain comes at
the price of a 1-year mortality of 55% in our high-risk
patients.
Table 1. Waiting times and outcomes
in the different risk categories. Risk category High Intermediate Low
Estimated median survival <1 year 1–3 years >3 years
Total 22 38 53
PBC 18 16 12
PSC 4 22 41
Still waiting or removed (n) 1 4 12
Waiting time in days [median (range)] 375 113 (18–246) 320 (44–949)
Deaths on the waiting list (n) 7 2 2
Waiting time in days [median (range)] 30 (6–89) 129, 390 212, 446
Transplanted (n) 14 32 39
Waiting time in days [median (range)] 23 (2–104) 40 (3–593) 166 (7–459)
Per- and postoperative deaths (n) 6 15 8
All deaths (n) 13 17 10
Table 2. Effect of patient selection
on survival in the different risk categories. Risk category High Intermediate Low
All candidates (n) 22 38 53
Actual 1-year survival
[% (95% confidence interval)]
45 (24–64) 69 (51–82) 94 (82–98)
Transplanted patients (n) 14 32 39
Survival 1 year post OLT
[% (95% confidence interval)]
64 (34–83) 69 (49–82) 89 (74–96)
Note: The actual 1-year survival percentages were calculated using the Kaplan–Meier method.
Table 3. Comparison of the estimated survival without transplanta-
tion with the actual survival in the different risk categories.
Risk category High Intermediate Low
All candidates (n) 22 38 53
Median estimated survival [% (range)]
1 year 27 (0–49) 72 (50–83) 94 (86–100)
2 years 7 (0–24) 49 (22–69) 87 (70–100)
3 years 0 (0–6) 31 (7–49) 80 (57–100)
4 years 0 (0–2) 20 (2–39) 74 (44–100)
Actual survival [% (95% CI)]
1 year 45 (24–64) 69 (51–82) 94 (82–98)
2 years 45 (24–64) 63 (45–77) 84 (69–92)
3 years 45 (24–64) 63 (45–77) 84 (69–92)
4 years 45 (24–64) 56 (37–71) 81 (65–90)
Median survival benefit (%)
1 year 18 )3 0
2 years 38 14 )3
3 years 45 32 4
4 years 45 36 7
Note: The estimated survival probabilities were calculated using the
Mayo-models for PBC and PSC. The actual survival was calculated
using the Kaplan–Meier method.
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The final point is what the implications of our study
are for the waiting list policy. It would be unfair to deny
high-risk patients the chance of liver transplantation
because of an increased postoperative mortality, and the
largest survival benefit is found in this group. Although
the current postoperative survival for high-risk patients
may be higher than in our series, it is likely to remain
worse than in the other groups. The effect of the waiting
list mortality will not disappear, and can only become
stronger with longer waiting times. When high-risk
patients are informed about their prognosis, the waiting
list mortality certainly should be included.
When a lower postoperative mortality than in our ser-
ies can be attained, intermediate-risk patients are the
most attractive candidates for liver transplantation. Both
waiting list mortality and postoperative mortality will be
lower than in high-risk patients, and there is a substantial
survival benefit, certainly on the longer term. Thus two of
the three goals mentioned in the introduction would be
reached. For selected low-risk patients with a relatively
good prognosis but a poor quality of life, liver transplan-
tation also seems worthwhile, as it does not diminish sur-
vival on the short term and may well improve it on the
longer term. In general, a policy of transplantation in an
early disease stage would reduce the waiting list mortality
and improve both overall and post-transplantation survi-
val. Whenever possible, transplantation should not be
postponed until the terminal, high-risk stage of chronic
liver disease is reached.
Appendix
The Rotterdam Liver Transplantation Group is formed by
HLA Janssen, RJ de Knegt, J Kwekkeboom, RA de Man,
HJ Metselaar, S de Rave, SW Schalm, Department of
Gastroenterology and Hepatology; CHJ van Eijck,
G. Kazemier, HW Tilanus, JNM Ijzermans, Department
of Surgery; ThN Groenland, L Visser, Department of
Anaesthesiology; PE Zondervan, Department of Patho-
logy; W Weimar, Department of Internal Medicine, Eras-
mus Medical Center Rotterdam, Dr Molewaterplein 40,
3015 GD Rotterdam, The Netherlands.
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SUMMARY 
 
Background Between 1986 and 1990 we performed heterotopic liver 
transplantation (HLT) in 17 patients with chronic liver disease. In spite of 
theoretical advantages and favorable short-term results, we abandoned 
HLT because of doubts about the long-term outcome and the improved 
results of standard orthotopic liver transplantation (OLT). There are, 
however, no studies comparing the long-term survival after HLT and OLT 
for chronic liver disease. 
Patients and methods We performed a case-control study of HLT vs. 
OLT, with long-term patient and graft survival as the main outcome 
measures. Known confounders and differences in baseline characteristics 
between HLT and OLT patients were corrected for. 
Results At 1 year, 5 of the 17 HLT patients had died, compared with 9 of 
the 34 OLT patients (relative risk [RR] 1.15; 95% confidence interval [CI] 
0.33-4.02; P=0.83). After correction for confounders, the long-term risk of 
graft failure (RR, 18.0; 95% CI, 1.5-223.5; P=0.02) and of death (RR, 5.2; 
95% CI, 0.8-34.8; P=0.09) was higher after HLT than after OLT. The main 
causes of graft loss and death at more than 1 year after HLT were de novo 
malignancies and a variety of biliary complications. 
Conclusions In conclusion, our data, from one of the largest single-center 
series of HLT available, showed no significant difference between HLT and 
OLT in 1-year survival. However, the long-term outcome of HLT was 
inferior. HLT cannot be recommended as an alternative to OLT for any of 
the indications we studied, even though only 1 of the late deaths was 
definitely related to the heterotopic technique. 
 
 
INTRODUCTION 
 
In 1988, we reported on the favorable short-term results of auxiliary partial 
liver transplantation in a small number of patients with end-stage chronic 
liver disease.1 Originally, this procedure, which will be referred to as 
heterotopic liver transplantation (HLT), was developed for patients deemed 
too ill for standard orthotopic liver transplantation (OLT). Encouraged by 
the early successes, we subsequently did HLT's in less severely affected 
patients as well. In 1991, we described the short-term outcomes in our 
HLT series.2 Later, 17 HLT's from the UK and another series of 10 patients 
from Turkey were reported.3,4 
 
HLT has, however, never gained general acceptance. In our center, the 
technique of HLT was abandoned in 1990 because of the improved results 
of OLT, even in very ill patients, and the risk of hepatocellular carcinoma in 
the host liver, especially in patients with viral hepatitis. Yet little is known 
about the long-term outcome of HLT, and a formal comparison with OLT 
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has never been made. Therefore, we examined the long-term survival after 
HLT and performed a case-control study of HLT vs. OLT. Because the 
advantages of HLT over OLT were expected to become evident during and 
early after transplantation, and certainly within the first year, we also took 
1-year survival as an outcome measure. Other outcome measures were 
peroperative and in-hospital mortality, incidence of graft primary non-
function, and frequency of retransplantation. 
 
 
PATIENTS AND METHODS 
 
Study population – cases 
Between 1986 and 1990, elective HLT's for chronic liver disease were 
performed in 17 patients. Indications were hepatitis B (n=2), hepatitis B+D 
(n=3), primary biliary cirrhosis (n=5), primary sclerosing cholangitis (n=2), 
alcoholic cirrhosis (n=2), autoimmune hepatitis (n=1), cryptogenic cirrhosis 
(n=1), and cirrhosis caused by metabolic liver disease (n=1). 
 
Selection of controls 
Between July 1989 and December 2002, 234 patients underwent OLT in 
our institution. Excluded were 74 patients with a diagnosis not represented 
in the HLT group, mainly hepatitis C or hepatocellular carcinoma. From the 
remaining 160 patients, 2 controls were selected for each HLT patient, 
matched for diagnosis and as far as possible for disease severity 
measured using the Child-Turcotte-Pugh score. When more than 2 
matches were found, the earliest OLT's were chosen. The characteristics 
of cases and controls, together with data on the operations and on the 
follow-up, were retrieved from our liver transplantation database and from 
the patient files. The 126 potential controls who were not included in the 
study had less severe liver disease (Child-Turcotte-Pugh score median 8, 
range 5-15), underwent transplantation later (median 1998, range 1989-
2002), and had a higher 1-year survival (86%) than the actual controls. 
 
Statistics 
The baseline characteristics of cases and controls were compared to 
identify possible confounders. Because of the matched study design, 
advanced statistical methods were used for these comparisons, mixed 
model analysis of variance for continuous factors and fixed-effects logistic 
regression analysis for categorical factors. When the number of endpoints 
was too small for logistic regression analysis, Fisher's exact test was used. 
For the analysis of 1-year survival we also used fixed-effects logistic 
regression. Overall survival was calculated using the Kaplan-Meier 
method, starting at the day of transplantation, until death or until January 
1, 2003, the closing date of the study. A stratified Cox proportional hazard 
rate model was used to analyze the long-term patient and graft survival. In 
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the Cox analysis, the year of transplantation, the Child-Turcotte-Pugh 
score, and the peroperative blood loss were entered as covariates. A 
score based on a recent European Liver Transplant Registry (ELTR) 
study, which identified a number of factors predicting mortality after liver 
transplantation, was included as a time-dependent variable.5 Graft failure 
was defined as either retransplantation or patient death, regardless of 
clinical or biochemical graft function. All calculations were done using 
Stata (version 5.0; Stata, College Station, TX) SPSS (version 11.0.1.1; 
SPSS, Chicago, IL) and SAS (version 8.02; SAS Institute, Cary, NC) 
statistical software. 
 
 
RESULTS 
 
Matching criteria and baseline characteristics 
Matching was successful for etiology, but not for disease severity. The 
Child-Turcotte-Pugh score was slightly higher in the HLT group than in the 
OLT group (median 11, range 8-14 vs. median 10, range 8-13, P<0.001). 
The age and gender distributions showed no significant differences 
between cases and controls. The other baseline characteristics we studied 
were year of transplantation, peroperative blood loss, and the relative risk 
(RR) of dying after transplantation as predicted by a truncated ELTR 
model.5 The year of transplantation (median 1988 vs. 1994, range 1986-
1990 vs. 1989-2002, P<0.001) and the peroperative blood loss (median 
6.5 vs. 10.2 L, range 3.0-40.0 L vs. 2.5-95.0 L, P=0.03) also differed. 
Matched controls were transplanted at a median of 6.0 years (range 0.7-
15.2 years) after the HLT cases. 
 
Of the predictive factors identified by the ELTR study, 8 were relevant for 
our analysis. Euro-Collins solution was used for preservation in the first 7 
heterotopic grafts. University of Wisconsin fluid was used in the remaining 
10 heterotopic and in all of the 34 orthotopic grafts (P<0.001). Also, 16 of 
the 17 heterotopic grafts were reduced in size vs. 0 in the OLT group 
(P<0.001). The only full-size heterotopic graft came from a child. The other 
6 relevant factors are retransplantation, the use of ABO blood group-
compatible instead of ABO blood group-identical grafts, recipient age over 
59 years, cold ischemic time of 12 hours or more, donor age over 55 
years, and the combination of a female donor and a male recipient. For 
these 6 factors, no significant differences were found between cases and 
controls. The combined RR of death after transplantation, calculated using 
a truncated version of the ELTR model containing all 8 factors mentioned 
here, was considerably higher in cases than in controls (median 2.14 vs. 
1.17, range 1.00-2.97 vs. 1.00-1.86, respectively, P=0.001). These data 
are summarized in Table 1. 
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Table 1: Patient characteristics and possible confounders according to 
type of transplantation. 
 Heterotopic Orthotopic P 
n 17 34 -- 
Gender (male/female) 11 / 6 17 / 17 0.25٭ 
Recipient age in years, median 
(range) 
48                     
(20-60) 
50.5                  
(27-65) 
0.06† 
Year of transplantation, median 
(range) 
1988                    
(1986-1990) 
1994              
(1989-2002) 
<0.001† 
Child-Turcotte-Pugh score, median 
(range) 
11                       
(8-14) 
10                       
(8-13) 
<0.001† 
ELTR relative risk, median          
(range) 
2.14               
(1.00-2.97) 
1.17                
(1.00-1.86) 
0.001† 
  Partial graft 16 0 <0.001٭ 
  Preservation fluid non-UW 7 0 <0.001٭ 
  Retransplantation 2 1 0.26٭ 
  Cold ischemic time ≥12 hours 8 11 0.30‡ 
  Recipient age ≥60 years 1 5 0.31 
  Donor age >55 years 0 2 0.55٭ 
  ABO-compatible graft 3 8 0.65‡ 
  Donor female / recipient male 3 7 0.80‡ 
Blood loss in L, median             
(range) 
6.5                    
(3.0-40.0) 
10.2                  
(2.5-95.0) 
0.03† 
 
Abbreviations: ELTR, European Liver Transplant Registry; UW, University of Wisconsin. 
٭ Fisher's exact test for categorical variables when logistic regression analysis inappropriate. 
† Mixed model analysis of variance for continuous variables. 
‡ Fixed effects logistic regression analysis for categorical variables. 
 
Postoperative course and 1-year follow-up 
There was no significant difference between HLT and OLT in the number 
of primary non-functioning grafts (0 of 17 vs. 1 of 34, P=1.00), the need for 
early retransplantation (1 of 17 vs. 1 of 34, P=0.62), or the in-hospital 
mortality (5 of 17 vs. 7 of 34, P=0.50). At 1 year, 12 of the 17 HLT patients 
were alive (survival 71%) compared with 25 of the 34 OLT patients (74%). 
The RR of death within 1 year for HLT vs. OLT was 1.15 (95% confidence 
interval [CI] 0.33-4.02, P=0.83, fixed effects logistic regression analysis). 
This risk did not change significantly after addition of any of the possible 
confounders to the model. 
 
Long-term follow-up 
Between 1 year after transplantation and the closing date of the study, 10 
HLT patients died, compared with only 4 in the OLT group. The median 
patient survival after HLT was 2.00 years (95% CI, 1.15-2.85 years), 
whereas it exceeded the maximal follow-up of 12.8 years after OLT. The 
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RR of death after HLT was 5.2 (95% CI, 0.8-34.8; P=0.09; multivariate 
stratified time-dependent Cox analysis, corrected for all possible 
confounders). The RR of graft failure after HLT was 18.0 (95% CI, 1.5-
223.5; P=0.02). 
 
 
 
Two HLT patients were alive at the closing date of the study, 1 with α-1-
antitrypsin deficiency at 15.2 years after transplantation, and 1 with 
hepatitis B+D, who was followed for 14.7 years. In the HLT group, 4 
patients survived for more than 5 tears, and 3 of these for more than 10 
years (Fig. 1). The causes of graft failure or death at more than 1 year 
after transplantation in the HLT patients were biliary complications in 3, de 
novo extrahepatic malignancies in 3, hepatocellular carcinoma in 1, 
pulmonary embolism complicated by bronchopneumonia in 1, chronic 
rejection in 1, and sepsis in 1 (Table 2). Of the late deaths, 1 was definitely 
related, 6 were possibly related, and 3 were not related to the HLT 
procedure. 
 
Details on the HLT patients with biliary complications and de novo 
malignancies are given in Table 3. Two of the late biliary complications 
were found in primary sclerosing cholangitis patients and the 3rd in an 
autoimmune hepatitis patient. One can be classified as primary sclerosing 
cholangitis recurrence, 1 as an ischemic type biliary lesion, and 1 as an 
anastomotic stricture. Of the 4 de novo malignancies, 3 were located in the 
digestive tract. The only hepatocellular carcinoma occurred in the first HLT 
patient, who underwent transplantation because of a chronic hepatitis B, 
he remained infected and developed cirrhosis of the graft within 1 year. All 
tumors were diagnosed within 4 years after transplantation. 
Figure 1: Survival after 
heterotopic liver transplan-
tation (HLT) and orthotopic 
liver transplantation (OLT). 
One-year mortality HLT vs. 
OLT relative risk (RR) 1.15; 
95% confidence interval (CI) 
0.33-4.02; P=0.83; fixed 
effects logistic regression 
analysis. Overall mortality 
HLT vs. OLT RR 5.2; 95% CI 
0.8-34.8; P=0.09; stratified 
time-dependent Cox 
analysis, corrected for all 
possible confounders. 
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Table 2: Follow-up beyond 1 year after transplantation for heterotopic and 
orthotopic procedures. 
 Heterotopic Orthotopic P 
n 17 34 -- 
Alive at 1 year 12 25 0.83٭ 
Retransplantation at >1 year 1 0 0.32† 
Death/graft failure at >1 year 10 4 <0.001† 
Causes of death/graft failure at >1 year    
  De novo malignancy 4‡ -- 0.01† 
  Biliary complications 3§ -- 0.03† 
  Chronic rejection 1║ -- 0.32† 
  Sepsis 1║ -- 0.32† 
  Pulmonary embolism/pneumonia 1║ -- 0.32† 
  Hepatitis B recurrence -- 2 0.55† 
  Femur neck fracture -- 1 1.00† 
  Unknown -- 1 1.00† 
 
٭ Univariate fixed effects logistic regression analysis. 
† Fisher's exact test. 
‡ One definitely and 3 possibly related to HLT technique. 
§ All 3 possibly related to HLT technique. 
║ Not related to HLT technique. 
 
Of the 4 OLT patients who died after more than 1 year, 2 had hepatitis B 
recurrences, 1 died after a femur neck fracture, and 1 died of an unknown 
cause. In the OLT group, in which 61 patients were followed for more than 
5 years, no graft losses due to late biliary complications and no deaths due 
to de novo malignancies were observed. The frequency of late biliary 
complications and of de novo malignancies was higher after HLT than after 
OLT (P=0.028 and P=0.007, respectively, Fisher's exact test). 
 
 
DISCUSSION 
 
Our formal comparison of HLT and OLT confirms the general opinion that 
the long-term outcome after HLT is inferior, even though the 1-year 
survival appears to be similar. A definite answer to the question as to 
whether the short-term results of HLT and OLT are equal cannot be given, 
because of the limitations of our study. One is the relatively small number 
of cases and controls, leading to a low power and wide CIs.6 Also, the 
comparison between our HLT and OLT groups is not as simple as in the 
average randomized controlled trial, due to the matched study design, the 
differences in baseline characteristics, and the presence of other potential 
confounders. Differences between HLT and OLT were found for year of 
transplantation, disease severity, type of preservation fluid, and 
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peroperative blood loss. The use of a partial grafts, confined to the HLT 
group, is also an independent risk factor.5 These factors and other known 
confounders were incorporated in the statistical models used to compare 
the 2 groups. However, it should be noted that most known confounders 
are disadvantageous for the HLT patients, and a 1-year survival lower than 
in the OLT group would have been expected. 
 
Table 3: Heterotopic liver transplantation: late biliary complications and de 
novo malignancies. 
Late biliary complications Case 1 Case 2 Case 4  
Localization of biliary lesion Intrahepatic Intrahepatic Extrahepatic  
Type of biliary lesion Small duct Large duct Anastomotic  
Biliary lesion found after (years) 2.0 1.0 2.2  
Death or graft failure after (years) 3.3 8.9 2.2  
Potential risk factors     
  Original liver disease PSC/AIH PSC AIH  
  Preservation fluid Euro-
Collins 
UW UW  
  Cold ischemic time (hours) 5.0 12.5 13.5  
  Warm ischemic time (minutes) 42 50 75  
  Hepatic artery Patent Stenotic Patent  
     
De novo malignancies Case 1 Case 2 Case 3 Case 4 
Tumor origin Pancreas Colon Esophagus Liver 
Tumor diagnosed after (years) 1.8 1.3 3.7 2.0 
Death after (years) 1.8 1.5 4.2 2.0 
Potential risk factors     
  Original liver disease ALC PBC ALC HBV 
  Age (years) 59 60 48 35 
  Gender Male Female Male Male 
 
Abbreviations: PSC, primary sclerosing cholangitis; ALC, alcoholic cirrhosis; AIH, auto-
immune hepatitis; PBC, primary biliary cirrhosis; UW, University of Wisconsin; HBV, hepatitis 
B virus infection. 
 
The divergence in survival that occurs at more than 1 year after 
transplantation is mainly caused by a higher frequency of late biliary 
complications and de novo malignancies in HLT patients. Given the 
diversity of the late biliary complications after HLT, the difference with OLT 
could be a chance finding. The use of partial grafts for HLT is a possible 
explanation, but recent comparisons of right lobe and full-size grafts in 
OLT do not show a difference in the number of biliary complications.7-9 
There are, however, no studies that specifically address the problem of 
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late biliary complications with partial liver grafts, so in our patients they are 
at most possibly related to the technique of HLT. 
 
The higher de novo tumor frequency in the HLT group probably is not 
related to a longer follow-up, since at least 50% of the OLT patients have 
been followed for a period longer than the maximal interval between HLT 
and the diagnosis of malignancy. A possible but rather speculative 
explanation for the higher number of de novo malignancies after HLT is the 
growth promoting effect of implanting a partial liver. The influence on the 
environment of such a large regenerating organ might be an additional risk 
factor for patients already prone to cancer development for other reasons, 
such as chronic viral hepatitis or alcohol abuse.10 Support for this 
hypothesis has been found in an animal experiment, at least for 
intrahepatic metastases.11 On the other hand, there is no evidence of 
excess mortality from de novo malignancies after transplantation of split or 
reduced size livers in the overall ELTR data (update June 2003), but these 
figures include pediatric cases, and it is not clear how many individuals 
had a higher than average risk of developing de novo malignancies. Thus, 
only the 1 hepatocellular carcinoma in our series can be considered as 
definitely related to HLT, whereas the other 3 tumors are only possibly 
related to the technique. 
 
In conclusion, our study strongly suggests that HLT is equal to OLT in the 
short term but inferior in the long term. The exact cause of the divergence 
between HLT and OLT that occurs at more than 1 year after 
transplantation remains uncertain, but the use of partial liver grafts for HLT 
could play a role. Apart from ELTR data indicating a poorer outcome, little 
is known about the survival at more than 2 years after transplantation of 
partial liver grafts. One publication cites a 77% 5-year survival, but here 
the median follow-up is only 22.6 months.7 The unexpected divergence we 
find in our study of HLT vs. OLT implies that more data on the long-term 
follow-up after other forms of partial liver transplantation are needed. In 
spite of the fact that survival of more than 10 years is possible after HLT, 
we found no advantage over OLT. HLT cannot be recommended as an 
alternative to OLT for any of the indications we studied. 
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Heterotopic vs. Orthotopic Liver Transplantation for
Chronic Liver Disease: A Case-Control Comparison of
Short-Term and Long-Term Outcomes
Sjoerd de Rave,1 Bettina E. Hansen,2 Theo H.N. Groenland,3 Geert Kazemier,4
Robert A. de Man,1 Herold J. Metselaar,1 Onno T. Terpstra,4 Hugo W. Tilanus,4
Jan H.N.M. IJzermans,4 and Solko W. Schalm1
Between 1986 and 1990 we performed heterotopic liver
transplantation (HLT) in 17 patients with chronic liver
disease. In spite of theoretical advantages and favorable
short-term results, we abandoned HLT because of doubts
about the long-term outcome and the improved results of
standard orthotopic liver transplantation (OLT). There
are, however, no studies comparing the long-term survival
after HLT and OLT for chronic liver disease. We per-
formed a case-control study of HLT vs. OLT, with long-
term patient and graft survival as the main outcome mea-
sures. Known confounders and differences in baseline
characteristics between HLT and OLT patients were cor-
rected for. At 1 year, 5 of the 17 HLT patients had died,
compared with 9 of the 34 OLT patients (relative risk
[RR], 1.15; 95% confidence interval [CI], 0.33-4.02; P
0.83). After correction for confounders, the long-term risk
of graft failure (RR, 18.0; 95% CI, 1.5-223.5; P  0.02)
and of death (RR, 5.2; 95% CI, 0.8-34.8; P  0.09) was
higher after HLT than after OLT. Themain causes of graft
loss and death at more than 1 year after HLTwere de novo
malignancies and a variety of biliary complications. In
conclusion, our data, from 1 of the largest single-center
series of HLTs available, showed no significant difference
between HLT and OLT in 1-year survival. However, the
long-term outcome of HLT was inferior. HLT cannot be
recommended as an alternative to OLT for any of the
indications we studied, even though only 1 of the late
deaths was definitely related to the heterotopic technique.
(Liver Transpl 2005;11:396-401.)
In 1988, we reported on the favorable short-termresults of auxiliary partial liver transplantation in a
small number of patients with end-stage chronic liver
disease.1 Originally, this procedure, which will be
referred to as heterotopic liver transplantation (HLT),
was developed for patients deemed too ill for standard
orthotopic liver transplantation (OLT). Encouraged by
the early successes, we subsequently did HLTs in less
severely affected patients as well. In 1991, we described
the short-term outcomes in our HLT series.2 Later, 17
HLTs from the UK and another series of 10 patients
from Turkey were reported.3,4
HLT has, however, never gained general accep-
tance. In our center, the technique of HLT was aban-
doned in 1990 because of the improved results of
OLT, even in very ill patients, and the risk of hepa-
tocellular carcinoma in the host liver, especially in
patients with viral hepatitis. Yet little is known about
the long-term outcome of HLT, and a formal com-
parison with OLT has never been made. Therefore,
we examined the long-term survival after HLT and
performed a case-control study of HLT vs. OLT.
Because the advantages of HLT over OLT were
expected to become evident during and early after
transplantation, and certainly within the first year,
we also took 1-year survival as an outcome measure.
Other outcome measures were perioperative and in-
hospital mortality, incidence of graft primary non-
function, and frequency of retransplantation.
Patients and Methods
Study Population—Cases
Between 1986 and 1990, elective HLTs for chronic liver
disease were performed in 17 patients. Indications were hep-
atitis B virus (n 2), hepatitis BD (n 3), primary biliary
cirrhosis (n  5), primary sclerosing cholangitis (n  2),
alcoholic cirrhosis (n  2), autoimmune hepatitis (n  1),
cryptogenic cirrhosis (n  1), and cirrhosis caused by meta-
bolic liver disease (n 1).
Abbreviations: HLT, heterotopic liver transplantation; OLT,
orthotopic liver transplantation; RR, relative risk; CI, confidence
interval; ELTR, European Liver Transplant Registry.
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Selection of Controls
Between July 1989 and December 2002, 234 patients under-
went OLT in our institution. Excluded were 74 patients with
a diagnosis not represented in the HLT group, mainly hepa-
titis C or hepatocellular carcinoma. From the remaining 160
patients, 2 controls were selected for each HLT patient,
matched for diagnosis and as far as possible for disease severity
measured using the Child-Turcotte-Pugh score. When more
than 2 matches were found, the earliest OLTs were chosen.
The characteristics of cases and controls, together with data
on the operations and on the follow-up, were retrieved from
our liver transplantation database and from the patient files.
The 126 potential controls who were not included in the
study had less severe liver disease (Child-Turcotte-Pugh score
median 8; range 5-15), underwent transplantation later
(median 1,998; range 1,989-2,002), and had a higher 1-year
survival (86%) than the actual controls.
Statistics
The baseline characteristics of cases and controls were com-
pared to identify possible confounders. Because of the
matched study design, advanced statistical methods were used
for these comparisons: mixed model analysis of variance for
continuous factors and fixed-effects logistic regression analysis
for categorical factors. When the number of endpoints was
too small for logistic regression analysis, Fisher’s exact test was
used. For the analysis of 1-year survival we also used fixed-
effects logistic regression. Overall survival was calculated
using the Kaplan-Meier method, starting at the day of trans-
plantation, until death or until January 1, 2003, the closing
date of the study. A stratified Cox proportional hazard rate
model was used to analyze the long-term patient and graft
survival. In the Cox analysis, the year of transplantation, the
Child-Turcotte-Pugh score, and the perioperative blood loss
were entered as covariates. A score based on a recent European
Liver Transplant Registry (ELTR) study, which identified a
number of factors predicting mortality after liver transplanta-
tion, was included as a time-dependent variable.5 Graft failure
was defined as either retransplantation or patient death,
regardless of clinical or biochemical graft function. All calcu-
lations were done using STATA (version 5.0; Stata, College
Station, TX), SPSS (version 11.0.1; SPSS, Chicago, IL), and
SAS (version 8.02; SAS Institute, Cary, NC) statistical soft-
ware.
Results
Matching Criteria and Baseline Characteristics
Matching was successful for etiology, but not for disease
severity. The Child-Turcotte-Pugh score was slightly
higher in the HLT group than in the OLT group
(median 11, range 8-14 vs. median 10, range 8-13; P
0.001). The age and gender distributions showed no
significant differences between cases and controls. The
other baseline characteristics we studied were year of
transplantation, perioperative blood loss, and the rela-
tive risk (RR) of dying after transplantation as predicted
by a truncated ELTR model.5 The year of transplanta-
tion (median 1988 vs. 1994; range 1986-1990 vs.
1989-2002; P  0.001) and the perioperative blood
loss (median 6.5 vs. 10.2 L; range 3.0-40.0 vs. 2.5-95.0
L; P 0.03) also differed.Matched controls were trans-
planted at a median of 6.0 years (range 0.7-15.2 years)
after the HLT cases. Of the predictive factors identified
by the ELTR study, 8 were relevant for our analysis.
Euro-Collins solution was used for preservation in the
first 7 heterotopic grafts, University of Wisconsin fluid
was used in the remaining 10 heterotopic and all of the
34 orthotopic grafts (P  0.001). Also, 16 of the 17
heterotopic grafts were reduced in size vs. 0 in the OLT
group (P 0.001). The only full-size heterotopic graft
came from a child. The other 6 relevant factors are
retransplantation, the use of ABO blood group–com-
patible instead of ABO blood group–identical grafts,
recipient age over 59 years, cold ischemic time of 12
hours or more, donor age over 55 years, and the com-
bination of a female donor and a male recipient. For
these 6 factors, no significant differences were found
between cases and controls. The combined RR of death
after transplantation, calculated using a truncated ver-
sion of the ELTR model containing all 8 factors men-
tioned here, was considerably higher in cases than in
controls (median 2.14 vs. 1.17, range 1.00-2.97 vs.
1.00-1.86, respectively; P  0.001). These data are
summarized in Table 1.
Postoperative Course and 1-Year Follow-Up
There was no significant difference between HLT and
OLT in the number of primary nonfunctioning grafts
(0 of 17 vs. 1 of 34; P  1.00), the need for early
retransplantation (1 of 17 vs. 1 of 34; P 0.62), or the
in-hospital mortality (5 of 17 vs. 7 of 34; P 0.50). At
1 year, 12 of the 17 HLT patients were alive (survival
71%) compared with 25 of the 34OLTpatients (74%).
The RR of death within 1 year for HLT vs. OLT was
1.15 (95% confidence interval [CI], 0.33-4.02; P 
0.83, fixed-effects logistic regression analysis). This risk
did not change significantly after addition of any of the
possible confounders to the model.
Long-Term Follow-Up
Between 1 year after transplantation and the closing
date of the study, 10HLT patients died, compared with
only 4 in the OLT group. The median patient survival
after HLT was 2.00 years (95% CI, 1.15-2.85 years),
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whereas it exceeded the maximal follow-up of 12.8
years after OLT. The RR of death after HLT was 5.2
(95% CI, 0.8-34.8; P  0.09; multivariate stratified
time-dependent Cox analysis, corrected for all possible
confounders). The RR of graft failure after HLT was
18.0 (95% CI, 1.5-223.5; P  0.02).
Two HLT patients were alive at the closing date of
the study, 1 with -1-antitrypsin deficiency at 15.2
years after transplantation, and 1 with hepatitis B 
D, who was followed for 14.7 years. In the HLT
group, 4 patients survived for more than 5 years and
3 of these for more than 10 years (Fig. 1). The causes
of graft failure or death at more than 1 year after
transplantation in the HLT patients were biliary
complications in 3, de novo extrahepatic malignan-
cies in 3, hepatocellular carcinoma in 1, pulmonary
embolism complicated by bronchopneumonia in 1,
chronic rejection in 1, and sepsis in 1 (Table 2). Of
the late deaths, 1 was definitely related, 6 were pos-
sibly related, and 3 were not related to the HLT
procedure.
Details on the HLT patients with biliary compli-
cations and de novo malignancies are given in Table
3. Two of the late biliary complications were found
in primary sclerosing cholangitis patients and the 3rd
in an autoimmune hepatitis patient. One can be
classified as primary sclerosing cholangitis recur-
rence, 1 as an ischemic type biliary lesion, and 1 as an
anastomotic stricture. Of the 4 de novo malignan-
cies, 3 were located in the digestive tract. The only
hepatocellular carcinoma occurred in the first HLT
patient, who underwent transplantation because of a
chronic hepatitis B; he remained infected and devel-
oped cirrhosis of the graft within 1 year. All tumors
were diagnosed within 4 years after transplantation.
Table 1. Patient Characteristics and Possible Confounders According to Type of Transplantation
Heterotopic Orthotopic P
n 17 34 —
Gender (male/female) 11 / 6 17 / 17 0.25*
Recipient age in years, median (range) 48 (20-60) 50.5 (27-65) 0.06†
Year of transplantation, median (range) 1988 (1986-1990) 1994 (1989-2002) 0.001†
Child-Turcotte-Pugh score, median (range) 11 (8-14) 10 (8-13) 0.001†
ELTR relative risk, median (range) 2.14 (1.00-2.97) 1.17 (1.00-1.86) 0.001†
Partial graft 16 0 0.001*
Preservation fluid non-UW 7 0 0.001*
Retransplantation 2 1 0.26*
Cold ischemic time 12 hours 8 11 0.30‡
Recipient 60 years 1 5 0.31‡
Donor age 55 years 0 2 0.55*
ABO-compatible graft 3 8 0.65‡
Donor female / recipient male 3 7 0.80‡
Blood loss in L, median (range) 6.5 (3.0-40.0) 10.2 (2.5-95.0) 0.03†
Abbreviations: ELTR, European Liver Transplant Registry; UW, University of Wisconsin.
*Fisher’s exact test for categorical variables when logistic regression analysis inappropriate.
†Mixed model analysis of variance for continuous variables.
‡Fixed effects logistic regression analysis for categorical variables.
Figure 1. Survival after heterotopic liver transplantation
(HLT) and orthotopic liver transplantation (OLT). One-
year mortality HLT vs. OLT (RR, 1.15; 95% CI, 0.33-
4.02; P  0.83; fixed-effects logistic regression analysis).
Overall mortality HLT vs. OLT (RR, 5.2; 95% CI, 0.8-
34.8; P  0.09; stratified time-dependent Cox analysis,
corrected for all possible confounders).
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Of the 4 OLT patients who died after more than 1
year, 2 had hepatitis B recurrences, 1 died after a femur
neck fracture, and 1 died of an unknown cause. In the
OLT group, in which 16 patients were followed for
more than 5 years, no graft losses due to late biliary
complications and no deaths due to de novo malignan-
cies were observed. The frequency of late biliary com-
plications and of de novo malignancies was higher after
Table 2. Follow-up Beyond 1 Year After Transplantation for Heterotopic and Orthotopic Procedures
Heterotopic Orthotopic P
n 17 34 —
Alive at 1 year 12 25 0.83*
Retransplantation at  1 year 1 0 0.32†
Death/graft failure at  1 year 10 4 0.001†
Causes of death/graft failure at 1 year
De novo malignancy 4‡ — 0.01†
Biliary complications 3§ — 0.03†
Chronic rejection 1 — 0.32†
Sepsis 1 — 0.32†
Pulmonary embolism/pneumonia 1 — 0.32†
Hepatitis B recurrence — 2 0.55†
Femur neck fracture — 1 1.00†
Unknown — 1 1.00†
*Univariate fixed effects logistic regression analysis.
†Fisher’s exact test.
‡One definitely and 3 possibly related to HLT technique.
§All 3 possibly related to HLT technique.
Not related to HLT technique.
Table 3. Heterotopic Liver Transplantation: Late Biliary Complications and De Novo Malignancies
Case 1 Case 2 Case 3
Late biliary complications
Localization of biliary lesion Intrahepatic Intrahepatic Extrahepatic
Type of biliary lesion Small duct Large duct Anastomotic
Biliary lesion found after (years) 2.0 1.0 2.2
Death or graft failure after (years) 3.3 8.9 2.2
Potential risk factors
Original liver disease PSC/AIH PSC AIH
Preservation fluid Euro-Collins UW UW
Cold ischemic time (hours) 5.0 12.5 13.5
Warm ischemic time (minutes) 42 50 75
Hepatic artery Patent Stenotic Patent
Case 1 Case 2 Case 3 Case 4
De novo malignancies
Tumor origin Pancreas Colon Esophagus Liver
Tumor diagnosed after (years) 1.8 1.3 3.7 2.0
Death after (years) 1.8 1.5 4.2 2.0
Potential risk factors
Original liver disease ALC PBC ALC HBV
Age (years) 59 60 48 35
Gender Male Female Male Male
Abbreviations: PSC, primary sclerosing cholangitis; ALC, alcoholic cirrhosis; AIH, auto-immune hepatitis; PBC, primary biliary
cirrhosis; UW, University of Wisconsin; HBV, hepatitis B virus infection.
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HLT than after OLT (P  0.028 and P  0.007,
respectively, Fisher’s exact test).
Discussion
Our formal comparison of HLT andOLT confirms the
general opinion that the long-term outcome after HLT
is inferior, even though the 1-year survival appears to be
similar. A definite answer to the question as to whether
the short-term results of HLT and OLT are equal can-
not be given, because of the limitations of our study.
One is the relatively small number of cases and controls,
leading to a low power and wide CIs.6 Also, the com-
parison between our HLT and OLT groups is not as
simple as in the average randomized controlled trial,
due to the matched study design, the differences in
baseline characteristics, and the presence of other
potential confounders. Differences between HLT and
OLT were found for year of transplantation, disease
severity, type of preservation fluid, and perioperative
blood loss. The use of a partial grafts in the HLT group
is also an independent risk factor.5 These factors and
other known confounders were incorporated in the sta-
tistical models used to compare the 2 groups. However,
it should be noted that most known confounders are
disadvantageous for the HLT patients, and a 1-year
survival lower than in the OLT group would have been
expected.
The divergence in survival that occurs at more than
1 year after transplantation is mainly caused by a higher
frequency of late biliary complications and de novo
malignancies in HLT patients. Given the diversity of
the late biliary complications after HLT, the difference
with OLT could be a chance finding. The use of partial
grafts for HLT is a possible explanation, but recent
comparisons of right lobe and full-size grafts inOLT do
not show a difference in the number of biliary compli-
cations.7-9 There are, however, no studies that specifi-
cally address the problem of late biliary complications
with partial liver grafts, so in our patients they are at
most possibly related to the technique of HLT.
The higher de novo tumor frequency in the HLT
group probably is not related to a longer follow-up, since
at least 50% of theOLT patients have been followed for
a period longer than the maximum interval between
HLT and the diagnosis of malignancy. A possible but
rather speculative explanation for the higher number of
de novo malignancies after HLT is the growth promot-
ing effect of implanting a partial liver. The influence on
the environment of such a large regenerating organ
might be an additional risk factor for patients already
prone to cancer development for other reasons, such as
chronic viral hepatitis or alcohol abuse.10 Support for
this hypothesis has been found in an animal experi-
ment, at least for intrahepatic metastases.11 On the
other hand, there is no evidence of excess mortality
from de novomalignancies after transplantation of split
or reduced size livers in the overall ELTR data (update
June 2003), but these figures include pediatric cases,
and it is not clear how many individuals had a higher
than average risk of developing de novo malignancies.
Thus, only the 1 hepatocellular carcinoma in our series
can be considered as definitely related to HLT, whereas
the other 3 tumors are only possibly related to the
technique.
In conclusion, our study strongly suggests that HLT
is equal to OLT in the short term but inferior in the
long term. The exact cause of the divergence in survival
betweenHLT andOLT that occurs at more than 1 year
after transplantation remains uncertain, but the use of
partial liver grafts forHLT could play a role. Apart from
ELTR data indicating a poorer outcome, little is known
about the survival at more than 2 years after transplan-
tation of partial liver grafts.5 One publication cites a
77% 5-year survival after right lobe split-liver trans-
plantation, but here the median follow-up is only 22.6
months.7 The unexpected divergence we find in our
study of HLT vs. OLT implies that more data on the
long-term follow-up after other forms of partial liver
transplantation are needed. In spite of the fact that
survival of more than 10 years is possible after HLT, we
found no advantage over OLT. HLT cannot be recom-
mended as an alternative to OLT for any of the indica-
tions we studied.
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SUMMARY 
 
We studied three patients who survived for more than 10 years after 
Heterotopic Liver Transplantation because of end-stage chronic liver 
disease. Two patients had hepatitis B and D infections. Although their 
grafts rapidly became infected too, and severe fibrosis of the graft 
developed within five years, the liver function has remained normal or near 
normal during a follow-up of at least 10 years, and no signs of portal 
hypertension have occurred. One of these two patients died of sepsis 11.5 
years after transplantation, the other was alive at 16.5 years, with 
moderate renal dysfunction as the main long-term complication. The 
remaining patient had α-1-antitrypsin deficiency and was cured after 
transplantation. She was alive at 17 years post-transplantation, with 
complications that can be ascribed to long-term immunosuppression, such 
as overweight, hypertension, osteopenia and recurrent basal cell skin 
cancers. Near-complete atrophy of the native liver was found on imaging in 
all patients. Hepatocellular carcinoma did not occur. Although in general 
the results of Heterotopic Liver Transplantation are inferior to those of 
Orthotopic Liver transplantation, these cases show that Heterotopic Liver 
Transplantation for end-stage chronic liver disease can result in long-term 
survival with normal clinical and biochemical graft function. 
 
 
INTRODUCTION 
 
Heterotopic Liver Transplantations (HLT) have been performed since 
19641. Although we have reported favourable short-term results of HLT in 
our first 6 chronic liver disease patients, the procedure has never become 
a generally accepted alternative for the standard Orthotopic Liver 
Transplantation (OLT)2. Long-term survivors of HLT have been described, 
but the maximum follow up of these patients was 6.5 years3-6. We have 
recently compared the long-term survival of our 17 HLT patients with 
chronic liver disease with that of 34 matched OLT patients7. In the HLT 
group, 3 patients have survived for more than 10 years. Here we report the 
clinical course of these 3 exceptional long-term survivors in more detail. 
 
 
PATIENTS AND METHODS 
 
Our initial report on Auxiliary Partial Liver Transplantation described 6 
patients2. Patient A died of hepatocellular carcinoma 2.0 years after 
transplantation, patient C died during attempted retransplantation for 
recurrence of his Primary Sclerosing Cholangitis after 3.3 years and 
patient E died of pulmonary embolism complicated by bronchopneumonia 
after 1.3 years. Patients B, D and F survived for more than 10 years, these 
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are the subject of the present report. Clinical and laboratory data were 
retrieved from our liver transplantation database and from the patient files. 
All biochemical measurements were done using standard automated 
techniques. Clinical data on the 3 patients are summarised in table 1. 
 
Table 1: Clinical data on the three patients who survived for more than 10 
years after heterotopic liver transplantation (HLT).  
Patient B D F 
Sex Male Female Male 
Age 40 53 32 
Liver disease Chronic hepatitis B+D α-1-antitrysin deficiency Chronic hepatitis B+D 
Child-Pugh 
score 
13 12 8 
Disease course  Recurrence in graft Cured Recurrence in graft 
Graft function Normal (11 years) Normal (17 years) Normal (16 years) 
Graft fibrosis Cirrhosis (5.0 years) None (5.0 years) Severe (4.5 years) 
Native liver Atrophic Atrophic Atrophic 
Late 
complications 
None Bacterial cholangitis 
Basal cell skin cancers 
Hypertension 
Overweight 
Osteopenia 
Femur neck fracture 
Biliary stricture (7 mths) 
Recurrent upper and 
lower respiratory tract 
infections 
Renal dysfunction 
Outcome Died (sepsis) Alive Alive 
Follow up (yrs) 11.5 17.0 16.5 
 
Data on laboratory measurements, Body Mass Index and abdominal 
ultrasound results at yearly follow up after heterotopic liver transplantation 
in table 2. Magnetic Resonance Images (MRI) of the grafts and the native 
livers of patients B, D and F obtained 3.2, 12.5 and 11.5 years after HLT, 
respectively, are shown in figure 1a, 1b and 1c. 
 
 
CASES 
 
Patient B was a 40-year old male who was transplanted for end-stage 
cirrhosis due to a chronic hepatitis B and D infection. He had an uneventful 
postoperative course and was discharged after 29 days. Initially his 
maintenance immunosuppressive regimen consisted of corticosteroids and 
Cyclosporin-A, after 2.5 years Cyclosporin-A was replaced by Azathioprin 
because of hypertension. Hepatitis B s-antigen became positive in the 
graft at 3 weeks and c-antigen at 9 weeks. The s-antigen has been 
positive in the graft throughout, the c-antigen became negative at 5 years. 
Delta-antigen was already detectable in the graft at 1 week and has 
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remained positive ever since. Progressive fibrosis was seen in biopsies 
taken from the liver graft between 6 months and 4 years after 
transplantation and cirrhosis was found at 5 years. Nevertheless, the 
function of the graft has always been normal or nearly normal. Values 
found during yearly follow-up were between 17 and 36 µmol/l for bilirubin, 
between 34 and 43 g/l for albumin, and between 0.9 and 1.2 for the 
prothrombin time International Normalised Ratio (INR). Repeated imaging 
showed atrophy of the host liver, and no evidence of hepatocellular 
carcinoma. The spleen has remained enlarged, but there have been no 
complications of portal hypertension. Apart from an inguinal hernia 
requiring surgical repair he has had no other important medical problems 
until he unexpectedly died from a gram-negative sepsis 11.5 years after 
transplantation. 
 
Table 2: Laboratory measurements, Body Mass Index and abdominal 
ultrasound results at yearly follow up after heterotopic liver transplantation 
for the 3 patients who survived for more than 10 years. 
Patient B Patient D Patient F  Normal 
values median 
(range) 
year 
11 
median 
(range) 
year 
17 
median 
(range) 
year 
16 
Laboratory 
measurements 
       
Albumin                     
(g/l) 
35-50 37           
(34-43) 
36 43          
(37-48) 
40 40          
(34-43) 
43 
Bilirubin              
(µmol/l) 
≤ 17 24           
(17-36) 
24 25          
(10-33) 
10 19          
(15-30) 
30 
Alanine amino-
transferase (U/l) 
M < 41           
F < 31 
30           
(21-109) 
30 22          
(14-33) 
20 45          
(23-259) 
32 
Creatinine             
(µmol/l) 
M 65-115      
F 55-90 
95           
(80-108) 
103 83          
(67-159) 
80 138       
(123-184) 
136 
Platelet count             
(x 109/l) 
150-400 92          
(68-139) 
78 105        
(82-133) 
94 112        
(92-136) 
122 
Leukocyte 
count (x 109/l) 
3.5-10.0 7.8        
(5.7-10.9) 
7.1 4.2        
(3.4-6.9) 
3.9 3.8        
(2.5-5.5) 
3.7 
Prothrombin 
time  (INR, -/-) 
≤ 1.4 1.1        
(0.9-1.2) 
1.2 1.0        
(0.9-1.1) 
1.1 1.3        
(1.1-1.4) 
1.4 
Antithrombin-III      
(U/ml) 
0.80-1.20 0.67       
(0.52-1.16) 
0.67 0.88   
(0.47-1.04) 
0.79 0.71       
(0.51-0.90) 
0.65 
Other 
measurements 
       
Body Mass 
Index (kg/m2) 
18.0-25.0 23.2     
(22.3-24.6) 
22.7 33.1      
(26.5-34.7) 
28.7 21.2     
(19.9-24.9) 
24.8 
Spleen size on 
US (cm) 
≤ 12 15.4     
(14.0-18.0) 
15.0 15.0     
(14.0-16.2) 
15.6 16.0     
(14.0-17.9) 
15.8 
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Patient D was a 53-year old female with α-1-antitrypsin deficiency. She 
quickly recovered from the transplantation and left the hospital 24 days 
later. It did, however, take 6 months for her ascites to resolve completely. 
Because of hypertension her maintenance immunosuppression was 
switched from corticosteroids and Cyclosporin-A to a low-dose triple drug 
regimen also containing Azathioprin at 1 year and to corticosteroids and 
Azathioprin at 2 years. The serum α-1-antitrypsin concentration rose from 
0.18 g/l before to 2.31 g/l one week after transplantation, and has 
remained normal thereafter. In the latest biopsy of the graft, taken at 5 
years after transplantation, no major abnormalities were seen. The 
function of the graft has been normal ever since the transplantation, with 
values at yearly follow-up between 10 and 33 µmol/l for bilirubin, between 
37 and 48 g/l for albumin, and between 0.9 and 1.1 for the INR. The native 
liver atrophied, as shown by repeated imaging. After the first six months 
there have been no signs or symptoms of portal hypertension, although 
the spleen size has not returned to normal. She was put on Sirolimus 
monotherapy at 15 years because of recurrent basal cell skin cancers. 
Other late complications have been recurrent staphylococcal infections of 
the skin, overweight and osteoporosis, with a fracture of the left femoral 
neck at 15.7 years. She has been hospitalised twice on suspicion of acute 
bacterial cholangitis at 12.4 and 12.9 years, but has been doing well 
otherwise. This patient has been followed postoperatively for 17 years. 
 
Figure 1: Magnetic Resonance Imaging of the abdomen after Heterotopic 
Liver Transplantation in 3 long-term survivors, coronal view. The images 
were selected to enable an optimal comparison between the grafts and the 
native livers. 
 
Patient B, 3.2 years 
after transplantation. A 
T1-weighted spin-echo 
sequence is shown. As 
usual, the signal 
intensity of the graft is 
higher than that of the 
spleen. The native liver 
(arrow) has almost 
disappeared and has a 
lower signal intensity 
than the graft, due to 
atrophy and fibrosis.  
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Patient D, 12.5 years 
after transplantation. 
T2-weighted single-shot 
turbo spin-echo 
sequence, higher signal 
intensities indicating fat 
and fluid. The graft 
signal intensity equals 
that of the spleen, due 
to the technique used. 
The remnant of the 
native liver (arrow) has 
a somewhat increased 
signal intensity, mainly 
due to atrophy. 
 
Patient F, 11.5 years 
after transplantation. 
T2-weighted single-shot 
turbo spin-echo 
sequence. The signal 
intensity of the graft is 
lower than that of the 
spleen, as expected in 
this sequence. As in 
patient D, the native 
liver (arrow) is atrophic, 
with a markedly 
increased signal 
intensity. 
 
 
 
Patient F was a 32-year old male who also suffered from a chronic 
hepatitis B and D infection. He had no major postoperative complications 
and was discharged after 21 days. He has been on corticosteroids and 
Cyclosporin-A for 10 years, and on Cyclosporin-A monotherapy thereafter. 
The hepatitis B s-antigen became positive in the graft at 3 weeks and the 
c-antigen at 7 weeks. The s-antigen has remained positive, while 
expression of the c-antigen reached a peak in the third month and then 
declined, but remained detectable. Delta antigen was first detected in the 
graft at 3 weeks and remained positive thereafter. Fibrosis in the graft 
progressed from minimal at 7 months to severe at 4.5 years. Like in patient 
B, the function of the graft has always been normal or nearly normal. Here 
values during yearly follow-up were between 15 and 30 µmol/l for bilirubin, 
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between 34 and 43 g/l for albumin, and between 1.1 and 1.4 for the INR. In 
this patient too, repeated imaging showed atrophy of the host liver, without 
evidence of hepatocellular carcinoma. The spleen has remained enlarged, 
but there have been no other signs of portal hypertension. A biopsy of the 
graft at 3 months was complicated by bleeding, sepsis, respiratory failure 
and renal failure, requiring several laparotomies, ventilatory support and 
haemodialysis. The renal function did recover after several weeks, but has 
not returned to normal. At 7 months another laparotomy was performed 
because of a biliary anastomotic stricture. Later on several admissions 
have been necessary because of recurrent upper and lower respiratory 
infections. This patient was still alive at 16.5 years after transplantation. 
 
 
DISCUSSION 
 
Long-term survival for up to 17 years after HLT is possible, as illustrated 
by our experience, even though the overall results of HLT are inferior to 
those of OLT7. We describe a follow up of 45 patient-years, with a 
maximum more than twice that published so far. HLT has resulted in long-
lasting  correction of the metabolic defect and of the liver function in our 
patient with α-1-antitrypsin deficiency. The graft function has also 
remained normal or near normal in the 2 patients with hepatitis B and D 
infections of the graft, in spite of the development of severe fibrosis or 
cirrhosis of the graft within 5 years. The spleen has remained enlarged in 
all 3 patients, but no other signs or symptoms of portal hypertension have 
occurred. 
 
One of the reasons we abandoned HLT was the risk of hepatocellular 
carcinoma in the remaining cirrhotic liver in general and the even greater 
risk in specific diagnostic categories like chronic viral hepatitis and haemo-
chromatosis. Hepatocellular carcinoma was looked for systematically in 
the 2 patients with chronic viral hepatitis, but was not found. As shown by 
imaging, the native liver has atrophied in all cases. It seems possible that 
the near-total atrophy of the native liver already seen at 3 years has played 
a role in the protection of even our high-risk patients against the 
development of hepatocellular carcinoma of recipient origin. In the third 
patient there is no clinical suspicion of hepatocellular carcinoma at more 
than 16 years, her own liver has also atrophied. In all 3 cases the quality of 
life generally has been good. Notwithstanding its limitations, HLT did prove 
to be worthwhile for at least some of our chronic liver disease patients. 
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SUMMARY 
 
Selection of patients with acute hepatic failure for liver transplantation 
remains difficult, and there is no definite proof of a survival effect. We 
therefore did a retrospective study in 75 consecutive patients referred over a 
12 year period. In two thirds we identified a cause, mostly viruses or drugs. 
Patients were grouped by the Clichy and King's College criteria. In 20 there 
was no indication for transplantation. Of the 5 with autoimmune hepatitis 3 
died, significantly differing from the other 15 (P=0.009). The remaining 55 
met our criteria, except 1. All 9 patients with absolute contraindications died. 
Of the 46 enlisted, 7 died without transplantation. One year survival after 
transplantation was 69%, compared with 58% by "intention to treat". For 
patients enlisted, transplantation reduced mortality by 78% (P=0.069). The 
Clichy and King's College criteria reliably predict survival without 
transplantation, except in autoimmune hepatitis. Our study strongly suggests 
that transplantation improves survival. 
 
 
INTRODUCTION 
 
Acute hepatic failure (AHF) is defined as a syndrome of severe hepatic 
dysfunction and hepatic encephalopathy in individuals with no evidence of 
preexisting liver disease. AHF is a medical emergency and the outcome can 
generally be determined in the first 12-24 hours after admission. O'Grady, 
Schalm and Williams13 proposed to divide AHF into three groups, based on 
differences in clinical features and prognosis. Hyperacute hepatic failure is 
the term used to describe patients who develop encephalopathy within 7 
days after the onset of jaundice. The most frequent causes are 
acetaminophen intoxications and acute hepatitis A virus (HAV) or herpes 
simplex virus (HSV) infections. About one third of the patients presenting 
with hyperacute hepatic failure survive without transplantation. AHF includes 
patients with an interval from jaundice to encephalopathy of 8-28 days. 
There is a high incidence of cerebral edema in this group, and survival 
without transplantation is less than 10%. Subacute hepatic failure describes 
those patients with an interval of 5-12 weeks between the appearance of 
jaundice and the onset of encephalopathy. Although the frequency of 
cerebral edema is low, the outcome is also poor, with a survival of 
approximately 15%.13 
 
The most frequent causes of AHF are hepatotropic viruses and drugs, but 
there is a large variety of other etiologic factors. In approximately 30% of all 
cases, no cause can be identified. Some conditions can be effectively 
treated by means other than liver transplantation, for instance N-acetyl-
cysteine in cases of paracetamol intoxication or portosystemic shunting in 
Budd-Chiari syndrome. For most other causes of AHF, medical therapy is 
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supportive only, aimed at prevention of complications such as infections and 
cerebral edema. In general, the mortality of patients with AHF treated 
without liver transplantation is high and ranges between 60 and 80%.10 
 
An early and accurate assessment of the individual patient is critical in 
deciding whether liver transplantation is indicated in the treatment of AHF. 
To identify patients with hepatitis B induced AHF who die without liver 
transplantation, Benhamou and Bernuau have developed the Clichy criteria, 
which predict which patients could benefit from orthotopic liver 
transplantation (OLT). Patients with hepatic encephalopathy (grade 3 to 4) 
and concentrations of coagulation factor V less than 20% in patients in the 
age group below 30 years and less than 30% in patients in the age group 
above 30 years die in 80% of all cases.2 In a retrospective study, Pauwels et 
al. have found a low predictive value for these criteria in patients with AHF 
by non-viral causes.15 
 
O'Grady and Williams have analyzed 588 patients with AHF at King's 
College Hospital and proposed their criteria for liver transplantation. In 
acetaminophen-induced AHF, survival correlated with arterial blood pH, 
peak prothrombin time, serum creatinine and grade of encephalopathy. In 
other patients, non-A-non-B hepatitis or idiosyncratic drug reactions, age 
less than 10 or more than 40 years, jaundice for more than 7 days before 
the onset of encephalopathy, serum bilirubin more than 300 µmol/l and a 
prothrombin time of more than 50 seconds were associated with a poor 
prognosis.12 
 
In this study we report the outcome in 75 patients with AHF referred for 
emergency liver transplantation. We also did a retrospective assessment 
of  the applicability of the Clichy and the King's College criteria, and 
evaluated the effect of OLT on survival in patients put on the high urgency 
waiting list. 
 
 
PATIENTS AND METHODS 
 
From 1 April 1987 until 1 January 1999, 83 patients with acute liver failure 
were referred for OLT. Two patients died before the indication for 
transplantation could be established. Six other patients were not considered 
suitable candidates because of advanced age (n=2), ongoing chronic 
alcohol abuse (n=2) and liver failure secondary to severe nonhepatic 
disease (n=2). These 8 patients were not included in this analysis. 
 
For the remaining 75 patients, emergency liver transplantation was 
considered. Diagnostic evaluation included routine hematological and 
biochemical tests, measurement of coagulation parameters, virological and 
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immunological screening, toxicologic and metabolic tests, abdominal 
ultrasound, and a CT scan of the brain, to assess cerebral edema. Clotting 
factor V was determined by measurement of prothrombin time in plasma 
deficient of factor V. Arterial blood was used to determine pH values and 
lactate levels in patients with acetaminophen-induced AHF. The grade of 
encephalopathy was assessed using the Opolon criteria14 and by spectral 
analysis of the electroencephalogram.16 
 
All patients with grade 3 or grade 4 encephalopathy were admitted to the 
ICU. According to protocol they were intubated,  ventilated, received 
antibiotic prophylaxis and, if necessary,  were treated with intravenous 
glucose, vasopressive drugs and mannitol. In each patient the indication for 
emergency liver transplantation was weighed against absolute or relative 
contra-indications (i.e. extrahepatic infection, sepsis, malignancies, or HIV-
positivity). Prior to publication of the King’s College and Cliichy criteria the 
indication was based mainly on clinical judgement. Candidates for 
emergency liver transplantation were placed on the Eurotransplant high-
urgency waiting list after consent was obtained from the nearest relative. 
Only blood group-compatible donors were accepted. Patients without an 
indication or not fit for liver transplantation received continuing conservative 
treatment according to protocol and were re-evaluated twice daily until 
recovery or death. 
 
Table 1: Indications for emergency liver transplantation according to the 
Clichy and King's College criteria. Of the 55 patients considered as 
candidates for emergency liver transplantation, six are not included. Three 
were anhepatic at the moment of enlistment, and in another three, who did 
meet the King's College criteria, no factor V measurement was made. 
  Clichy criteria met Clichy criteria not met 
Total n = 37 n = 2 
Hepatitis B n = 5 n = 0 
King's College 
criteria met 
Other causes n = 32 n = 2 
Total n = 9 n = 1 
Hepatitis B n = 4 n = 0 
King's College 
criteria not met 
Other causes n = 5 n = 1 
 
Twenty patients met neither the Clichy nor the King's College criteria for 
enlistment (group 1), and in nine patients absolute contraindications for 
transplantation were present (group 2). Group 3 consisted of 46 patients 
who were enlisted for emergency liver transplantation, of whom 7 died on 
the waiting list (group 3a) and 39 underwent OLT (group 3b). Three of the 
seven patients in group 3a were anhepatic at the moment of enlistment after 
total hepatectomy because of liver trauma. In three other group 3 patients 
the Clichy criteria could not be applied because no factor V measurement 
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was available. One patient with venoocclusive disease met only one of the 
two Clichy criteria and two of the five King's College criteria, but was 
nevertheless accepted for emergency liver transplantation. Of the other 48 
patients, two met only the King's College criteria and nine only the Clichy 
criteria, while the remaining 37 met both (Table 1). Grade 3 or 4 
encephalopathy was present in 49 of the 51 group 3 patients that could be 
evaluated. 
 
Group 1 consisted of 4 men and 16 women with a median age of 41 years 
(range 17-57 years), group 2 of 6 men and 3 women with a median age of 
45 years (27-62), group 3a of 4 men and 3 women with a median age of 40 
years (16-55), and group 3b of 15 men and 24 women with a median age of 
37 years (16-62). The largest diagnostic categories were acute viral hepatitis 
(n=18), drug induced hepatitis (n=12), acetaminophen intoxication (n=11), 
autoimmune hepatitis (n=6), and acute liver failure of unknown etiology 
(n=19). The other indications were irreparable liver trauma (n=3), Wilson's 
disease (n=3), Budd-Chiari syndrome (n=2), and acute fatty liver of 
pregnancy (n=1). These data are summarized in Table 2. 
 
For comparisons between groups, Fisher's exact test was used. The effect 
of liver transplantation on survival in patients put on the high urgency waiting 
list was investigated using Cox regression, with transplantation as time-
dependent variable. Calculations were done using the Logxact program 
(1993, CYTEL Software Corporation, Cambridge, Mass., USA). 
 
 
RESULTS 
 
Follow up in  group 1 patients (no indication, n=20), most of whom were 
sent back to the referring clinician after recovery, is limited to a median of 
14 days (range 2-1,859 days). Three of the five patients with autoimmune 
hepatitis in this group died: one at day 14 after admission of uncontrollable 
bleeding from a duodenal ulcer, one at day 25 of sepsis as a complication 
of immunosuppressive treatment and one at home, at 91 days from 
admission and after successful treatment of her liver disease, of an 
unknown cause. No deaths were observed in the 15 patients with other 
diagnoses (P=0.009, Fisher's exact test). All patients in group 2 (absolute 
contraindictions, n=9) died at a median of 2 days (range 0-11) after 
admission. The main causes of death in this group were irreversible shock 
and multiorgan failure. 
 
In group 3 (enlisted, n=46), 7 patients, including the 3 anhepatic patients, 
died while waiting for transplants at a median of 2 days (range 0-7) after 
enlistment. Causes of death were cerebral edema in three cases, 
uncontrollable bleeding in two and irreversible shock and sepsis in one 
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each. The median stay on the waiting list for the 39 transplanted patients 
was 1 day (range 0-5 days). The median follow up in the 27 survivors of 
transplantation was 2 years and 6 months (range 6 days to 9 years and 6 
months), with 23 patients followed up for at least 1 year, 17 for at least 2 
years and 9 for at least 5 years. 
 
Table 2: Etiology of liver disease and demographics in 75 patients with 
acute hepatic failure (AHF) according to indications and contraindications 
for liver transplantation. Group 1, criteria not met (n = 20); group 2, 
absolute contraindications (n = 9); group 3a, listed, died on list (n = 7); 
group 3b, transplanted (n = 39). 
 Total 1 2 3a 3b 
Indication  No Yes Yes Yes 
Contraindication   Yes No No 
Death on waiting list    Yes No 
Total number 75 20 9 7 39 
Male/female 29/46 4/16 6/3 4/3 15/24 
Age (years)      
  Median 39 41 45 40 37 
  Range  16-62 17-57 27-64 16-55 16-62 
Cause known 56 18 7 7 24 
-  Acute viral hepatitis -  18 -  2 -  4 -  2 -  10 
   -  Acute hepatitis B     -  12     -  1     -  4     -     -  7 
   -  Acute hepatitis A     -  2     -  1     -     -     -  1 
   -  Acute EBV hepatitis     -  2     -     -     -  1     -  1 
   -  Acute HSV hepatitis     -  1     -     -     -  1     - 
   -  Acute hepatitis E     -  1     -     -     -     -  1 
-  Drug-induced hepatitis -  23 -  10 -  3 -  2 -  8 
   -  Acetaminophen     -  11     -  9     -  2     -     - 
   -  NSAID     -  2     -     -     -  1     -  1 
   -  Ecstasy     -  2     -     -     -     -  2 
   -  Other drugs     -  8     -  1     -  1     -  1     -  5 
-  Other causes -  15 -  6 - -  3 -  6 
   -  Autoimmune hepatitis     -  6     -  5     -     -     -  1 
   -  Wilson's disease     -  3     -     -     -     -  3 
   -  Liver trauma     -  3     -     -     -  3     - 
   -  Budd-Chiari syndrome     -  2     -     -     -     -  2 
   -  Acute fatty liver in pregnancy     -  1     -  1     -     -     - 
Cause unknown 19 2 2  15 
 
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug. 
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All but one of the 12 deaths after transplantation occurred within 6 months, 
at a median of 14 days (range 2-159 days) after enlistment. Death after 
transplantation was caused by sepsis in 3 patients, by cerebral edema in 2 
patients and by a variety of other causes in 6 patients. The one remaining 
patient died of a pulmonary malignancy after 6 years and 3 months. The 
causes of death in the different patient groups are listed in Table 3. The 
actual survival of transplanted patients at 1 year, 2 years, and 5 years was 
69% compared with 58% when calculated according to the intention-to-treat 
principle. Cox regression, comparing mortality of transplanted patients with 
that of those still on the waiting list, showed a relative death rate of 0.22 
(95% confidence interval 0.03-1.47, P=0.069). 
 
Table 3: Causes of death in 31 patients with acute hepatic failure according 
to indication and contraindications for liver transplantation. 
Group Total 1 2 3a 3b 
Total number 75 20 9 7 39 
Number of deaths 31 3 9 7 12 
-  Causes of death      
Irreversible shock/MOF 10  8 1 1 
Sepsis 6 1 1 1 3 
Cerebral edema 5   3 2 
Uncontrollable bleeding 3 1  2  
Aorto-enteral fistula/MRSA 1    1 
Veno-occlusive disease 1    1 
Primary nonfunctioning graft 1    1 
Pneumonia (Legionella) 1    1 
Cardiac tamponade 1    1 
Unknown 1 1    
Bronchuscarcinoma (late) 1    1 
 
Abbreviations: MOF, multiorgan failure; MRSA, methicillin-resistant Staphylococcus Aureus. 
 
 
DISCUSSION 
 
OLT has changed the prognosis of patients with AHF and is recommended 
when spontaneous recovery appears unlikely. A large U.S. series from the 
late 1980s and early 1990s showed a 63% 1-year survival after liver 
transplantation for AHF4, with a 68% survival at 2 months reported in the 
largest contemporary European study.5 In a more recent U.S. multicenter 
study, the 1-year survival had increased to 76%,17 while in Europe it 
remained about 70%.6,11 Auxiliary liver transplantation, originally 
advocated as an alternative therapy for end-stage chronic liver disease,19 
has theoretical advantages over the conventional orthotopic procedure and 
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results in an approximately 60% survival,3,18 but is an accepted treatment 
for acute liver failure in selected cases only. Other therapies, such as 
artificial hepatic support systems and hepatocyte transplantation, are still 
in an experimental stage or only serve as a bridge to OLT.7,9 
 
We describe our single-centre experience with acute liver failure over a 12-
year period, which differs from other reports in at least one important aspect. 
Recently 295 cases seen in 13 centers were reported from the USA,12 with 
acetaminophen-induced acute liver failure as the most frequent diagnosis. In 
the UK acetaminophen even accounts for the majority of cases.1,14 
Acetaminophen intoxication was the cause of acute liver failure in only 11 of 
our 75 patients (15%), with only two, both with an absolute contraindication, 
meeting the criteria for transplantation. In our series the Clichy and King's 
College criteria accurately predicted survival without transplantation for all 
patients, with the exception of three out of five presenting with acute 
autoimmune hepatitis, who died of causes not directly related to the primary 
liver disease. The chance of finding a difference like the one in this study, 
when in fact the survival in these two subgroups is equal, is less than 1%. 
 
The outcome in the 39 patients who were transplanted most probably 
would have been worse without transplantation than the 69% 1-year 
survival observed in this group, given the results of our Cox regression 
analysis and the results of medical treatment reported in the pre-
transplantation era.8 Mortality among the patients on the waiting list for 
emergency liver transplantation and in the postoperative period does, 
however, remain a serious problem. Most deaths are due to irreversible 
complications already present at or shortly after enlistment, such as 
cerebral edema or infection. Of our 46 patients enlisted for emergency liver 
transplantation 18 (39%) died on the waiting list (n=7) or in the 
postoperative period (n=11). As expected, death in these patients was 
mainly caused by infections (n=6) and by cerebral edema (n=5). Various 
other causes accounted for the remaining 7 deaths. A totally different 
pattern is seen in patients with contraindications for transplantation, most 
of whom died of irreversible shock or multiorgan failure. 
 
Our study confirms that, in patients that do meet either the Clichy or the 
King's College criteria, emergency liver transplantation improves survival, 
although due to the small number of end points the difference with the 
patients that died on the waiting list was only of borderline significance. In 
the group of patients enlisted for emergency liver transplantation the short-
term mortality remains relatively high, but might be improved by measures 
aimed at preventing cerebral edema and infections. Of special interest 
might be the outcome in the five patients with acute autoimmune hepatitis 
without an indication, three of whom died. In acute autoimmune hepatitis, 
the selection criteria for emergency liver transplantation currently in use 
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appear not be appropriate. In these patients treatment with immuno-
suppressive drugs seems to be a hazardous course, and a different 
approach may be warranted. From this retrospective study in a relatively 
modest number of patients we conclude that the combined King's College 
and the Clichy criteria are useful in deciding which patients with acute liver 
failure will or will not benefit from emergency liver transplantation in most 
diagnostic categories. 
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Introduction
Acute hepatic failure (AHF) is defined as a syndrome of
severe hepatic dysfunction and hepatic encephalopathy
in individuals with no evidence of preexisting liver dis-
ease. AHF is a medical emergency and the outcome can
generally be determined in the first 12–24 h after ad-
mission. O’Grady, Schalm, and Williams [13] proposed
to divide AHF into three groups, based on differences in
clinical features and prognosis. Hyperacute hepatic
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Abstract Selection of patients with
acute hepatic failure for liver trans-
plantation remains difficult, and
there is no definite proof of a
survival effect. We therefore did a
retrospective study in 75 consecutive
patients referred over a 12-year
period. In two-thirds we identified a
cause, mostly viruses or drugs.
Patients were grouped by the Clichy
and King’s College criteria. In 20
there was no indication for trans-
plantation. Of the 5 with auto-
immune hepatitis, 3 died,
significantly differing from the other
15 (P=0.009). The remaining 55 met
our criteria, except 1. All 9 patients
with absolute contraindications
died. Of the 46 enlisted, 7 died
without transplantation. One-year
survival after transplantation was
69%, compared with 58% by
‘‘intention to treat.’’ For
patients enlisted, transplantation
reduced mortality by 78%
(P=0.069). The Clichy and King’s
College criteria reliably predict
survival without transplantation,
except in autoimmune hepatitis.
Our study strongly suggests
that transplantation improves
survival.
Keywords Acute hepatic failure Æ
Liver transplantation Æ Survival
failure is the term used to describe patients who develop
encephalopathy within 7 days after the onset of jaun-
dice. The most frequent causes are acetaminophen
intoxications and acute hemadsorption virus (HAV) or
herpes simplex virus (HSV) infections. About one-third
of the patients presenting with hyperacute hepatic failure
survive without transplantation. AHF includes patients
with an interval from jaundice to encephalopathy of
8–28 days. There is a high incidence of cerebral edema in
this group, and survival without transplantation is less
than 10%. Subacute hepatic failure describes those pa-
tients with an interval of 5–12 weeks between the ap-
pearance of jaundice and the onset of encephalopathy.
Although the frequency of cerebral edema is low, the
outcome is also poor, with a survival of approximately
15% [13].
The most frequent causes of AHF are hepatotropic
viruses and drugs, but there is a large variety of other
etiologic factors. In approximately 30% of all cases, no
cause can be identified. Some conditions can be effec-
tively treated by means other than liver transplantation,
for instance N-acetylcysteine in cases of paracetamol
intoxication or portosystemic shunting in Budd-Chiari
syndrome. For most other causes of AHF, medical
therapy is supportive only, aimed at prevention of
complications such as infection and cerebral edema. In
general, the mortality of patients with AHF treated
without liver transplantation is high and ranges between
60 and 80% [10].
An early and accurate assessment of the individual
patient is critical in deciding whether liver transplanta-
tion is indicated in the treatment of AHF. To identify
patients with hepatitis B-induced AHF who die without
liver transplantation, Benhamou and Bernuau have
developed the Clichy criteria, which predict which pa-
tients could benefit from orthotopic liver transplant
(OLT). Patients with hepatic encephalopathy (grade
3–4) and concentrations of coagulation factor V less
than 20% in patients in the age group below 30 years
and less than 30% in patients in the age group above
30 years die in 80% of all cases [2]. In a retrospective
study, Pauwels et al. have found a low predictive value
for these criteria in patients with AHF by nonviral
causes [15].
O’Grady and Williams have analyzed 588 patients
with AHF at King’s College Hospital and proposed
their criteria for liver transplantation. In acetamino-
phen-induced AHF, survival correlated with arterial
blood pH, peak prothrombin time, serum creatinine,
and grade of encephalopathy. In other patients, without
hepatitis A or B or idiosyncratic drug reactions, aged
less than 10 years or more than 40 years, jaundice for
more than 7 days before the onset of encephalopathy,
serum bilirubin more than 300 lmol/l, and a pro-
thrombin time more of than 50 s were associated with a
poor prognosis [12].
In this study we report the outcome in 75 patients
with AHF referred for emergency liver transplantation.
We also did a retrospective assessment of the applica-
bility of the Clichy and the King’s College criteria, and
evaluated the effect of OLT on survival in patients put
on the high-urgency waiting list.
Patients and methods
From 1 April 1987 until 1 January 1999, 83 patients with acute liver
failure were referred for OLT. Two patients died before the indi-
cation for transplantation could be established. Six other patients
were not considered suitable candidates because of advanced age
(n=2), ongoing chronic alcohol abuse (n=2), and liver failure
secondary to severe nonhepatic disease (n=2). These 8 patients
were not included in this analysis.
For the remaining 75 patients, emergency liver transplantation
was considered. Diagnostic evaluation included routine hemato-
logical and biochemical tests, measurement of coagulation pa-
rameters, virological and immunological screening, toxicologic and
metabolic tests, abdominal ultrasound, and a CT scan of the brain,
to assess cerebral edema. Clotting factor V was determined by
measurement of prothrombin time in plasma deficient of factor V.
Arterial blood was used to determine pH values and lactate levels
in patients with acetaminophen-induced AHF. The grade of en-
cephalopathy was assessed using the Opolon criteria [14] and by
spectral analysis of the electroencephalogram [16]. All patients with
grade 3 or grade 4 encephalopathy were admitted to the ICU.
According to protocol they were intubated, ventilated, received
antibiotic prophylaxis, and if necessary were treated with intrave-
nous glucose, vasopressive drugs, and mannitol. In each patient the
indication for emergency liver transplantation was weighed against
absolute or relative contraindications (i.e., extrahepatic infection,
sepsis, malignancies, or HIV positivity). Prior to publication of the
King’s College and Cliichy criteria, the indication was based mainly
on clinical judgement. Candidates for emergency liver transplan-
tation were placed on the Eurotransplant high-urgency waiting list
after consent was obtained from the nearest relative. Only blood
group-compatible donors were accepted. Patients without an in-
dication or not fit for liver transplantation received continuing
conservative treatment according to protocol and were reevaluated
twice daily until recovery or death.
Twenty patients met neither the Clichy nor the King’s College
criteria for enlistment (group 1), and in nine patients absolute
contraindications for transplantation were present (group 2).
Group 3 consisted of 46 patients who were enlisted for emergency
liver transplantation, of whom 7 died while waiting for a transplant
(group 3a) and 39 underwent orthotopic liver transplantation
(group 3b). Three of the seven patients in group 3a were anhepatic
at the moment of enlistment after total hepatectomy because of
liver trauma. In 3 other group 3 patients, the Clichy criteria could
not be applied because no factor V measurement was available.
One patient with veno-occlusive disease met only one of the two
Clichy criteria and two of the five King’s College criteria, but was
nevertheless accepted for emergency liver transplantation. Of the
other 48 patients, two met only the King’s College criteria and nine
only the Clichy criteria, while the remaining 37 met both (Table 1).
Grade III or grade IV encephalopathy was present in 49 of the 51
group 3 patients that could be evaluated.
Group 1 consisted of 4 men and 16 women with a median age of
41 years (range 17–57 years), group 2 of 6 men and 3 women with a
median age of 45 years (27–62), group 3a of 4 men and 3 women
with a median age of 40 years (16–55), and group 3b of 15 men and
24 women with a median age of 37 years (16–62). The largest di-
agnostic categories were acute viral hepatitis (n=18), drug-induced
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hepatitis (n=12), acetaminophen intoxication (n=11), autoim-
mune hepatitis (n=6), and acute liver failure of unknown etiology
(n=19). The other indications were irreparable liver trauma (n=3),
Wilson’s disease (n=3), Budd-Chiari syndrome (n=2), and acute
fatty liver of pregnancy (n=1). These data are summarized in
Table 2.
For comparisons between groups, Fisher’s exact test was used.
The effect of liver transplantation on survival in patients put on the
high-urgency waiting list was investigated using Cox regression,
with transplantation as time-dependent variable. Calculations were
done using the Logxact program (1993; CYTEL Software Corpo-
ration, Cambridge, Mass., USA).
Results
Follow-up in group 1 patients (no indication, n=20),
most of whom were sent back to the referring clinician
after recovery, is limited to a median of 14 days (range
2–1,859 days). Three of the five patients with autoim-
mune hepatitis in this group died: one at day 14 after
uncontrollable bleeding from a duodenal ulcer, one at
day 25 of sepsis as a complication of immunosuppres-
sive treatment, and one at home, at 91 days from ad-
mission and after successful treatment of her liver
disease, of an unknown cause. No deaths were observed
in the 15 patients with other diagnoses (P=0.009,
Fisher’s exact test). All patients in group 2 (absolute
contraindictions, n=9) died at a median of 2 days
(range 0–11) after admission. The main causes of death
in this group were irreversible shock and multiorgan
failure.
In group 3 (enlisted, n=46), 7 patients, including the
3 anhepatic patients, died whilst waiting for transplants
at a median of 2 days (range 0–7) after enlistment.
Causes of death were cerebral edema in three cases,
uncontrollable bleeding in two, and irreversible shock
and sepsis in one each. The median stay on the waiting
list for the 39 transplanted patients was 1 day (range
0–5 days). The median follow-up in the 27 survivors of
transplantation was 2 years and 6 months (range 6 days
to 9 years and 6 months), with 23 patients followed up
for at least 1 year, 17 for at least 2 years, and 9 for at
least 5 years. All but one of the 12 deaths after trans-
plantation occurred within 6 months, at a median of
14 days (range 2–159 days) after enlistment. Death after
transplantation was caused by sepsis in 3 patients, by
cerebral edema in 2 patients, and by a variety of other
causes in 6 patients. The one remaining patient died of a
pulmonary malignancy after 6 years and 3 months. The
causes of death in the different patient groups are listed
in Table 3. The actual survival of transplant patients at
1 years, 2 years, and 5 years was 69% compared with
58% when calculated according to the intention-to-
treat principle. Cox regression, comparing mortality
of transplanted patients with that of those still on
the waiting list, showed a relative death rate of 0.22
(95% confidence interval 0.03–1.47, P=0.069).
Discussion
OLT has changed the prognosis of patients with AHF
and is recommended when spontaneous recovery ap-
pears unlikely. A large US series from the late 1980s and
early 1990s showed a 63% 1-year survival after liver
transplantation for AHF [4], with a 68% survival at
2 months reported in the largest contemporary Euro-
pean study [5]. In a more recent US multicenter study,
the 1-year survival had increased to 76% [17], while in
Europe it remained at about 70% [6, 11]. Auxiliary liver
transplantation, originally advocated as an alternative
therapy for end-stage chronic liver disease [19], has
theoretical advantages over the conventional orthotopic
procedure and results in an approximately 60% survival
[3, 18], but is an accepted treatment for acute liver
failure in selected cases only. Other therapies such as
artificial hepatic support systems and hepatocyte trans-
plantation are still at an experimental stage or only serve
as a bridge to OLT [7, 9].
We describe our single-centre experience with acute
liver failure over a 12-year period, which differs from
other reports in at least one important aspect. Recently
295 cases seen in 13 centers were reported from the USA
[12], with acetaminophen-induced acute liver failure as
the most frequent diagnosis. In the UK, acetaminophen
even accounts for the majority of cases [1, 14]. Aceta-
minophen intoxication was the cause of acute liver
failure in only 11 of our 75 patients (15%), with only 2,
both with an absolute contraindication, meeting the
criteria for transplantation.
In our series the Clichy and King’s College criteria
accurately predicted survival without transplantation for
all patients, with the exception of three out of five pre-
senting with acute autoimmune hepatitis, who died of
causes not directly related to the primary liver disease.
The chance of finding a difference like the one in this
study, when in fact the survival in these two subgroups
is equal, is less than 1%.
Table 1 Indication for emergency liver transplantation according
to the Clichy and King’s College criteria. Of the 55 patients con-
sidered as candidates for emergency liver transplantation, six are
not included. Three were anhepatic at the moment of enlistment
and, in another three who did meet the King’s College criteria, no
factor V measurement was made
Clichy
criteria met
Clichy
criteria not met
King’s College Total n=37 n=2
criteria met Hepatitis B n=5 n=0
Other causes n=32 n=2
King’s College Total n=9 n=1
criteria not met Hepatitis B n=4 n=0
Other causes n=5 n=1
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The outcome in the 39 patients who received trans-
plants most probably would have been worse without
transplantation than the 69% 1-year survival observed
in this group, given the results of our Cox regression
analysis and the results of medical treatment reported in
the pretransplantation era [8]. Mortality among the pa-
tients on the waiting list for emergency liver transplan-
tation and in the postoperative period does, however,
remain a serious problem. Most deaths are due to irre-
versible complications already present at or shortly after
enlistment, such as cerebral edema or infection. Of our
46 patients enlisted for emergency liver transplantation,
18 (39%) died on the waiting list (n=7) or in the post-
operative period (n=11). As expected, death in these
patients was mainly caused by infections (n=6) and by
cerebral edema (n=5). Various other causes accounted
for the remaining 7 deaths. A totally different pattern is
seen in patients with contraindications for transplanta-
tion, most of whom died of irreversible shock or
multiorgan failure.
Our study confirms that, in patients that do meet
either the Clichy or the King’s College criteria, emer-
gency liver transplantation improves survival, although
due to the small number of end points the difference to
the patients that died on the waiting list was only of
borderline significance. In the group of patients enlisted
for emergency liver transplantation, the short-term
mortality remains relatively high, but might be im-
proved by measures aimed at preventing cerebral ede-
ma and infections. Of special interest might be the
outcome in the five patients with acute autoimmune
hepatitis without an indication, three of whom died. In
acute autoimmune hepatitis, the selection criteria for
emergency liver transplantation currently in use appear
not be appropriate. In these patients treatment with
immunosuppressive drugs seems to be a hazardous
course, and a different approach may be warranted.
From this retrospective study in a relatively modest
number of patients, we conclude that the combined
King’s College and the Clichy criteria are useful in
deciding which patients with acute liver failure will or
will not benefit from emergency liver transplantation in
most diagnostic categories.
Table 2 Etiology of liver dis-
ease and demographics in 75
patients with acute hepatic fail-
ure (AHF) according to indica-
tion and contraindications for
liver transplantation. Group 1,
criteria not met (n=20); group
2, absolute contraindications
(n=9); group 3a, listed, died on
list (n=7); group 3b, listed,
transplanted (n=39) (NSAID
nonsteroidal anti-inflammatory
drug)
Group Total 1 2 3a 3b
Indication No Yes Yes Yes
Contraindication Yes No No
Death on waiting list Yes No
Total number 75 20 9 7 39
Male/female 29/46 4/16 6/3 4/3 15/24
Age (years)
Median 39 41 45 40 37
Range 16–62 17–57 27–62 16–55 16–62
Acute viral hepatitis 18 2 4 2 10
Acute hepatitis B 12 1 4 7
Acute hepatitis A 2 1 1
Acute EBV hepatitis 2 1 1
Acute HSV hepatitis 1 1
Acute hepatitis E 1 1
Drug-induced hepatitis 23 10 3 2 8
Acetaminophen 11 9 2
NSAID 2 1 1
Ecstasy 2 2
Other drugs 8 1 1 1 5
Other causes 15 6 3 6
Autoimmune hepatitis 6 5 1
Wilson’s disease 3 3
Liver trauma 3 3
Budd-Chiari syndrome 2 2
Acute fatty liver in pregnancy 1 1
Cause unknown 19 2 2 15
Table 3 Causes of death in 21 patients with acute hepatic
failure according to indication and contraindications for liver
transplantation. MOF multiorgan failure, MRSA methicillin-
resistant Staphylococcus aureus
Group Total 1 2 3a 3b
Total number 75 20 9 7 39
Number of deaths 31 3 9 7 12
Causes of death
Irreversible shock/MOF 10 8 1 1
Sepsis 6 1 1 1 3
Cerebral edema 5 3 2
Uncontrollable bleeding 3 1 2
Aorto-enteral fistula/MRSA 1 1
Veno-occlusive disease 1 1
Primary nonfunctioning graft 1 1
Pneumonia (Legionella) 1 1
Cardiac tamponade 1 1
Unknown 1 1
Bronchuscarcinoma (late) 1 1
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SUMMARY 
 
Background Little is known about the long-term sequelae of acute liver 
failure treated by liver transplantation. We therefore studied the clinical 
course of patients who survived at least 10 years. 
Methods From 65 patients transplanted for acute liver failure between 
1989 and 2002 we selected those that had a complete follow-up of at least 
10 years. In this group of 10 patients we conducted a retrospective study 
aimed at general health aspects and specific complications, including graft 
dysfunction, hypertension, renal dysfunction, obesity, diabetes, 
dyslipidemia and bone loss at 5 and at 10 years. 
Results Of the 10 patients seven were functioning normally at both time 
points, limitations due to pre-existing diseases were present in three. 
Frequent complications were obesity, dyslipidemia, hypertension and mild 
renal dysfunction. One or more of these problems were found in nine 
patients at 5 years and in all 10 at 10 years. Other complications were 
either uncommon or absent. 
Conclusions In spite of some frequent late postoperative complications, 
liver transplantation leads to complete rehabilitation in the majority of 
patients with acute liver failure who survive the initial period after the 
operation. 
 
 
INTRODUCTION 
 
Liver transplantation is regarded as an effective treatment of acute liver 
failure, resulting in survival rates between 60% and 80%1-5. Yet little is 
known about long-term sequelae in surviving patients. Studies on long-
term outcomes after transplantation for acute liver failure have 
concentrated mainly on survival, and only few on retransplantation, 
hepatitis B virus reinfection and neuropsychologic function1,6. We, 
therefore, decided to study the clinical course after transplantation, and 
especially the prevalence of late complications in our long-term survivors 
of acute liver failure. 
 
 
PATIENTS AND METHODS 
 
Until the end of 2002 we performed orthotopic liver transplantations in 65 
patients with acute liver failure. Of these 65, 18 were done prior to 
November, 1994. In this group of 18, there were five deaths within two 
weeks after transplantation, and one at five months. One patient died from 
a pulmonary tumour at 6 years after transplantation, and one was lost to 
follow up after 7 years. The study group was formed by the ten remaining 
patients, that have been followed for at least 10 years. These were two 
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males and eight females with a median age at transplantation of 33 years 
(range 20-50 years). All 10 patients were included in an earlier report, 
where more details on the severity of the liver disease were given5. The 
causes of liver failure were acute hepatitis B in four patients, acute 
hepatitis A in one, drug-induced hepatitis in two, Wilson’s disease in one, 
Budd-Chiari syndrome in one and unknown in the last patient. One patient 
was retransplanted after three days because of hepatic artery thrombosis, 
a second patient had to be retransplanted after five months because of 
ischemic type biliary lesions. 
 
After transplantation, all patients had yearly check-ups, consisting of a 
routine clinical visit, recording of medication, length, weight and blood 
pressure, biochemical tests, virological tests, and measurement of bone 
mass. We chose the 5- and 10-year time-points for this study. Liver 
biopsies were not done on a protocol basis but only when indicated. Data 
were retrieved from our liver transplantation database and from patient 
files. All laboratory measurements were done using standard automated 
methods. Hypertension was defined as the use of one or more 
antihypertensive drugs. Diabetes was diagnosed according to current 
international standards7. Values for triglycerides or cholesterol above the 
desired range are referred to as dyslipidemia. Bone mass was measured 
by dual photon absorptiometry. 
 
 
RESULTS 
 
General health, treatment and pregnancies The number of patients that 
could be classified as “alive and well” was seven at both 5 and 10 years. 
Two patients suffered from chronic psychiatric disorders and one had 
progressive multiple sclerosis, these diseases were already present before 
transplantation in all cases. Readmissions were concentrated in the first 
year after transplantation with a median of 17.5 days (range 0-76 days), 
and accounted for a median of 5.4 hospital-days per year (range 0.0-23.6 
days/year) in the first 5 years after transplantation, and for 0.3 days/year 
(range 0.0-8.6 days/year) in the next 5 years (table 1). All four patients with 
acute hepatitis B were treated with hepatitis B immunoglobulin only during 
the first year after transplantation, none developed reinfection of the graft 
although antibodies to the hepatitis B surface-antigen remained positive in 
only two. At 5 years all ten patients were treated with calcineurin-inhibitors, 
three were on a triple immuno- suppressive regimen, four on a two-drug 
regimen and three on mono-therapy. At 10 years these numbers were ten, 
two, one and seven. There have been four pregnancies in three patients, 
one ending in intra-uterine foetal death and three in delivery of a healthy 
child. 
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Table 1: Clinical and anthropometric data on long-term survivors at 5 and 
at 10 years after transplantation for acute liver failure. 
5 years 10 years  
median (range) n= median (range) n= 
Readmissions (days/year) 5.4 (0.0-23.6) 10 0.3 (0.0-8.6) 10 
Immunosuppressive drugs 2 (1-3) 10 1 (1-2) 10 
    CNI1 + STE2 + AZA3  3  2 
    CNI + STE  4  1 
    CNI monotherapy  3  7 
Hypertension  7  8 
Diabetes  0  0 
Body Mass Index (kg/m2) 26 (21-36) 10 25 (20-34) 10 
    BMI > 25 / > 30  6/3  4/2 
BMD L2-L4 (g/cm) 1.19 (1.01-1.35) 10 1.23 (1.04-1.38) 10 
    Z-score < -1 / < -2  1/0  1/0 
BMD femoral neck (g/cm) 0.94 (0.67-1.22) 10 0.94 (0.71-1.22) 10 
    Z-score < -1 / < -2  5/1  3/1 
1) CNI: Calcineurin inhibitors 
2) STE: Corticosteroids 
3) AZA: Azathioprine 
4) BMD: Bone Mineral Density (dual photon absorptiometry) 
5) Z-score: difference from age- and sex-matched controls in S.D. 
 
Graft function and histology The function of the liver grafts was 
measured by serum concentrations of bilirubin, albumin and coagulation 
factors. At 5 years, the graft function was normal in all but two of the 
patients, who had slightly elevated bilirubin levels. At 10 years bilirubin 
was also above normal in two patients, one of these and one additional 
patient had an antithrombin-III level just below the normal range. Mild liver 
enzyme abnormalities, mainly of the cholestatic type, were found in two of 
the patients at 5 years and in five at 10 years (table 2). Measurements of 
the spleen size were available for five patients at 5 years (median length 
9.9 cm, range 7.7-13.0 cm), and for six at 10 years (9.6 cm, 7.6-13.0 cm). 
There was only one patient with a spleen size >12.0 cm both at 5 and at 
10 years. No other signs or symptoms of portal hypertension were found in 
any of the patients. Between 5 and 10 years after transplantation four liver 
biopsies were done in 3 patients, these showed signs of nodular 
regenerative hyperplasia and mild ductopenia at 7.4 years in one, 
moderate fibrosis in another one at 8.2 years, and only minimal 
abnormalities at 8.0 years in the last patient. 
 
Hypertension and renal dysfunction Hypertension requiring drug 
treatment was present in seven patients at 5 years and in eight at 10 years 
(table 1). At 5 years serum creatinine concentrations were above normal in 
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four of the seven hypertensive patients and in one of the three 
normotensive patients. At 10 years these figures were six of the eight and 
one of the two. The median serum creatinine concentration was 96 µmol/l 
(range 72-152 µmol/l) at 5 years and 115 µmol/l (range 82-154 µmol/l) at 
10 years (table 2). 
 
Table 2: Laboratory measurements in long-term survivors at 5 and at 10 
years after transplantation for acute liver failure. 
5 years 10 years  normal range       
– or –             
target range 
median 
(range) 
normal median 
(range) 
normal 
Bilirubin        
(µmol/l) 
<17 11                  
(9-24) 
9/10 10                 
(7-31) 
8/10 
Albumin              
(g/l) 
35-50 44               
(39-49) 
10/10 41                
(39-48) 
10/10 
Prothrombin time  
(INR, -/-) 
≤1.4 0.9              
(0.9-1.0) 
7/7 1.0              
(0.9-1.1) 
10/10 
Antithrombin-III  
(U/ml) 
0.80-1.20 1.10         
(0.85-1.40) 
10/10 1.10           
(0.77-1.19) 
8/10 
    All liver enzymes   3/7  5/10 
Alkaline 
phosphatase (U/l) 
<120 60               
(26-158) 
7/9 84                
(53-129) 
9/10 
γ-glutamyl 
transferase (U/l) 
M <50              
F <35 
29               
(17-181) 
5/8 40                
(20-135) 
5/10 
Aspartate amino-
transferase (U/l) 
M < 37              
F <31 
16               
(12-40) 
9/10 27                
(20-29) 
10/10 
Alanine amino-
transferase (U/l) 
M <41               
F <31 
19                
(11-55) 
9/10 23               
(13-41) 
9/10 
Creatinine    
(µmol/l) 
M 65-115          
F 55-90 
96                
(72-152) 
5/10 115             
(82-154) 
3/10 
Triglycerides 
(mmol/l) 
≤2.0 1.54         
(1.33-3.00) 
3/5 1.36          
(0.93-2.72) 
8/9 
Cholesterol 
(mmol/l) 
≤5.0 6.2              
(4.8-6.6) 
1/5 5.4             
(3.5-6.6) 
1/10 
HDL-cholesterol 
(mmol/l) 
≥1.55 1.51          
(0.87-1.61) 
2/4 1.58         
(0.94-2.71) 
5/10 
Haemoglobin 
(mmol/l) 
M 8.6-10.5       
F 7.5-9.5 
8.5              
(6.9-9.8) 
8/10 8.5             
(6.7-10.2) 
7/10 
Leukocyte count 
(x109/l) 
3.5-10.0 8.1              
(5.0-9.9) 
10/10 7.3             
(6.0-8.5) 
10/10 
Platelet count 
(x109/l) 
150-400 238            
(182-317) 
10/10 219            
(161-330) 
10/10 
 
Obesity, diabetes and dyslipidemia At 5 years the median Body Mass 
Index (BMI) was 26 kg/m2 (range 21-36 kg/m2), and at 10 years 25 kg/m2 
(20-34 kg/m2). At 5 years six patients had a BMI > 25 kg/m2 and three of 
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these a BMI > 30 kg/m2. At 10 years these figures were four and two. 
Between 5 and 10 years weight was gained by three patients and lost by 
three patients, while four remained stable. Diabetes was found in none of 
the patients (table 1). Hypercholesterolemia was found in four out of five 
patients at 5 years and in nine out of ten at 10 years. Hypertriglyceridemia 
was present in one patient with a BMI >30 kg/m2 at 5 as well as at 10 
years, in one other patient triglycerides were elevated at 5 years but 
normal at 10 years. The median serum cholesterol was 6.2 mmol/l (range 
4.8-6.6 mmol/l) at 5 years and 5.4 mmol/l (3.5-6.6 mmol/l) at 10 years. For 
the serum triglycerides these figures were 1.54 mmol/l (1.33-3.00 mmol/l) 
and 1.36 mmol/l (0.93-2.72 mmol/l) (table 2). 
 
Bone loss Bone mineral mass of the lumbar spine at the level of L2 to L4 
and of the femoral neck was measured routinely in all patients. To prevent 
or treat bone loss Calcium and vitamin D were prescribed to three patients 
at 5 years and at 10 years. The median lumbar spine Bone Mineral 
Density (BMD) at 5 years was 1.19 g/cm (range 1.01-1.35 g/cm) and 1.23 
g/cm (1.04-1.38 g/cm) at 10 years. For the femoral neck these figures 
were 0.94 g/cm (0.67-1.22 g/cm) and 0.94 (0.71-1.22 g/cm). At 5 and at 10 
years, only one female patient had a lumbar spine BMD of more than 1 
S.D. below the mean for age- and sex-matched controls (Z-score), she 
was the only one with frank osteopenia of the femoral neck, with a Z-score 
< -2 (table 1). 
 
 
DISCUSSION 
 
We observed a survival of more than 10 years in 10 of our 18 patients with 
acute liver failure who underwent emergency orthotopic liver 
transplantation. No objective quality of life measurements were done, but 
the subjective quality of life has been good in most of these 10 patients. 
Some frequent long-term complications were found, the main ones being 
obesity, dyslipidemia, hypertension and mild renal dysfunction. In various 
combinations these problems were present in nine of the patients at 5 
years and in all ten at 10 years, with a mean number of complications per 
patient of 2.2 at 5 years and of 2.8 at 10 years. At 10 years the 
biochemical graft function was normal in all but three of the patients but 
only minimal abnormalities were found in these three. Histological 
abnormalities of the graft were found in two patients at 7.4 and 8.2 years 
after transplantation. None has developed signs or symptoms of portal 
hypertension. Osteopenia was uncommon in our patients. 
 
No overt neuropsychological complications developed after transplantation 
in our 10 long-term survivors. However, we did not use specific tests of 
neuropsychologic function like others have done6. Nevertheless, most of 
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our patients have been able to lead a fairly normal life for at least 10 years 
after transplantation, without clear limitations due to the original disease, 
the operation or the long-term immunosuppressive treatment. The three 
patients that did not function at a normal level all had pre-existing 
psychiatric or neurologic diseases. We conclude that for patients with 
acute liver failure emergency liver transplantation not only improves 
survival, but also leads to complete rehabilitation in most patients that 
survive the operation. However, obesity, dyslipidemia, hypertension and 
renal dysfunction are common and increase over time. Most of these 
problems are related to the immunosuppressive therapy, especially the 
treatment with calcineurin inhibitors. Changes in and minimisation of 
immunosuppression might lead to a decrease in the prevalence or the 
severity of these complications. 
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SUMMARY 
 
Background Individualised immunosuppressive treatment after liver 
transplantation requires an estimate of the risk of acute rejection. We 
therefore studied 120 potential risk factors in patients that were mainly 
treated with calcineurin inhibitors and did not receive anti-lymphocyte 
antibodies or Interleukin-2-receptor blocking antibodies. 
Patients and methods Data on all consecutive patients meeting the 
inclusion criteria for the study were extracted from our liver transplantation 
database and from patient files. The study group consisted of 95 males 
and 89 females with a median age of 47 years (range 16-70 years). There 
were 68 acute rejections in the first 3 months after transplantation. 
Statistical methods used were Kaplan-Meier survival estimates and 
univariate as well as multivariate Cox regression analysis. 
Results Age under 50 years and the presence of the HLA-DR6 and DR7 
antigens in recipients were associated with an increased risk of early acute 
rejection. Other factors that significantly increased the risk were 
peroperative cryoprecipitate use and postoperative intravenous 
Cyclosporin treatment. Anti-hepatitis B immunoglobulin treatment was 
associated with a lower risk. A score containing four of these factors, 
without cryoprecipitate use and intravenous Cyclosporin treatment, turned 
out to have a c-statistic of 0.660, very near the optimum. 
Conclusions Our study suggests that it is possible to define patient 
groups at different risks of acute rejection using a limited number of four 
factors known at the moment of transplantation. Confirmation of pur 
findings would pave the road for individualised immunosuppression after 
liver transplantation. 
 
 
INTRODUCTION 
 
The calcineurin inhibitors Cyclosporin and Tacrolimus are currently used 
by virtually all liver transplantation centers to prevent acute rejections. Still, 
in two large studies comparing both agents incidences of acute rejection of 
40%1 and 76%2 were found. In our center the incidence of Early Acute 
Rejection (EAR) in the first three months after liver transplantation has 
dropped from 39% to 18% after the introduction of interleukin-2-receptor 
blocking antibodies as part of the primary immunosuppressive therapy in 
1998. These data imply that interleukin-2-receptor blocking antibodies are 
very effective in preventing acute rejection, but also that between 25% and 
60% of patients could have been treated with a two-drug regimen 
consisting of corticosteroids and calcineurin inhibitors, and received an 
additional immunosuppressive agent in spite of the fact that they were not 
at risk for acute rejection. Given these figures it seems important to identify 
patients that have a low risk of acute rejection and can be spared the 
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potential danger of over-immunosuppression, and patients with a high risk 
that might benefit from an intensified immunosuppressive regimen 
containing interleukin-2-receptor blocking antibodies. 
 
Recipient factors, donor factors and factors related to matching of donor 
and recipient, the operative procedure and postoperative events that can 
be used to predict acute rejection after liver transplantation have been 
identified in earlier studies3-14. There are a number of differences between 
these studies, for instance in the immunosuppressive treatment that was 
used. It is, therefore, not surprising that the outcomes of these studies are 
different, and that conflicting results have been reported15-20. To address 
this problem, and to identify factors associated with EAR in a patient group 
treated mainly with calcineurin inhibitors, we studied our liver 
transplantation patients treated with an immunosuppressive regimen not 
containing anti-lymphocyte antibodies or interleukin-2-receptor blocking 
antibodies. 
 
 
PATIENTS AND METHODS 
 
All consecutive patients that underwent orthotopic liver transplantation in 
our center between 1990 and 2004 who were not treated with anti-
lymphocyte antibodies or interleukin-2-receptor blocking antibodies were 
entered in the analysis. The study comprised 199 transplantations in 184 
patients. In two cases late retransplantations were included while the 
primary ones were not. Of all transplantations, 157 (79%) were done in the 
6-year period between 1993 and 1999. Data were extracted from patient 
files and from our liver transplantation database. All biochemical 
measurements were done using standard automated tests. Human 
Leukocyte Antigen (HLA) typing of recipients and donors was done by the 
National Reference Centre for Histocompatibility Testing in Leiden, the 
Netherlands, using standard lymphocytotoxicity tests. 
 
There were 95 male and 89 female recipients with a median age of 47 
years (range 16 to 70 years). Acute liver failure was the indication for 
primary transplantation in 39 patients, active chronic hepatitis B in 17, 
hepatitis C in 19, primary biliary cirrhosis in 15, primary sclerosing 
cholangitis in 28, alcoholic liver disease in 17, cryptogenic liver disease in 
13, hepatocellular carcinoma in 10, and a variety of other liver diseases in 
26. Two diagnoses were found in 19 patients and three in 2 patients. 
Postoperative treatment consisted of corticosteroids and either 
Cyclosporin (n=136) or Tacrolimus (n=42). Cyclosporin was given 
intravenously 118 times. Calcineurin inhibitors were not used in 19 cases 
of intraoperative death or immediate postoperative graft failure, and for 
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other reasons in 2 cases. Azathioprine or Mofetil-mycophenolate was used 
as additional immunosuppressive agent in 120 patients. 
 
EAR was defined as deterioration of liver graft function in the first 3 months 
after liver transplantation with no other identifiable cause and a compatible 
liver graft histology, responding to high-dose corticosteroids or anti-
lymphocyte immunoglobulins. Incidences of EAR were calculated 
according to the Kaplan-Meier method. Of the 199 transplantations 68 
(42%) were followed by EAR (table 1). The effects of different factors on 
 
Table 1: Characteristics of patients in the study group. 
 All patients Complete data 
Number of patients 184 137 
Males / Females 95 / 89 71 / 66 
Number of transplantations 199 147 
Primary transplantation only 182 135 
Primary transplantation and retransplantation 15 10 
Retransplantation only 2 2 
Age in years, median (range) 47 (16 – 70) 48 (16 – 67) 
Liver disease   
Acute liver failure 41 26 
Chronic hepatitis B 26 19 
Chronic hepatitis C 27 21 
Primary biliary cirrhosis 18 15 
Primary sclerosing cholangitis 33 28 
Alcoholic liver disease 23 19 
Cryptogenic liver disease 38 26 
Other liver diseases (diagnostic restgroup) 44 28 
Hepatocellular carcinoma 11 7 
Primary immunosuppressive treatment   
Cyclosporin (intravenous) 136 (118) 114 (101) 
Tacrolimus 42 32 
No calcineurin inhibitors 21 1 
Azathioprine 118 98 
Acute rejections 68 (42%) 60 (44%) 
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the incidence of EAR were calculated using the Cox proportional hazard 
rate model. A first round of screening by univariate analysis was done in all 
patients. Factors with a P-value ≤ 0.20 and factors found to be significant 
in multivariate analyses by others were entered in a multivariate Cox 
model using a step-forward approach and excluding patients with 
incomplete data. Here categorical factors with at less than 20 cases in 
either category were not analysed. In the multivariate analysis P-values 
<0.05 were considered significant. Finally, different risk scores were 
calculated by dropping the least influential factors from the final Cox-model 
in a stepwise fashion. C-statistics were calculated for these models 
according to the method described by Harrell21. All statistical tests were 
done using STATA (version 5.0, Stata Corporation, 702 University Drive 
East, College Station, TX 77840 USA). 
 
 
RESULTS 
 
The variables found to be of possible predictive value in the first round of 
univariate testing can be divided in recipient factors, donor factors and 
other factors related to matching, operative procedure and postoperative 
treatment (table 2). There were 5 recipient factors with P < 0.05 and 13 
with a P between 0.05 and 0.20. For donor factors these numbers were 0 
and 4, and for other factors 11 and 5. In the subsequent step-forward 
multivariate Cox-analysis we added another 13 factors identified as 
independent predictors in earlier studies that used multivariate tests. A 
cold ischemic time > 15 hours occurred only 15 times in our series and 
was not included in the analysis. Also not used for multivariate testing 
were 100 other factors, mainly specific HLA-types (n=51) and 
immunological factors (n=22), 71 with univariate P-values >0.20 and 29 
with too few cases in either category. 
 
In the second round of testing 52 (26%) of the 199 transplantations were 
excluded because of incomplete data. Of these 52, 23 did not survive with 
a functioning graft for long enough to be at risk of acute rejection. In 19 
cases HLA-typing was incomplete or missing, and various other data were 
not recorded in the remaining 10 cases. The frequencies of postoperative 
intravenous Cyclosporin treatment and EAR were lower in dropped cases 
than in those with complete data (P≤0.001, logistic regression analysis). 
For other relevant factors no significant differences were found.  
 
The multivariate Cox analysis resulted in a model consisting of 
postoperative intravenous Cyclosporin treatment (HR 4.01, 95% CI 1.88 – 
8.54, P<0.001), HLA-DR6 in the recipient (HR 2.07, 95% CI 1.21 – 
3.53,P=0.008), HLA-DR7 in the recipient (HR 2.15, 95% CI 1.18 – 3.94, 
P=0.013), peroperative cryoprecipitate use (HR 1.14 for each unit, 95% CI 
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Table 2: Factors possibly predicting acute rejection in the first 3 months 
after liver transplantation identified by screening using univariate Cox 
regression analysis or in earlier studies. 
P <0.100 Rejection HR (95% CI) P 
Recipient factors    
HLA-DR6 positive 30 / 69 1.87 (1.14 – 3.06) 0.013 
Acute liver failure 19 / 41 1.86 (1.10 – 3.17) 0.022 
Diagnostic restgroup 9 / 44 0.44 (0.24 – 0.89) 0.022 
HLA-B12 positive 19 / 38 1.88 (1.10 – 3.21) 0.022 
HLA-DR1 positive 4 / 26 0.36 (0.13 – 0.99) 0.049 
Other factors    
Postoperative intravenous Cyclosporin 
treatment 
56 / 118 3.72 (1.72 – 6.63) <0.001 
Period 1990 – 1996 (versus 1997 – 2004) 47 / 104 2.17 (1.30 – 3.64) 0.003 
Postoperative intravenous or oral 
Cyclosporin treatment 
60 / 135 2.83 (1.36 – 5.93) 0.006 
Postoperative Tacrolimus treatment 7 / 42 0.35 (0.16 – 0.76) 0.008 
Number of HLA-A mismatches 1: 27 / 82     
2: 34 / 72 
1.72 (1.14 – 2.59) 0.010 
Waiting time (in days) -- 0.995             
(0.991 – 0.999) 
0.013 
Postoperative anti-Cytomegalovirus 
immunoglobulin treatment 
14 / 23 2.12 (1.17 – 3.82) 0.013 
Anti-Cytomegalovirus IgG donor positive 
and recipient negative 
15 / 31 1.98 (1.11 – 3.51) 0.020 
Duration of transplantation (in minutes) -- 1.002               
(1.000 – 1.004) 
0.023 
HLA-A partial or complete match 24 / 80 0.58 (0.35 – 0.97) 0.037 
Postoperative Azathioprine treatment 52 / 118 1.81 (1.03 – 3.17) 0.038 
 
1.02 – 1.26, P=0.016), postoperative anti-hepatitis B virus immunoglobulin 
treatment (HR 0.34, 95% CI 0.12 – 0.95, P=0.039) and recipient age under 
50 years (HR 1.79, 95% CI 1.02 – 3.14, P=0.43). The final Cox model is 
shown in table 3. A risk score was calculated by adding the natural 
logarithms of the hazard ratio's for the factors. Intravenous Cyclosporin 
treatment was not used for the calculation of this risk score because this 
factor is unknown at the time of transplantation. The other factors were 
dropped one by one according to their influence on the c-statistics, leading 
to scores containing 5, 4, 3 and 2 factors (table 4). The score containing 5 
factors ([recipient HLA-DR6 x 0.76] + [recipient HLA-DR7 x 0.56] + 
[peroperative cryoprecipitate use in U x 0.14] – [postoperative anti-
hepatitis B virus immunoglobulin treatment x 1.01] + [recipient age under 
50 years x 0.62]) appeared to be the optimal one, with 0.665 as the c- 
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Table 2: continued 
P 0.050-0.200 Rejection HR (95% CI) P 
Recipient factors    
Preoperative serum bilirubin < 85 µmol/l 41 / 100 1.62 (1.00 – 2.64) 0.050 
Age < 50 years 46 / 112 1.65 (0.99 – 2.75) 0.054 
Ln(preoperative serum bilirubin in µmol/l) -- 1.21 (0.99 – 1.47) 0.069 
Anti-Cytomegalovirus IgG positive 37 / 127 0.64 (0.39 – 1.04) 0.071 
HLA-DR3 positive 17 / 57 0.61 (0.35 – 1.07) 0.085 
Edema present 24 / 88 0.65 (0.39 – 1.07) 0.088 
Chronic Hepatitis B (s- antigen positive) 5 / 26 0.47 (0.19 – 1.16) 0.100 
HLA-DR7 positive 19 / 44 1.55 (0.90 – 2.61) 0.112 
Preoperative serum bilirubin in µmol/l -- 1.0007         
(0.9998 – 1.0017) 
0.123 
Blood group B or AB 16 / 33 1.55 (0.88 – 2.71) 0.128 
Chronic viral infection (Cytomegalovirus / 
hepatitis B / hepatitis C) 
39 / 132 0.68 (0.42 – 1.12) 0.129 
HLA-B7 positive 6 / 25 0.53 (0.23 – 1.22) 0.136 
Cryptogenic cirrhosis 16 / 38 1.53 (0.87 – 2.68) 0.139 
Donor factors    
HLA-B35 positive 17 / 40 1.56 (0.90 – 2.71) 0.111 
HLA-B8 positive 10 / 39 0.59 (0.30 – 1.16) 0.129 
HLA-DR6 positive 22 / 51 1.46 (0.88 – 2.43) 0.145 
HLA-A3 positive 20 / 61 0.69 (0.41 – 1.16) 0.162 
Other factors    
Postoperative anti-hepatitis B virus 
immunoglobulin treatment 
6 / 27 0.45 (0.20 – 1.05) 0.064 
Peroperative cryoprecipitate use (in units) -- 1.102             
(0.986 – 1.232) 
0.085 
HLA-class 1 partial or complete match 34 / 102 0.67 (0.41 – 1.09) 0.105 
Donor-recipient ethnic mismatch 10 / 43 0.60 (0.31 – 1.17) 0.135 
Peroperative red blood cell concentrate use 
(in units) 
-- 1.015               
(0.993 – 1.037) 
0.197 
 
statistic. The c-statistic was 0.660 for a score with 4 factors, without 
peroperative cryoprecipitate use, and declined to 0.63 or lower for scores 
with 3 or 2 factors. Since cryoprecipitate was used only in a minority of 
cases we chose the four-factor score consisting of [recipient HLA-DR6 x 
0.81] + [recipient HLA-DR7 x 0.64] – [postoperative anti-hepatitis B virus 
immunoglobulin treatment x 1.01] + [recipient age under 50 years x 0.56] 
for further calculations. EAR occurred in 8 of 47 patients (18%, 95% CI 9% 
to 33%) with a four-factor score up to 0, in 25 of 56 (48%, 95% CI 36% to 
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Table 2: continued 
P >0.200 Rejection HR (95% CI) P 
Recipient factors    
Disease category: 1) chronic viral hepatitis;       
2) alcoholic liver disease; 3) hepatocellular 
carcinoma; 4) Primary Biliary Cirrhosis and 
Primary Sclerosing Cholangitis 
1) 10 / 38    
2)   9 / 22      
3)   5 / 10      
4) 20 / 51 
1.14 (0.91 – 1.43) 0.265 
Preoperative kreatinine ≥176 µmol/l or on 
dialysis 
8 / 22 1.45 (0.69 – 3.03) 0.324 
Age category: 16-29 = 1                                        
- 30-39 = 2                                                                
- 40-49 = 3                                                                
- 50-59 = 4                                                               
- 60+ = 5 
1: 11 / 26      
2:   8 / 28        
3: 27 / 58     
4: 13 / 60      
5:   9 / 27 
0.91 (0.75 – 1.10) 0.325 
Age (in years) -- 0.99 (0.97 – 1.01) 0.347 
Preoperative ASAT >5x(ULN)                                             
- ASAT >5xULN versus ASAT ≤ULN                            
- ASAT >5xULN versus ASAT 1-5xULN 
22 / 58 1.25 (0.75 – 2.07)        
1.62 (0.49 – 5.42)        
1.24 (0.74 – 2.07) 
0.396 
0.432 
0.421 
Chronic hepatitis C 11 / 27 1.32 (0.69 – 2.51) 0.405 
Female sex 34 / 96 1.21 (0.75 – 1.94) 0.437 
Child-class A (cirrhotic patients only) 7 / 21 0.94 (0.42 – 2.11) 0.882 
Donor factors    
Age ≥30 years 50 / 141 1.20 (0.70 – 2.06) 0.508 
Other factors    
Partial HLA-class 1 match (in recipients 
chronically infected with hepatitis B-, 
hepatitis C- or Cytomegalo-virus) 
22 / 73 0.77 (0.40 – 1.48) 0.433 
HLA-class 2 partial or complete match 26 / 66 1.00 (0.61 – 1.65) 0.998 
 
63%) with a score up to 1, and in 27 of 44 (67%, 95% CI 52% to 81%) with 
a score over 1. There was a small very high risk group of 7 patients 
scoring 1.45 or more and a 100% incidence of EAR. 
 
 
DISCUSSION 
 
Our study shows that it is possible to identify patient groups at low risk, 
intermediate risk, and high risk of acute rejection in the first 3 months after 
liver transplantation, as can also be concluded from earlier reports 
mentioned in the introduction. These studies do, however, differ from each 
other and from ours in the predictive factors that come out, and also in 
other ways. Most of the earlier studies8-20 used only univariate tests. There 
are five3-7 that used multivariate tests, but these still show considerable 
differences in other aspects. In- and exclusion criteria vary, as does the 
definition of EAR, and also the factors tested (table 5). Our study is by far 
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the most comprehensive one in this category, even though it is not the 
largest one. When compared to other studies using multivariate tests, ours 
confirms only the significance of recipient age, albeit modelled differently 
as recipient age under 50 years, with a borderline significant additional 
effect of the age category (HR 1.44, 95% CI 0.99 – 2.10, P=0.058). 
 
Table 3: Final multivariate Cox models of factors predicting acute rejection 
in the first 3 months after liver transplantation. 
 Hazard ratio 95% confidence interval P 
Final model (log likelihood = –259)   < 0.001 
Postoperative intravenous 
Cyclosporin treatment 
4.01 1.88 – 8.54 <0.001 
Recipient HLA-DR6 positive 2.07 1.21 – 3.53 0.008 
Recipient HLA-DR7 positive 2.15 1.18 – 3.94 0.013 
Peroperative cryoprecipitate use (U) 1.14 1.02 – 1.26 0.016 
Postoperative anti-hepatitis B virus 
immunoglobulin treatment 
0.34 0.12 – 0.95 0.039 
Recipient age < 50 years 1.79 1.02 – 3.14 0.043 
 
Table 4: Coefficients, model log-likelihoods and model P-values derived 
from Cox models containing 6, 5, 4, 3 and 2 factors predicting acute 
rejection within 3 months after liver transplantation, with factors left out one 
by one according to their impact on the c-statistics. 
Cox regression analysis 
 6 factor 
model 
5 factor 
model 
4 factor 
model 
3 factor 
model 
2 factor 
model 
Recipient HLA-DR6 positive 0.73 0.76 0.81 0.66 0.74 
Recipient age < 50 years 0.58 0.62 0.56 0.64 0.63 
Postoperative anti-hepatitis B virus 
immunoglobulin treatment 
– 1.08 – 1.01 – 1.01  – 1.08 -- 
Recipient HLA-DR7 positive 0.77 0.56 0.64 -- -- 
Peroperative cryoprecipitate use (U) 0.13 0.14 -- -- -- 
Intravenous Cyclosporin treatment 1.39 -- -- -- -- 
Model Log Likelihood – 258.9 – 267.6 – 269.7 – 271.8 – 274.8 
Model P (chi-square test) <0.001 <0.001 <0.001 <0.001 0.001 
c-statistics -- 0.665 0.660 0.648 0.623 
 
None of the 11 remaining factors from the earlier reports on multivariate 
testing turned out to be significant in our analysis (table 6). Borderline 
significance was reached only by hepatitis C as the indication for 
transplantation (HR 1.77, 95% CI 0.90–3.49, P=0.096) and in the 
diagnostic rest-group (HR 0.4, 95% CI 0.21–1.07, P=0.073). Unlike earlier 
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Table 5: Characteristics of studies on acute rejection after liver 
transplantation using multivariate tests 
reference 3 4 5 6 7 current 
study 
year of publication 1998 1998 1998 2001 2004  
Multi-center / Single-center M S S S S S 
start entry period 1990 1988 1989 1990 1999 1990 
entry period duration (years) 4 7 8 9 4 15 
exclusion criteria1 abcd cefg hijk cghjm cghjl cn 
induction immunosuppression2 var. ATG var. CNI triple CNI 
definition of rejection3 CH CHT CH CH CH CHT 
number of subjects 762 252 126 133 285 147 
follow up period (in weeks) 6 (52) 52 22 6.5 26 13 
number of acute rejections -- (490) -- 46 47 117 60 
% of acute rejections 48 (65) 43 36.5 35.3 41 44 
statistical test4 cox cox lra lra cox cox 
recipient factors tested (n) 9 4 1 4 6 28 
donor factors tested (n) 2 0 0 0 3 5 
matching factors tested (n) 1 1 4 0 0 7 
operative procedure factors tested (n) 3 4 0 1 3 5 
postoperative factors tested (n) 7 0 0 2 2 6 
total number of factors tested 22 9 5 7 14 51 
number of factors in final model 8 1 1 5 2 6 
Legend to table 5: 
1) a: no informed consent 
 b: multi-organ transplantation 
 c: pediatric cases (age <16 years or <18 years) 
 d: death or graft failure within 3 days 
 e: cirrhosis not caused by virus, alcohol or cholestatic liver disease 
 f: metabolic liver disease 
 g: acute liver failure 
 h: retransplantation 
 i: patient or graft failure not caused by acute rejection within 1 or 2 weeks 
 j: no HLA-typing of donor and/or recipient 
 k: ABO-incomapatibility 
 l: non-cirrhotic liver disease 
 m: no CNI-inhibitors immediately after transplantation 
 n: use of IL2-receptor blocking agents 
2) var.: variable 
 ATG: anti-thymocyte immunoglobulin followed by Cyclosporin 
 CNI: calcineurin inhibitors 
 triple: triple therapy with steriods, tacrolimus and mycophenolate-mofetil 
3) C: clinical diagnosis.   H: histological diagnosis. 
 T: anti-rejection treatment. 
4) lra: logistic regression analysis.  cox: cox regression analysis. 
 
studies, we found no other significant effects of specific diseases. On the 
other hand, we found five additional significant factors, of which presence 
of the HLA-DR6 antigen in the recipient, peroperative cryoprecipitate use 
and postoperative treatment with anti-hepatitis B virus immunoglobulin 
have been implicated in studies using univariate tests6,8,9,14. The 
significance of the HLA-DR6 antigen is contradicted in two studies6,15. 
Likewise, in the first of these no effect of the HLA-DR7 antigen or of 
intravenous Cyclosporin treatment was found. Undoubtedly, some of the 
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Table 6: Predictors of acute rejection after liver transplantation identified 
by studies using multivariate analysis. 
Reference 1 2 3 4 5 current 
study 
Recipient factors                                    
[–(HR) / +(HR) / 0 / NT1] 
      
Female sex NT 0 0 NT +(1.79) 0 
Age NT 0 NT - (0.92) 0 0 
Age category - (0.81) NT NT NT NT 0 
Age ≤50 years NT NT NT NT NT +(1.79) 
Current edema - (0.71) NT NT NT NT 0 
Creatinine ≥176 µmol/l (≥2 mg/dl)             
or on dialysis 
- (0.48) NT NT NT NT 0 
Child class A vs. B+C                               
(cirrhotic patients only) 
NT NT NT +(5.22) NT 0 
Preoperative AST >5xULN vs. ≤ULN +(1.92) NT NT NT NT 0 
Preoperative AST >5xULN vs. 2-5xULN +(1.52) NT NT NT NT 0 
Underlying liver disease       
Disease category NT +(1.4) NT NT NT 0 
Hepatitis C vs. all others 0 NT NT NT +(1.71) 0 
Hepatitis C vs. alcoholic liver disease NT NT NT +(3.13) 0 NT 
Autoimmune hepatitis + Primary Biliary 
Cirrhosis + idiopathic ductopenia vs. 
alcoholic liver disease 
NT NT NT +(16.1) NT NT 
metabolic liver disease vs.                        
alcoholic liver disease 
NT NT NT +(12.3) NT NT 
Specific HLA-types       
DR6 NT NT NT 0 NT +(2.07) 
DR7 NT NT NT 0 NT +(2.15) 
Donor factors       
Age ≥30 years +(1.27) NT NT NT NT 0 
Operative procedure factors       
Cold ischemic time ≥15 hours +(1.61) NT NT NT NT NT2 
Cryoprecipitate                                          
(U administered during LT) 
NT NT NT 0 NT +(1.14) 
HLA matching factors       
Class 1 matches                                        
(in chronic virally infected patients only) 
NT NT +(7.71) NT NT 0 
Class 2 matches 0/1/2 - (0.74) NT 0 0 NT 0 
Postoperative factors       
Intravenous Cyclosporin treatment NT NT NT 0 NT +(4.01) 
Anti-hepatitis B virus            
immunoglobulin treatment 
NT NT NT NT NT - (0.34) 
1) NT: not tested 
2) number too small 
 
significant univariate test results have to be ascribed to chance. For the 
multivariate tests the situation is less clear. However, the number of 6 
factors in our final Cox model is not unreasonable given the 60 endpoints 
in the group of patients with complete data sets we studied. Finally, each 
of the six factors in our final model was significant at all stages of our 
multivariate analysis. 
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An effect of the HLA-DR6 antigen is not found in all studies, as is also the 
case in renal transplantation22,23. This might be partly explained by the 
differences between the studies on liver transplantation, and the genetic 
background of the populations involved could also play a role. The same 
holds true for the new finding that the HLA-DR7 antigen in the recipient is 
associated with an increased risk of EAR. Older age probably is 
accompanied by a decline in immune-responsiveness, as suggested by for 
instance vaccination studies24, but it could also partly substitute for other 
factors not included in our analysis. 
 
Contrary to anti-hepatitis B virus immunoglobulin, postoperative treatment 
with anti-Cytomegalovirus immunoglobulin appeared to increase the risk of 
EAR in our patients, although significance was reached only in the 
univariate analysis. At first sight this seems to rule out a general effect of 
polyclonal immunoglobulins, but differences in immunoglobulin preparation 
and dose could well play a role25. The effect of anti-hepatitis B virus 
immunoglobulin probably is caused by inhibition of functional maturation of 
antigen-presenting dendritic cells and of proliferation of T-cells. 
 
Intravenous CYA treatment is by far the strongest predictor in our model. 
When this factor is corrected for, there is no difference between 
Cyclosporin and Tacrolimus. The effect of intravenous Cyclosporin 
treatment, therefore, appears to be unrelated to the choice of drug. Rather, 
the need to give Cyclosporin intravenously probably indicates inadequate 
early immunosuppression. Finally, there is no obvious explanation for the 
effect of cryoprecipitate, but this was used in only a small number of 
transplantations. 
 
The prognostic model described here may not seem very promising with a 
c-statistic as low as 0.66, but in our patient group it certainly seems 
possible to identify different risk groups using a four-factor score. However, 
this score lacks external validation and cannot be regarded as definitive. 
More work on the prediction of EAR after liver transplantation remains to 
be done, but such work has important implications. Low risk patients only 
require treatment with corticosteroids and calcineurin inhibitors, and could 
possibly benefit from a lower-than-usual level of immunosuppression. In 
the high-risk group additional treatment with IL-2-R blocking antibodies or 
other immunosuppressive agents might be beneficial. In any case, future 
studies on immunosuppression after liver transplantation should deal with 
risk factors for EAR in their design and in the analysis of outcomes. 
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CHAPTER 7 
 
 
 
EPILOGUE 
 
 
 
LIVER TRANSPLANTATION IN ROTTERDAM: 
ACHIEVEMENTS AND CHALLENGES 
 
 
S. de Rave 
 
 
 
“The most important thing about a treatment is that it is effective, not 
merely that it ought to be effective.” (R. Asher1) 
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The main topic of this thesis is the outcome of liver transplantation using 
the conventional orthotopic technique or the alternative heterotopic 
technique. A model predicting waiting list mortality was tested and 
modified, and another model predicting early acute rejection was 
developed. In a separate study the results of orthotopic and heterotopic 
liver transplantation were compared. Last but not least, we tried to 
determine where improvements in the process are required. This resulted 
in a number of new hypotheses that have to be verified or falsified in future 
studies. 
 
After many years of preparation, the Rotterdam clinical program started in 
1986. The first liver transplantation in our centre was done on October 24. 
The recipient was a 35 year old male with end-stage chronic liver disease 
caused by hepatitis B. He received a partial liver graft placed in the right 
upper abdomen, below his own liver. This diseased organ was left in 
place. The operation took 6 hours and the peroperative blood loss was 6.5 
litres. He left the Intensive Care Unit after 3 days and could be discharged 
after 28 days, without having experienced any serious complications. 
 
The idea behind this heterotopic procedure was that avoidance of the 
hemodynamic and metabolic problems associated with the anhepatic 
phase of the conventional orthotopic procedure would make it easier for 
the recipient to survive the transplantation. Our hope was that potential 
short-term advantages of heterotopic liver transplantation would 
materialise and would lead to a better long-term prognosis. Heterotopic 
liver transplantation also served as a stepping stone to the conventional 
technique of orthotopic liver transplantation, with complete replacement of 
the diseased organ. Eventually, heterotopic liver transplantation fell into 
disuse. Since 1991 only orthotopic liver transplantations have been done. 
The yearly number of transplantations has risen to around 40 during the 
last decade. 
 
Here I want to highlight the fields where we have booked progress and 
those where more work still has to be done. Heterotopic liver 
transplantation may not have brought the results we would have liked, but 
ours is the largest of the series published so far, and our three long-term 
survivors are exceptional. On the positive side the improvements in the 
operative procedure have to be mentioned, together with the better-than-
average results of transplantation for acute liver failure. One of the 
important problems that needs to be addressed is the waiting list mortality. 
Also, there has been much talk about individualised immunosuppression 
after transplantation, but no real progression. The treatment of chronic 
hepatitis C before as well as after liver transplantation is another area 
where more needs to be done. These points will be dealt with one by one 
in the remainder of this chapter. 
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Heterotopic liver transplantation 
Do we have to close the book on heterotopic liver transplantation? At first 
sight the answer given by our comparison with orthotopic transplantation in 
chapter 4 is “yes”. This conclusion might be qualified as an achievement, 
but some notes have to be made. Due to its small size and the lack of a 
contemporary control group our study does not provide definitive evidence 
that the results of heterotopic liver transplantation are inferior to those of 
the orthotopic procedure, even though it is the best evidence currently 
available. Also we cannot exclude the possibility that the difference 
between the two groups is mainly caused by the use of partial grafts for 
heterotopic transplantation, in spite of correction for this factor in our 
analysis. Another point is that, in response to the shortage of donor 
organs, the use of partial liver grafts from cadaveric as well as living 
donors probably will increase. Perhaps it is time for a randomised trial of 
heterotopic versus orthotopic liver transplantation using partial grafts in 
adult patients not at risk for hepatocellular carcinoma or cholangio-
carcinoma, which could be done in the setting of a living donor program. 
Maybe even left lobe grafts could be used for heterotopic transplantation, 
with the advantage of reducing the risk for the donors. 
 
The operative procedure 
The technique of liver transplantation certainly has evolved since the early, 
experimental days. Replacement of the liver may not yet be a routine 
procedure, but can no longer be called experimental or exceptional. The 
current surgical team has been active since 1991, and has managed to 
improve their liver transplantation skills on a number of points. An 
important one is the median warm ischemic time of the graft, that has more 
than halved since the period 1994-1998, when it was around 80 minutes. 
Equally important is the median peroperative blood loss, which also has 
halved since the same period, and currently is between 4 and 5 litres. Both 
Figure 1: effect of the piggy-back technique on the 
peroperative blood loss
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factors probably are related to the introduction of the piggyback technique, 
that leaves the recipient inferior caval vein intact (figure 1). This piggyback 
technique avoids the problems associated with interruption of the venous 
blood flow from the lower part of the body to the heart, and shortens the 
time needed for implantation of the donor liver. Another surgical 
achievement is the successful performance of two Living Related Donor 
Liver Transplantations in 2004. 
 
Acute liver failure 
The treatment of patients with acute liver failure requires quick and 
concerted action by specialists in the fields of intensive care medicine, 
hepatology and transplantation surgery. Such a co-operation has led to 
referral to our centre of 143 patients in the period 1986-2002, half of whom 
were actually placed on the emergency liver transplantation waiting list. 
Thanks to a relatively short median waiting time of 1 to 2 days, about 90% 
of the enlisted patients could be transplanted. The 66% 5-year survival 
after transplantation is better than the average reported by the ELTR for a 
similar period2 (table 1), and can be seen as an achievement of the entire 
team. 
 
Table 1: Comparison of 5-year survival after transplantation for different 
indications, Rotterdam versus ELTR 
1988-2001 1986-2002 5-YEAR SURVIVAL (95% CI) 
ELTR ROTTERDAM ELTR ROTTERDAM 
INDICATION 
N N   
Acute liver failure 3709 65 59% 66% (53-76%) 
Alcoholic cirrhosis 6950 33 72% 68% (48-82%) 
Chronic hepatitis B 3050 43 70-85% 68% (51-80%) 
Chronic hepatitis C 6436 30 67-85% 57% (36-74%) 
PBC / PSC / SBC 5213 78 77% 71% (54-80%) 
Hepatocellular carcinoma 3364 21 34-58% 31% (13-51%) 
Autoimmune hepatitis 991 16 72% 87% (56-96%) 
 
The waiting list 
One of the major challenges of liver transplantation lies in the allocation of 
donor organs. A choice has to be made between a rule-of-rescue policy 
(the most endangered patient comes first), a policy based on utility (the 
greatest good for the greatest number), and a policy based on fairness 
(the patient that has the longest waiting time comes first)3. Politicians 
dictate waiting list criteria and priorities, but it is up to clinicians to provide 
the data that can support these political decisions. Involvement of 
physicians that treat liver transplantation candidates in policy-making leads 
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to conflicts of interest and is best avoided. Treating physicians are bound 
by the rule-of-rescue and, therefore, cannot chose. Policy-makers have 
more freedom of choice, but do need guidance. 
 
The rule-of-rescue policy implies that the patient who most urgently needs 
a liver transplantation is treated first, and fulfils the obligation of the 
treating physicians. It forms the basis of emergency liver transplantation 
for acute liver failure, where it is not challenged. For patients with chronic 
liver disease the situation may be somewhat different. Here transplanting 
the most severe cases probably results in the largest possible gain of life-
years, but also to the lowest postoperative survival and to an avoidable 
loss of valuable donor organs. 
 
Thus the rule-of-rescue violates the utility principle, that guards against 
desperate attempts to treat very high-risk patients. Beyond that, the utility 
principle is mainly economic in its nature and its effects and therefore 
should not influence decisions on transplantation, according to a statement 
of the World Health Organisation4. By aiming at an optimal graft survival, 
reached by transplanting relatively low-risk patients, it will, however, be 
attractive to the public (the potential donors) and to patients that otherwise 
would have to wait a long time for transplantation or would not be 
transplanted at all. 
 
Fairness is a dominant principle in many fields in our society, and cannot 
be discarded easily in liver graft allocation systems. The rule-of-rescue 
seems to satisfy the fairness principle, but under the latter equal sharing of 
the burden of disease and of the benefits of transplantation takes 
preference5. This implies a more or less equal distribution of waiting times, 
or – in other words – transplantation in order of enlistment. The fairness 
principle of course requires some discipline from physicians, by not placing 
patients on the waiting list too early. 
 
In my view a balance should be found between the rule-of-rescue (with an 
upper limit for acceptable risk of dying after transplantation) and the 
fairness principle (with a lower limit for acceptable disease severity). 
Where this balance and these limits should lie has to be decided in an 
open, well-informed discussion. If it is not choice, what tasks should 
physicians undertake? First, they can develop models predicting mortality 
of liver transplantation candidates and thus set the criteria for disease 
severity. Example of such models are MELD and its modified versions. 
Second, they can develop models predicting mortality after liver 
transplantation based on preoperative patient and donor characteristics, 
setting the limits for high-risk patients. Models of this second type have 
already been described6-11, as summarised in table 2. The problem with 
these models is that different measures for disease severity and different 
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cut-off points for recipient and donor age were used. Development of a 
model incorporating all relevant factors is one of the challenges that have 
to be met. 
 
Tabel 2: Preoperative recipient and donor characteristics and other factors 
predicting death after liver transplantation in adult patients 
Reference 6 7 8 9 10 11 
Recipient       
- age Yes Yes Yes -- -- Yes 
- renal function -- Yes Yes -- Yes -- 
- indication for transplantation Yes -- -- -- -- -- 
- disease severity -- Yes Yes -- Yes Yes 
- prior transplantation Yes -- Yes -- -- -- 
Donor       
- age Yes Yes Yes -- Yes -- 
- sodium -- Yes -- -- -- -- 
- preservation fluid non-UW Yes -- -- -- -- -- 
Recipient and donor       
- recipient M / donor F Yes -- -- Yes -- -- 
- ABO compatible, non-
identical 
Yes -- -- -- -- -- 
Other factors       
- center volume Yes -- -- -- -- -- 
 
Immunosuppression 
Acute rejection has been reported to influence both patient and graft 
survival at 6 months after liver transplantation12. In our own patient group 
the incidence of acute rejection in the first 3 months after transplantation 
has dropped from about 40% to 18% since the introduction of interleukin-
2-receptor blocking antibodies as part of the primary immunosuppressive 
regimen in 1998. This does, however, imply that more than half of the 
patients are overtreated with immunosuppressive drugs. Overimmuno-
suppression might lead to a higher incidence of severe infections and 
possibly also of post-transplantation lymphoproliferative disease, and 
thereby have a negative influence on the overall outcome. The induction of 
donor-specific tolerance is the Holy Grail of transplantation, and has the 
potential of making maintenance immunosuppression obsolete, but has yet 
to be found. In the mean time, identifying patients with a low risk of acute 
rejection, and reducing the amount of immunosuppressive drugs given 
after transplantation in this group seems a viable alternative. On the other 
hand there are high-risk patients, who might benefit from heavier immuno-
suppression, but it still has to be proven that such an approach in this 
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patient group leads to a better survival. It seems possible to identify patient 
groups at low and at high risk of early acute rejection, but our results await 
external validation. 
 
Hepatitis C 
Liver transplantation for chronic hepatitis C is a subject that lies outside the 
scope of this thesis, but certainly deserves to be mentioned here as one of 
the challenges to be met. In Rotterdam the yearly number of patients 
transplanted for chronic hepatitis C has grown from 0 until 1993 to 4 (or 
just over 10% of the total number) in recent years. As shown in table 1 
long-term survival after transplantation in this group is below our own 
average, most likely because of disease recurrence. A similar but smaller 
negative effect of hepatitis C on post-transplantation survival was also 
found in database-studies from Europe2 and from the United States13. As 
stated in the editorial accompanying the latter report14, “the coming and 
present challenges to maintaining and improving outcomes for recipients 
with HCV infection should focus our attention on maximising the efficacy 
and tolerability of antiviral therapies in this fragile population”. Given our 
limited number of patients, the only way forward lies in joining large, 
multicenter trials. 
 
Conclusion 
We can only learn from our experiences if we are willing to draw 
conclusions from them. One has to be that heterotopic liver transplantation 
is not an alternative to conventional orthotopic transplantation of full-size 
liver grafts. The heterotopic technique might, however, have advantages in 
certain patient groups when partial grafts are used. Management of the 
waiting list remains a challenge, but physicians have a limited role in policy 
making. Treatment of patients with hepatocellular carcinoma still is far from 
optimal, and here lies an important area for future research. The same can 
be said of patients with chronic hepatitis C. The final point is the standard 
immunosuppressive treatment currently given to prevent acute rejection 
after transplantation. A more balanced approach, based on individualised 
treatment guided by estimates of the risk of early acute rejection, could 
lead to better outcomes. We may have booked some successes, like in the 
treatment of patients with acute liver failure, but more work still has to be 
done. 
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CHAPTER 8 
 
 
 
SUMMARY 
 
 
 
In chapter 1 a brief description of the scientific strategy followed in the 
papers that form the main part of this thesis is given, along with a division 
in study categories. Here this division will be followed. There are 3 
descriptive studies, 3 hypothesis-generating observational studies and 2 
hypothesis-testing observational studies. The distinction between these 
study types is, however, not always very clear. Both the descriptive and 
the hypothesis-testing studies contain elements that can be regarded as 
hypothesis-generating. 
 
The first descriptive study can be found in chapter 2. It marks the field by 
describing the group of patients referred to the Erasmus Medical Center 
Rotterdam department of Hepatology for liver transplantation from 1986 
through 2002, as well as the treatment decisions and outcomes in this 
group. Also, the fields covered by the studies in the following chapters are 
pointed out. No attempt is made here to generate hypotheses. 
 
Three exceptional patients that have survived for more than 10 years after 
heterotopic liver transplantation are described in chapter 4b. Heterotopic 
liver transplantation is a surgical technique designed to solve some of the 
problems of the conventional orthotopic procedure by avoiding the removal 
of the patient's own liver. Heterotopic transplantation has never become a 
viable alternative for orthotopic transplantation, and was abandoned even 
in Rotterdam after 23 were done in the 5-year period between 1986 and 
1990. In this paper the possibility is raised that recipients of heterotopic 
liver grafts are protected from hepatocellular carcinoma development in 
their own liver by the nearly complete atrophy of this organ. Admittedly, 
this statement can hardly be called a hypothesis because it cannot really 
be tested. 
 
Chapter 5b hosts the last descriptive paper. Here details are given on the 
long-term follow up of patients transplanted for acute liver failure. The main 
finding is that complete rehabilitation is the rule rather than the exception 
in patients that survive after transplantation, though there are some 
frequently occurring complications that become even more prevalent over
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the period from 5 to 10 years after the operation. These complications are 
obesity, dyslipidemia, hypertension and a moderate decline of the renal 
function. The hypothesis that can be distilled a from our data is that 
modification and minimisation of the immunosuppressive treatment might 
reduce the number and severity of long-term complications. 
 
The hypothesis-generating part starts with chapter 3a, where the Model for 
End-stage Liver Disease (MELD) developed by the Mayo Clinics in the 
United States is examined. The hypothesis arising from this study is that a 
simplified model containing only two of the factors used in MELD 
transformed into their natural logarithms predicts mortality on the waiting 
list for liver transplantation better than MELD does in its original form. In 
the same paper partial external validation of this new model is presented. 
 
The effect of disease severity in patients with Primary Biliary Cirrhosis and 
Primary Sclerosing Cholangitis on the outcome after enlistment for liver 
transplantation is the subject of study in chapter 3b. Here it is shown that 
the optimal timing of transplantation depends on the choice of the starting 
point for the analysis and of the outcome measure. The best absolute 
survival is found when low-risk patients are transplanted, but the largest 
survival benefit is found in the high-risk group. The resulting hypothesis is 
that transplanting patients with chronic cholestatic liver diseases before 
they reach a more advanced stage of their disease is the optimal strategy, 
at least from the perspective of the patient. 
 
A type of study similar to that in chapter 3a is presented in chapter 6. Here 
we identify the factors associated with the occurrence of early acute 
rejection after liver transplantation in our patient group using the Cox 
proportional hazard rate model. The resulting hypothesis is that a risk 
score derived from this model can be used to separate patient groups with 
low and high risks of acute rejection, that could possibly benefit from a 
level of postoperative immunosuppression adjusted to this risk. 
 
Two studies can be qualified as hypothesis-testing. In chapter 4a the claim 
that the results of heterotopic liver transplantation for end-stage chronic 
liver disease are superior to those of the conventional orthotopic procedure 
is examined in an observational study covering a relatively long period and 
using a case-control approach. This study has a number of shortcomings, 
but still provides the best evidence available that the hypothesis should be 
rejected, at least for the specific liver diseases forming the indication for 
transplantation in our patients. In hindsight, a somewhat more definitive 
answer would have been given by a less complex analysis of patient 
survival on an intention-to-treat basis, disregarding the crossover of one 
patient from the case group to the control group at the time of 
retransplantation. Apart from that, based on the observations in this study 
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two other hypotheses can be formulated. One is that the use of a partial 
liver graft in patients at a more-than-average risk of developing malignant 
diseases further increases this risk. The second one, explicitly stated in 
chapter 7, is that heterotopic transplantation may still be superior to 
orthotopic transplantation in the setting of a living related donor program. 
 
Finally, in chapter 3a the hypothesis that emergency liver transplantation 
improves the survival for patients with acute liver failure is tested in 
another observational study. Although the alternative hypothesis that there 
is no effect cannot be rejected on statistical grounds, our data strongly 
suggest that the original hypothesis is correct. It should be noted that it is 
hard to reach statistical significance here because of the relatively small 
number of patients that died before they could be transplanted in our 
single-centre study. Our paper does, however, point out the optimal 
statistical method to test the hypothesis in a larger study that does not rely 
on historical controls. 
 
To summarise the summary, the studies in this thesis have generated 6 
more or less new hypotheses, that are again explicitly stated here: 
 
1. After liver transplantation for acute hepatic failure the number of 
long-term complications increases with time, and modification or 
minimisation of the immunosuppressive treatment might reverse 
this trend. 
 
2. A simplified version of the MELD-score predicts survival on the 
waiting list for liver transplantation better than the original does. 
 
3. In patients with chronic cholestatic liver diseases the optimal time 
for liver transplantation is in a relatively early stage of the disease. 
 
4. Patient groups at different risks of early acute rejection after liver 
transplantation can be identified by using a model containing a 
limited number of factors. 
 
5. In patients prone to the development of malignancies this risk is 
increased after liver transplantation when a partial graft is used. 
 
6. The use of the left liver lobe for heterotopic transplantation in the 
setting of a living related donor program reduces the risk for the 
donor as well as the recipient. 
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Two other hypotheses were tested, the first one being rejected and the 
second one not being confirmed as has already been described above: 
 
1. In the treatment of patients with end-stage chronic liver failure 
heterotopic liver transplantation is superior to the conventional 
orthotopic procedure. 
 
2. The survival of patients with acute liver failure is improved by 
orthotopic liver transplantation. 
 
The achievements of the Rotterdam liver transplantation program are 
highlighted in chapter 7, and potential future goals or challenges are also 
pointed out here. These challenges lie in testing the yet untested 
hypotheses. The most important fields are the waiting list strategy and 
heterotopic transplantation of liver grafts from living donors. As usual, the 
analysis of our data has generated more questions than it has answered, 
but if we are to make real progress generating new hypotheses may well 
be more important than testing old ones. 
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CHAPTER 9 
 
 
 
SUMMARY (IN DUTCH) 
 
SAMENVATTING 
 
 
 
Hoofdstuk 1 beschrijft kort de wetenschappelijke strategie die is gevolgd in 
de studies die het belangrijkste deel van dit proefschrift vormen, en plaatst 
deze studies in verschillende categorieën. Volgens deze indeling zijn er 3 
descriptieve studies, 3 hypothesegenererende observationele studies en 2 
observationele studies waarin hypothesen worden getest. Het is echter 
niet altijd makkelijk om een onderscheid te maken tussen de verschillende 
studiecategorieën. In feite bevatten bijna alle studies elementen die als 
hypothesegenererend kunnen worden beschouwd. 
 
De eerste descriptieve studie staat in hoofdstuk 2. Het beschrijft het 
onderwerp van dit proefschrift, de groep patiënten die tussen 1986 en 
2002 naar de afdeling Hepatologie van het Erasmus Medisch Centrum 
Rotterdam zijn verwezen voor levertransplantatie. Ook wordt aandacht 
geschonken aan de beslissingen met betrekking tot de behandeling en 
aan de uitkomsten in deze groep. Daarnaast worden de gebieden 
aangeduid die worden bestreken door de studies in de volgende 
hoofdstukken. Er wordt hier nog geen poging gedaan om hypothesen te 
ontwikkelen. 
 
Drie uitzonderlijke patiënten die na heterotope levertransplantatie meer 
dan 10 jaar hebben geleefd worden beschreven in hoofdstuk 4b. 
Heterotope levertransplantatie is een chirurgische techniek die is 
ontwikkeld om een deel van de problemen te ondervangen van de meer 
gebruikelijke orthotope procedure, die ontstaan door de verwijdering van 
de eigen lever van de patiënt. Heterotope transplantatie heeft geen ingang 
gevonden als alternatief voor orthotope transplantatie, en is ook in 
Rotterdam in onbruik geraakt nadat er 23 waren gedaan in de 5 jaar 
tussen 1986 en 1990. In deze studie wordt de mogelijkheid besproken dat 
patiënten die met de heterotope techniek zijn getransplanteerd beschermd 
worden tegen ontwikkeling van hepatocellulair carcinoom in hun eigen 
lever door de vrijwel complete atrofie hiervan. Deze mogelijkheid kan
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echter niet als een hypothese worden beschouwd, omdat er geen 
mogelijkheden zijn de juistheid ervan te testen. 
 
Ook de studie in hoofdstuk 5b is voornamelijk descriptief van aard. Hierin 
wordt het beloop na transplantatie voor acuut leverfalen gedetailleerd 
beschreven. De belangrijkste bevinding is dat volledige rehabilitatie eerder 
regel dan uitzondering is voor patiënten die de operatie overleven. Er is 
echter een aantal veel voorkomende complicaties, die in toenemende 
mate optreden in de periode tot 10 jaar na transplantatie. Deze 
complicaties zijn overgewicht, dyslipidemie, hypertensie en matige 
nierinsufficiëntie. De hypothese die uit deze gegevens te destilleren valt is 
dat de toename van het aantal late complicaties na levertransplantatie met 
de tijd mogelijk omgebogen kan worden door modificatie of vermindering 
van de immunosuppressieve medicatie. 
 
Het hypothesegenerende deel van dit proefschrift begint met hoofdstuk 3a, 
waarin het "Model for End-stage Liver Disease" (MELD), ontwikkeld door 
de Mayo Clinics in de Verenigde Staten, wordt onderzocht. De hypothese 
die uit deze studie voortkomt is dat een vereenvoudigd model, dat slechts 
twee van de drie oorspronkelijke factoren bevat in de vorm van hun 
natuurlijke logaritmen, de mortaliteit op de wachtlijst voor 
levertransplantatie beter voorspelt dan MELD in zijn oorspronkelijke vorm. 
In dezelfde studie wordt een gedeeltelijke externe validering van dit 
nieuwe model gepresenteerd. 
 
Onderwerp van studie in hoofdstuk 3b is de invloed van ziekte-ernst op de 
overleving van patiënten met Primaire Biliaire Cirrose en Primaire 
Scleroserende Cholangitis op de wachtlijst voor levertransplantatie en na 
de operatie. Deze studie laat zien dat het antwoord op de vraag wat het 
optimale moment voor transplantatie is afhangt van de keuze van het 
startpunt van de analyse en van de uitkomstmaat. De beste overleving in 
absolute zin wordt gevonden in de groep van laagrisicopatiënten, maar de 
grootste overlevingswinst wordt geboekt in de hoogrisicogroep. De 
hypothese die hieruit voorkomt is dat, althans vanuit het perspectief van de 
patiënt, transplantatie vóórdat het eindstadium van de leverziekte wordt 
bereikt de beste strategie is. 
 
De studie in hoofdstuk 6, waarin wordt gezocht naar factoren die de kans 
op vroege acute afstoting na levertransplantatie beïnvloeden, is van 
hetzelfde type als die in hoofdstuk 3a. Ook hier wordt gebruik gemaakt van 
een "Cox proportional hazard rate model". De hypothese is ditmaal dat 
een risicoscore afgeleid van dit model gebruikt kan worden om een 
onderscheid te maken tussen patiënten met een lage en een hoge kans op 
acute afstoting, die baat zouden kunnen hebben bij een mate van 
postoperatieve immunosuppressie aangepast aan dit risico. 
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In de twee overblijvende studies worden hypothesen getest. In hoofdstuk 
4a wordt de claim dat de resultaten van heterotope levertransplantatie 
voor chronische leverziekten beter zijn dan die van de conventionele 
orthotope procedure onder de loep genomen. Dit wordt gedaan in een 
observationele studie met een case-control opzet, die een relatief groot 
aantal patiëntjaren beslaat. Hoewel deze studie een aantal tekortkomingen 
heeft, levert zij het beste tot nu toe beschikbare bewijs dat deze hypothese 
verworpen moet worden, op zijn minst voor de specifieke aandoeningen 
die in deze studie zijn onderzocht. Achteraf had een minder ingewikkelde 
analyse op intention-to-treat basis, waarin geen rekening wordt gehouden 
met de verhuizing van één patiënt van de studiegroep naar de 
controlegroep ten tijde van retransplantatie, tot een meer definitief 
antwoord kunnen leiden. Daarnaast kunnen op grond van de observaties 
in deze studie nog twee nieuwe hypothesen worden geformuleerd. De 
eerste is dat gebruik van een transplantaat bestaand uit slechts een deel 
van de donorlever bij patiënten met een bovengemiddelde kans op 
maligniteiten dit risico verder vergroot. De tweede, expliciet verwoord in 
hoofdstuk 7, is dat in de setting van een living-related donorprogramma 
heterotope transplantatie toch beter zou kunnen zijn dan orthotope 
transplantatie. 
 
Tenslotte wordt in hoofdstuk 3a de hypothese getest dat 
levertransplantatie de overleving van patiënten met acuut leverfalen 
verbetert, wederom in een observationele studie. Hoewel de alternatieve 
hypothese, dat er geen effect is, op statistische gronden niet verworpen 
kan worden, leveren onze gegevens sterke aanwijzingen op dat de 
oorspronkelijke hypothese correct is. Daarbij moet worden aangetekend 
dat, door het kleine aantal patiënten in onze single-center studie die zijn 
overleden voordat zij konden worden getransplanteerd, het niet makkelijk 
is statistische significantie te bereiken. Wel wordt hiermee aangegeven 
wat de optimale statistische methode is om de hypothese te testen zonder 
gebruik te maken van historische controles in een grotere studie. 
 
Om de samenvatting samen te vatten, de studies in dit proefschrift hebben 
7 min of meer nieuwe hypothesen opgeleverd, die hier nog eens worden 
weergegeven: 
 
1. De toename van het aantal late complicaties na levertransplantatie 
voor acuut leverfalen hangt samen met de immunosuppressive 
medicatie, en kan mogelijk worden tegengegaan door verandering 
of vermindering daarvan. 
 
2. Een vereenvoudigde versie van de MELD-score geeft een betere 
voorspelling van de mortaliteit op de wachtlijst voor 
levertransplantatie dan het origineel. 
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3. Voor patiënten met cholestatische leverziekten is een relatief 
vroeg stadium van de ziekte het optimale moment voor 
levertransplantatie. 
 
4. Door gebruik te maken van een model met een beperkt aantal 
factoren kunnen groepen patiënten met een verschillende kans op 
vroege acute afstoting na levertransplantatie van elkaar worden 
onderscheiden. 
 
5. Patiënten met een al verhoogde kans op maligniteiten lopen na 
levertransplantatie een extra risico als gebruik wordt gemaakt van 
een gedeeltelijk transplantaat. 
 
6. Gebruik van de linker leverkwab voor heterotope transplantatie in 
de setting van een living-related donorprogramma verkleint het 
risico voor zowel de donor als de ontvanger. 
 
Twee andere hypothesen werden getest, waarbij de eerste moest worden 
verworpen en de tweede niet geheel kon worden bevestigd, zoals 
hierboven reeds beschreven: 
 
1. Als behandeling van patienten met chronische leverziekten geeft 
heterotope levertransplantatie betere resultaten dan de 
gebruikelijke orthotope procedure. 
 
2. De overleving van patienten met acuut leverfalen wordt verbeterd 
door orthotope levertransplantatie. 
 
De verworvenheden van het Rotterdamse levertransplantatieprogramma 
worden nog eens uitgelicht in hoofdstuk 7, en hier worden ook mogelijke 
doelen en uitdagingen voor de toekomst aangegeven. De uitdagingen 
liggen in het testen van de nieuwe hypothesen. De belangrijkste hiervan 
hebben betrekking op de wachtlijststrategie en heterotope transplantatie 
van gedeeltelijke levers van levende donoren. Zoals gebruikelijk heeft de 
analyse van onze gegevens meer vragen opgeroepen dan beantwoord, 
maar om werkelijk vooruitgang te maken zou het ontwikkelen van nieuwe 
hypothesen wel eens belangrijker kunnen zijn dan het testen van oude. 
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CHAPTER 10 
 
 
 
ACKNOWLEDGMENTS (IN DUTCH) 
 
 
 
DANKWOORD 
 
 
 
Levertransplantatie is een "teamsport". Het is dan ook moeilijk een 
dankwoord te beginnen zonder te melden dat het ontstaan van dit 
proefschrift niet mogelijk was geweest zonder de inspanningen van allen 
die in de loop van de tijd hebben bijgedragen aan het Rotterdamse 
levertransplantatieprogramma en daarmee de gegevens hebben 
geproduceerd waarop dit proefschrift is gebaseerd. Daarbij denk ik aan 
medisch specialisten uit allerlei disciplines, maar ook aan 
verpleegkundigen en ondersteunde diensten. Het verzamelen, ordenen en 
analyseren van deze gegevens is echter een activiteit geweest van een 
beperkt aantal leden van het team. Dit vindt zijn weerslag in het 
auteurschap van de artikelen in dit proefschrift. Ook de verschillende 
medeauteurs wil ik hierbij bedanken. Een andere groep die onmisbaar is 
wordt gevormd door de patiënten, die evenals een deel van de teamleden 
geen aanspraak kunnen maken op medeauteurschap, maar zeker ook 
aparte vermelding verdienen. 
 
Mijn promotor professor doctor Solko W. Schalm stond niet alleen aan de 
wieg van het Rotterdamse levertransplantatieprogramma, maar ook aan 
die van mijn carrière in de hepatologie. Daarnaast heeft hij dit proefschrift 
vanaf de conceptie begeleid, en is hij er steeds in blijven geloven, ondanks 
de extreem lange duur van de embryonale en foetale periode, met een 
aantal beslissingen over de ontwikkeling die in een latere fase moesten 
worden bijgesteld, en daarnaast de eigenwijsheid en een paar andere 
nukken van de promovendus. Beste Solko, mijn grote dank hiervoor! Ik 
hoop dat je me stelling 14 uit dit proefschrift niet al te kwalijk neemt, maar 
ook jij hebt een paar eigenaardigheden. 
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In een laat stadium heeft Huug Tilanus zich bereid verklaard mijn eerste 
promotor te ontlasten door mede-promotor te worden en mij in het gareel 
te houden. Dat laatste is hem wonderwel gelukt, voor deze niet geringe 
prestatie ben ik hem uiterst dankbaar. De overige leden van de promotie-
commissie ben ik erkentelijk voor hun bereidheid zich door dit boekje heen 
te werken en er hun kritiek op te leveren. In het bijzonder wil ik mijn eerste 
afdelingshoofd professor J.H.P. Wilson bedanken, die mij (als kersvers 
geregistreerd internist) in 1984 binnenhaalde in de afdeling Inwendige 
Geneeskunde 2 van het toenmalige Academisch Ziekenhuis Rotterdam – 
Dijkzigt, en die mij altijd heeft gesteund in mijn werk. Na het ontstaan van 
een zelfstandige afdeling Maag-, Darm- en Leverziekten is zijn rol 
overgenomen door professor doctor E.J. Kuipers, die mij in staat heeft 
gesteld dit proefschrift uiteindelijk af te ronden. 
 
Bij zijn afscheid als hoogleraar in de leverziekten heeft mijn promotor het 
begrip "hepatologen van Hoboken" geïntroduceerd, waarvan hij als de 
pater familias kan worden beschouwd. Als we deze analogie doortrekken 
is Henk van Buuren de oudste zoon. Henk heeft deze rol met verve 
vervuld, en niet alleen vele anderen maar ook mij altijd met raad en daad 
terzijde gestaan. Ook de ongedwongen vrijdagmiddag-bijeenkomsten, als 
regel op zijn kamer, worden door mij node gemist. Ineke van der Ende is 
lange tijd een tweede steun en toeverlaat geweest. Zij was de baas van 
het Practicum Klinische Vaardigheden, waar ik ooit mijn academische 
loopbaan ben begonnen, en gedurende vele jaren mijn kamergenoot op de 
D-vleugel. Het besluit om een andere kamer te betrekken betreur ik nog 
steeds. Natuurlijk moet ik hier ook Marion Hoogendoorn noemen, die zich 
met nimmer aflatende blijmoedigheid steeds door de chaos die ik haar 
bezorgde heen werkte, en er altijd iets leesbaars van wist te maken. 
 
Hoezeer ik ieders bijdrage ook waardeer, ik was nooit gekomen waar ik nu 
ben zonder mijn ouders en vooral mijn levensgezellin van de afgelopen 25 
jaar, Jeltje Zeelenberg. Mijn vader, die in 1990 is overleden, heeft altijd 
stilzwijgend achter me gestaan. Voor mijn moeder geldt hetzelfde, zij het 
dat die wat meer vocaal is aangelegd. Beiden hebben mij altijd in al mijn 
ondernemingen gestimuleerd. Jeltje, je hebt mijn nukken nu al 25 jaar 
verdragen, en meer dan dat. Ondanks je eigen veeleisende werk heb je 
jarenlang méér dan je deel in het huishouden gedaan en niet alleen mij 
alle gelegenheid gegeven voor mijn eigen activiteiten, maar me daarin ook 
aangemoedigd. Ik vertel altijd graag dat ik zonder jou nooit de top van de 
Kilimanjaro zou hebben gehaald, maar zonder jou zou ik helemaal niets 
hebben bereikt. Van promoveren wordt gezegd dat het leuker is dan 
trouwen, omdat je het in je eentje doet: niet waar! 
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CHAPTER 11 
 
 
 
CURRICULUM VITAE (IN DUTCH) 
 
 
 
De schrijver dezes is geboren te Rotterdam op 23 januari 1953. In deze 
zelfde stad volgde hij van 1972 tot 1979 de studie Geneeskunde aan de 
Medische Faculteit van de Erasmus Universiteit. De opleiding tot internist 
vond in zijn geheel plaats in het St. Elisabeth Ziekenhuis in Tilburg, tussen 
1979 en 1984, met dr. V.A.M. Terwindt en dr. J.H.M. Lockefeer als 
opleiders. Het jaar 1984 werd doorgebracht op de dienst Nierziekten van 
het Universitair Ziekenhuis Gasthuisberg te Leuven, België (hoofd: prof. dr. 
P. Michielsen). Dit was de eerste kennismaking met het transplantatie-vak, 
onder het toeziend oog van dr. Y. Vanrenterghem. 
 
Het dienstverband met de Erasmus Universiteit Rotterdam begon eind 
1984, eerst als medewerker van het Practicum Klinische Vaardigheden, 
later aangevuld met een aanstelling bij de afdeling Inwendige 
Geneeskunde 2. Daar werd vanaf 1986 deelgenomen aan de activiteiten 
rond het beginnende levertransplantatieprogramma. Vanaf dat moment 
vormde het verzamelen, ordenen en beheren van de gegevens over het 
programma een belangrijk deel van de werkzaamheden. Analyse van deze 
gegevens heeft uiteindelijk geleid tot dit proefschrift, in een proces dat 
bijna 20 jaar heeft gevergd. 
 
In 1999 werd de overstap gemaakt van de Inwendige Geneeskunde naar 
de nieuw gevormde afdeling Maag-, Darm- en Leverziekten. Op 20 
februari 2001 volgde registratie als gastroenteroloog. Eind 2004 werd 
Rotterdam op eigen initiatief min of meer verlaten, het dienstverband werd 
omgezet in een gastvrijheidovereenkomst, hetgeen mede de voltooiing 
van dit proefschrift mogelijk heeft gemaakt. Naast de stukken in dit 
proefschrift heeft de medische loopbaan 29 publicaties opgeleverd, 
waarvan 25 in internationale Engelstalige tijdschriften en 12 van deze 25 
als eerste auteur. 
 
In augustus 1980 werd de relatie met Jeltje Zeelenberg een feit, hetgeen 
op 28 november 1989 werd bezegeld met een huwelijk. De omzwervingen 
door Nederland en België zijn in 1991 geëindigd in Bennekom. 
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